

## Hot topics in women's health

Update includes mastitis, vaginitis, intertrigo and ovarian cancer detection

► [pulse-learning.co.uk](http://pulse-learning.co.uk)



## Diabetes and CVD Update

Extended early bird rate – book before 24 August and save £50

► [pulse-seminars.com](http://pulse-seminars.com)



# PULSE

pulsetoday.co.uk

04.07.12

Issue 24 | Volume 72

BriefingMedia

At the heart  
of general  
practice  
since 1960

## DH to ramp up QOF diabetes workload

Proposed 'composite indicator' would require GPs to run nine checks for every patient

### EXCLUSIVE

By Madlen Davies

GPs will be forced to conduct nine separate checks in each patient with diabetes under Department of Health plans to create a single diabetes QOF indicator worth over \$5,000, Pulse can reveal.

The DH is also pushing for a change in thresholds along with the 'composite indicator', which would include HbA<sub>1c</sub>, cholesterol, blood pressure and foot checks, in an attempt to boost achievement in the routine assessment of patients with diabetes.

The move comes after a national audit suggested only half of patients with diabetes were receiving all nine checks – a result described as 'appalling' by patient groups.

But the findings of the National Diabetes Audit for 2010/11, published last month, have been plunged into controversy after the GPC filed a complaint to the NHS Information Centre over the data used in the audit.

The DH has launched an investigation into the GPC's complaint, which is due to report in September. In the meantime, it has written to NICE, asking it to look at bundling all the nine checks – currently separate indicators worth 39 points (equivalent to £5,217 per year for an average practice) – into one single indicator.

NHS medical director Sir Bruce Keogh wrote to NICE last month asking it to consider 'replacing the current QOF indicators relating to the nine processes for diabetes with a composite indicator measuring the proportion of patients who received all nine of the processes'.

In the letter, he also asked



Foot examinations – one of nine checks GPs will need to perform under the 'composite indicator'

NICE to review 'the range of target measurements and associated payment thresholds'.

If successful, the new indicator could be included in the 2015 QOF.

But GPs warned the changes could mean much more work for

practices and potentially lost income, and the GPC said the profession was being 'unfairly criticised' because of the National Diabetes Audit's findings.

Dr Bill Beeby, chair of the GPC's clinical and prescribing subcommittee, told Pulse the figures from the national audit were 'incomparable' to the achievement recorded in the QOF: 'GPs are not putting in the codes that the National Diabetes Audit looks for, because they're not being asked to.'

'If you look for the wrong thing you won't find it. Some areas are being unfairly criticised as a result.'

GPC negotiator Dr Beth Mc-

Carron-Nash said the proposed changes would be considered as part of the normal negotiation process, but added: 'GPs asked for stability in the QOF and we are mindful of that.'

Dr Stephen Mann, a GP in Stourbridge in the West Midlands, said the change could have a drastic impact on practice income, with the increased number of checks likely to hit uptake: 'You'll get patients who won't comply, won't turn up, won't want to be monitored.'

'GPs will have to jump through hoops, and if they miss one thing they'll fail.'

Dr Paul Conley, a GP in Bas-

### Which indicators could be bundled together?

#### BMI check

DM2 (1 point)

#### Checking HbA<sub>1c</sub> levels

No equivalent indicator currently in QOF

#### Retinal screening

DM21 (5 points)

#### Foot examinations

DM29 (4 points)

#### Measuring blood pressure

No equivalent indicator currently in QOF

#### Urinary albumin test

DM13 (3 points)

#### Creatinine test

DM22 (1 point)

#### Measuring cholesterol levels

No equivalent indicator currently in QOF

#### Recording smoking status

Smoking 5 (25 points)

Source: Department of Health

### Analysis

Dr Bill Beeby  
on the  
proposed  
QOF changes



[pulsetoday.co.uk/analysis](http://pulsetoday.co.uk/analysis)

### News

2 Treasury to force through pension reform

4 GPs denied dementia treatment alternatives

### Views

14 Editorial BMA chair must listen, then lead

16 Peverley Free at the point of abuse


17 Margaret McCartney Don't settle science in court

18 Opinion Telehealth shows enormous potential for the NHS

19 Letters Pathology variation down to poor practice

### Clinical

20 Key questions HIV



24 ENT clinic Otitis media

25 Ten top tips Bronchiectasis

26 Post-op problems GI surgery complications

### Business & Commissioning

32 Countdown to CQC registration The steps you need to take

35 Working with a charity How working with the third sector helped improve care for stroke

CPD in this issue: 2.5 hours

Earn CPD for our Key questions on HIV and article on post-operative problems

**SEMINAR**  
Diabetes and CVD  
Update 2012  
[pulse-seminars.com](http://pulse-seminars.com)



# The week in general practice

## INSIDE

GPs are being offered few alternatives to antipsychotic prescribing  
**page 4**

A PCT has warned CCGs they will inherit multimillion-pound deficits next April  
**page 9**



Children suffering maltreatment are being missed because of concerns over recording information, GPs have been told  
**page 10**

Framingham has 'no clinical utility' for predicting cardiovascular events, say researchers  
**page 12**

## MORE ONLINE

New NHS guidance has set out how CCGs should manage conflicts of interest  
[pulsetoday.co.uk/commissioning-news](http://pulsetoday.co.uk/commissioning-news)

**Download of the week**  
Read Dr Hamish Meldrum's farewell speech to the BMA  
[pulsetoday.co.uk/news-analysis](http://pulsetoday.co.uk/news-analysis)

**Video of the week**  
Watch Dr Peter Swinyard, chair of the Family Doctor Association, talk about where the profession goes next on pensions  
[pulsetoday.co.uk/videos](http://pulsetoday.co.uk/videos)



## PULSENEWS

# Treasury to force through reform of pensions

Controversial changes will be formally unveiled before BMA decides on further industrial action

## EXCLUSIVE

By Jaimie Kaffash

The Government is to push through its controversial reforms to GPs' pensions before the BMA has a chance to decide whether to take further industrial action, Pulse understands.

A source close to health secretary Andrew Lansley told Pulse the Treasury is set to formally announce the reforms before parliamentary recess in mid-July, ahead of the next meeting of BMA Council on 18 July, where it will decide what action to take next.

Mr Lansley last week wrote to Unison, which is co-ordinating the NHS staff side of the pensions negotiations, suggesting the overall package - which will lead to higher contributions

rent role until the age of 68.

The source told Pulse these issues would not need to be resolved before the Treasury announcement.

The news comes after a disappointing turnout for the BMA's day of action last month. Despite this, the BMA's Annual Representative Meeting passed motions last week calling on BMA Council to consider further industrial action including a boycott of the commissioning process, separate actions for different branches of practice and further days of action.

At the end of the conference in Bournemouth, BMA Council elected as its new chair Dr Mark Porter (see above). However, the meeting did not discuss whether to take further industrial action.

Immediately after his election, Dr Porter said he would seek an 'urgent meeting' with Mr Lansley to discuss pensions. But the Department of Health said any negotiations would have to be through the official trades union talks.

Rachael Maskell, the head of healthcare at Unite, said the Government was willing to discuss limited changes, but seemed determined to force through the major thrust of the reforms:

'The battle is never over until it is won'  
**Dr Peter Swinyard**



from GPs and a pension age of 68 - will be formalised imminently.

The Treasury announcement will end all talks on higher contribution rates for GPs post-2015, and a move to career-average revalued earnings for salaried NHS staff. Mr Lansley said there were two outstanding issues to resolve - the contribution rate for 2013 and 2014, and the arrangements for NHS staff who felt unable to sustain their cur-

# List cleansing

## EXCLUSIVE

By Madlen Davies

As many as one in three foreign nationals is being de-registered as part of increasingly tough list-cleansing drives, far exceeding projected numbers and raising fears that genuine patients may be left without a GP.

Figures obtained by Pulse show that many more patients have been removed than anticipated as part of PCTs' drive to wipe so-called 'ghost patients' from practice lists.

PCTs are scrambling to meet the Department of Health's target to identify and remove 2.5 million extra patients by next April.

But LMC leaders claimed the list validation exercises were removing genuine patients, and said the policy was discriminating against vulnerable patients who were unable to respond to letters or were confused by the process.

In Buckingham and Oxford-

shire, 32% of foreign nationals reviewed - some 18,400 patients - were removed from practice lists in 2011/12, despite initial projections suggesting just 10% of patients would be deregistered.

NHS Survey said it had removed more than a third of patients, including some foreign

**Proportion of patients removed from lists**

**34%**

NHS Survey

**32%**

NHS Buckinghamshire and Oxfordshire

**26%**

NHS Berkshire



**DEPO-MEDRONE®**

Methylprednisolone BP 4%

50+ years and still going strong



Working together for a healthier world

### Prescribing information

Depo-Medrone (Methylprednisolone) is available in 40 mg/ml, 80 mg/ml, 160 mg/ml, 320 mg/ml, 640 mg/ml, 1280 mg/ml, 2560 mg/ml, 5120 mg/ml, 10240 mg/ml, 20480 mg/ml, 40960 mg/ml, 81920 mg/ml, 163840 mg/ml, 327680 mg/ml, 655360 mg/ml, 1310720 mg/ml, 2621440 mg/ml, 5242880 mg/ml, 10485760 mg/ml, 20971520 mg/ml, 41943040 mg/ml, 83886080 mg/ml, 167772160 mg/ml, 335544320 mg/ml, 671088640 mg/ml, 1342177280 mg/ml, 2684354560 mg/ml, 5368709120 mg/ml, 10737418240 mg/ml, 21474836480 mg/ml, 42949672960 mg/ml, 85899345920 mg/ml, 171798691840 mg/ml, 343597383680 mg/ml, 687194767360 mg/ml, 1374389534720 mg/ml, 2748779069440 mg/ml, 5497558138880 mg/ml, 10995116277760 mg/ml, 21990232555520 mg/ml, 43980465111040 mg/ml, 87960930222080 mg/ml, 175921860444160 mg/ml, 351843720888320 mg/ml, 703687441776640 mg/ml, 1407374883553280 mg/ml, 2814749767106560 mg/ml, 5629499534213120 mg/ml, 11258999068426240 mg/ml, 22517998136852480 mg/ml, 45035996273704960 mg/ml, 90071992547409920 mg/ml, 180143985094819840 mg/ml, 360287970189639680 mg/ml, 720575940379279360 mg/ml, 1441151880758558720 mg/ml, 2882303761517117440 mg/ml, 5764607523034234880 mg/ml, 11529215046068469760 mg/ml, 23058430092136939520 mg/ml, 46116860184273879040 mg/ml, 92233720368547758080 mg/ml, 184467440737095516160 mg/ml, 368934881474191032320 mg/ml, 737869762948382064640 mg/ml, 1475739525896764129280 mg/ml, 2951479051793528258560 mg/ml, 5902958103587056517120 mg/ml, 11805916207174113034240 mg/ml, 23611832414348226068480 mg/ml, 47223664828696452136960 mg/ml, 94447329657392904273920 mg/ml, 188894659314785808547840 mg/ml, 377789318629571617095680 mg/ml, 755578637259143234191360 mg/ml, 1511157274518286468382720 mg/ml, 3022314549036572936765440 mg/ml, 6044629098073145873530880 mg/ml, 12089258196146291747061760 mg/ml, 24178516392292583494123520 mg/ml, 48357032784585166988247040 mg/ml, 96714065569170333976494080 mg/ml, 193428131138340667952988160 mg/ml, 386856262276681335905976320 mg/ml, 773712524553362671811952640 mg/ml, 1547425049106725343623905280 mg/ml, 3094850098213450687247810560 mg/ml, 6189700196426901374495621120 mg/ml, 12379400392853802748991242240 mg/ml, 24758800785707605497982484480 mg/ml, 49517601571415210995964968960 mg/ml, 99035203142830421991929937920 mg/ml, 198070406285660843983859875840 mg/ml, 396140812571321687967719751680 mg/ml, 792281625142643375935439503360 mg/ml, 1584563250285286751870879006720 mg/ml, 3169126500570573503741758013440 mg/ml, 6338253001141147007483516026880 mg/ml, 12676506002282294014967032053760 mg/ml, 25353012004564588029934064107520 mg/ml, 50706024009129176059868128215040 mg/ml, 101412048018258352119736256430080 mg/ml, 202824096036516704239472512860160 mg/ml, 405648192073033408478945025720320 mg/ml, 811296384146066816957890051440640 mg/ml, 1622592768292133633915780102881280 mg/ml, 3245185536584267267831560205762560 mg/ml, 6490371073168534535663120411525120 mg/ml, 12980742146337069071326240823050240 mg/ml, 25961484292674138142652481646100480 mg/ml, 51922968585348276285304963292200960 mg/ml, 103845937170696552570609926584401920 mg/ml, 207691874341393105141219853168803840 mg/ml, 415383748682786210282439706337607680 mg/ml, 830767497365572420564879412675215360 mg/ml, 1661534994731144841129758825350430720 mg/ml, 3323069989462289682259517650700861440 mg/ml, 6646139978924579364519035301401722880 mg/ml, 13292279957849158729038070602803445760 mg/ml, 26584559915698317458076141205606891520 mg/ml, 53169119831396634916152282411213783040 mg/ml, 106338239662793269832304564822427566080 mg/ml, 212676479325586539664609129644855132160 mg/ml, 425352958651173079329218259289710264320 mg/ml, 850705917302346158658436518579420528640 mg/ml, 1701411834604692317316873037158841057280 mg/ml, 3402823669209384634633746074317682114560 mg/ml, 6805647338418769269267492148635364229120 mg/ml, 13611294676837538538534984297270728458240 mg/ml, 2722258935367507707706996859454145691520 mg/ml, 5444517870735015415413993718908291383040 mg/ml, 10889035741470030830827987437816582766080 mg/ml, 21778071482940061661655974875633165532160 mg/ml, 43556142965880123323311949751266331064320 mg/ml, 87112285931760246646623899502532662128640 mg/ml, 174224571863520493293247799005065324257280 mg/ml, 348449143727040986586495598010130648514560 mg/ml, 696898287454081973172991196020261291029120 mg/ml, 1393796574908163946345982392040522582058240 mg/ml, 2787593149816327892691964784081045164116480 mg/ml, 5575186299632655785383929568162090328232960 mg/ml, 11150372599265311570767859136324180656465920 mg/ml, 22300745198530623141535718272648361312931840 mg/ml, 44601490397061246283071436545296722625863680 mg/ml, 89202980794122492566142873090593445251727360 mg/ml, 178405961588244985132285746181186890503454720 mg/ml, 356811923176489970264571492362373781006909440 mg/ml, 713623846352979940529142984724747562013818880 mg/ml, 1427247692705959881058285969449495124027637760 mg/ml, 2854495385411919762116571938898990248055275520 mg/ml, 5708990770823839524233143877797980496110551040 mg/ml, 11417981541647679048466287755595960992221102080 mg/ml, 22835963083295358096932575511191921984442204160 mg/ml, 45671926166590716193865151022383843968884408320 mg/ml, 91343852333181432387730302044767687937768816640 mg/ml, 182687704666362864775460604089535375875537633280 mg/ml, 365375409332725729550921208179070751751075266560 mg/ml, 730750818665451459101842416358141503502150533120 mg/ml, 1461501637330902918203684832716283007004301066240 mg/ml, 2923003274661805836407369665432566014008602132480 mg/ml, 5846006549323611672814739330865132028017204264960 mg/ml, 11692013098647223345629478661730264056034408529920 mg/ml, 23384026197294446691258957323460528112068817059840 mg/ml, 46768052394588893382517914646921056224137634119680 mg/ml, 93536104789177786765035829293842112448275268239360 mg/ml, 187072209578355573530071658587684224896550536478720 mg/ml, 374144419156711147060143317175368449793101072957440 mg/ml, 748288838313422294120286634350736899586202145914880 mg/ml, 1496577676626844588240573268701473799172404291829760 mg/ml, 2993155353253689176481146537402947598344808583659520 mg/ml, 5986310706507378352962293074805895196689617173319040 mg/ml, 11972621413014756705924586149611790393379234346638080 mg/ml, 23945242826029513411849172299223580786758468693276160 mg/ml, 47890485652059026823698344598447161573516937386552320 mg/ml, 95780971304118053647396689196894323147033874773104640 mg/ml, 191561942608236107294793378393788646294067749546209280 mg/ml, 383123885216472214589586756787577292588135499092418560 mg/ml, 766247770432944429179173513575154585176270998184837120 mg/ml, 1532495540865888858358347027150309170352541996369674240 mg/ml, 3064991081731777716716694054300618360705083992739348480 mg/ml, 6129982163463555433433388108601236721410167985478696960 mg/ml, 12259964326927110866866776217202473442820335970957393920 mg/ml, 24519928653854221733733552434404946885640671941914787840 mg/ml, 49039857307708443467467104868809893771281343883829575680 mg/ml, 98079714615416886934934209737619787542562687767659151360 mg/ml, 196159429230833773869868419475239575085125375535318302720 mg/ml, 392318858461667547739736838950479150170250751070636605440 mg/ml, 784637716923335095479473677900958300340501502141273210880 mg/ml, 1569275433846670190958947355801916600681003004282546421760 mg/ml, 3138550867693340381917894711603833201362006008565093043520 mg/ml, 6277101735386680763835789423207666402724012017130186087040 mg/ml, 12554203470773361527671578846415332805448024034260372174080 mg/ml, 25108406941546723055343157692830665610896048068520744348160 mg/ml, 50216813883093446110686315385661331221792096137041488696320 mg/ml, 100433627766186892221372630771322624443584192274082977361280 mg/ml, 200867255532373784442745261542645248887168384548165954722560 mg/ml, 401734511064747568885490523085290497774336769096331909445120 mg/ml, 803469022129495137770981046170580995548673538192663818890240 mg/ml, 1606938044258990275541962092341161991097347076385327637780480 mg/ml, 3213876088517980551083924184682323982194694152770655275560960 mg/ml, 6427752177035961102167848369364647964389388305541310551121920 mg/ml, 12855504354071922204335696738729295928778776611082621102243840 mg/ml, 25711008708143844408671393477458591857557553222165242204487680 mg/ml, 51422017416287688817342786954917183115115106444330484408975360 mg/ml, 102844034832575377634685573909834366230230212888660968817950720 mg/ml, 205688069665150755269371147819668732460460425777321937635901440 mg/ml, 411376139330301510538742295639337464920920851554643875271802880 mg/ml, 822752278660603021077484591278674929841841703109287750543605760 mg/ml, 1645504557321206042154969182557349859683683406218575501087215360 mg/ml, 3291009114642412084309938365114699719367366812437151002174430720 mg/ml, 6582018229284824168619876730229399438734733624874302004348861440 mg/ml, 131640364585696483372397534604587988774694672497486040086977280 mg/ml, 263280729171392966744795069209175977549389344994972080173954560 mg/ml, 526561458342785933489590138418351955098778689989944160347909120 mg/ml, 1053122916685571866979180276836703910197557379979888320695818240 mg/ml, 2106245833371143733958360553673407820395114759959776641391636480 mg/ml, 4212491666742287467916721107346815640790229519919553282783272960 mg/ml, 8424983333484574935833442214693631281580459039839106565566545920 mg/ml, 16849966666969149871666884429387262563160918079678213131133091840 mg/ml, 33699933333938299743333768858774525126321836159356426262266183680 mg/ml, 67399866667876599486667537717549050252643672318712852524532367360 mg/ml, 134799733335753198973335075435098100505287344637425705049064734720 mg/ml, 26959946667150639794667015087019620101057468927485141009812949440 mg/ml, 53919893334301279589334030174039240202114937854970282019625898880 mg/ml, 107839786668602559178668060348078480404229875709940564039251797760 mg/ml, 215679573337205118357336120696156960808459751419881128785003595520 mg/ml, 431359146674410236714672241392313921616911950279762257570007191040 mg/ml, 862718293348820473429344482784627843233823900559524515140014382080 mg/ml, 1725436586697640946858688965569255686467647801119049030280028764160 mg/ml, 345087317339528189371737793113851137293529560223809806056





## BMA elects new chair

The newly elected chair of the BMA, Dr Mark Porter, has warned doctors face a 'particularly challenging time' as the financial squeeze intensifies in the NHS.

The warning comes after Dr Porter was elected by BMA Council to replace GP Dr Hamish Meldrum as chair of the organisation. Dr Porter is a consultant anaesthetist at University Hospitals Coventry and Warwickshire NHS Trust, and was previously chair of the BMA's consultants committee.

Dr Porter said: 'I'm excited and privileged to be taking on this role at what is a particularly challenging time for the NHS and the medical profession.'

'The BMA will continue to work to help its members do the best for patients.'

▶ Editorial, page 14

## BMA: Lansley should resign

BMA representatives have defied their leadership in calling for the health secretary to resign in a vote of no confidence at the Annual Representative Meeting in Bournemouth.

The no confidence vote in Andrew Lansley was carried by 158 votes to 124, despite outgoing BMA chair Dr Hamish Meldrum calling on delegates to reject the motion.

Presenting the motion at the conference, Dr Gary Marlowe, a GP from Hackney, east London, said Mr Lansley's NHS and pension reforms meant he should no longer continue as health secretary.

He said: 'I've heard the argument that we cannot ask someone to resign if we have to negotiate with them tomorrow, but he doesn't listen. He sticks his

fingers in his ears. Trust lies at the heart of everything we do. I do not trust this man.'

However, Dr Meldrum said that it 'was not about one man' and the BMA should continue to campaign against policies, not personalities.

He warned it would be harder to negotiate with the Government if the conference passed the motion: 'I've got to negotiate with him, and it's awkward to say: "Here's your P45 - let's talk."'

'This wasn't about one man, there was a whole Government, a Liberal Democrat coalition, that supported it and others that helped it through.'

GPC negotiator Dr Peter Holden said: 'Resignation's too good for Lansley. Cameron should sack him.'

## Next steps in pensions battle

28 JUNE 2012	17 JULY 2012	18 JULY 2012	2015
BMA Council elects Dr Mark Porter as new chair	End of parliamentary term, by which time Treasury statement is expected	Next BMA Council meeting to discuss possible further action	Changes to NHS pensions due to be implemented

'Lansley is saying: "Sign a blank cheque and we will sort out the issues." That is unsatisfactory.'

Dr David Bailey, deputy chair of the BMA's pensions committee, said the total money available was still inadequate: 'This is not a change, because the DH clearly said the Treasury is not prepared to change on the total cost envelope. Our position remains that there was a cost-

sharing agreement reached in 2008, which said that the staff side will bear any future cost.'

Dr Peter Swinyard, chair of the Family Doctor Association, said: 'The battle is never over until it is won.'

**VIDEO**  
Dr Peter Swinyard discusses pensions action  
[pulsetoday.co.uk/videos](http://pulsetoday.co.uk/videos)



**TYPHARM**  
SPECIALIST SKIN CARE  
www.typharm.com

## For difficult-to-manage skin conditions, even in the most awkward positions

Wherever the problem is, however tricky, you can target it with Haelan Tape - on children and adults with inflammatory skin conditions like eczema and psoriasis.

Haelan Tape delivers a fixed dose of a moderately-potent topical steroid with a once-daily application.

It is self-adhesive, hypo-allergenic, not messy and waterproof.

For further information please call us on 01603 722480 or email [enquiries@typharm.com](mailto:enquiries@typharm.com)



Haelan Tape is a fixed dose, hydrocortisone, methylprednisolone that are applied to topical corticosteroids and particularly dry, scaling lesions. Please refer to the SmPC before prescribing, particularly relating to side effects, precautions and contra-indications. For further information contact us at Typharm Ltd, 140 Wellesley Road, Radmard Industrial Estate, Havant, Hants GU14 6UH. (UK) Date of Advertisements Preparation: March 2012. (H12/1283)

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Typharm Limited.

## busts targets

nationals, since April this year, with 363 of the 1,058 patients identified as possible 'ghost patients' taken off lists.

In Berkshire, 26% of the foreign nationals checked were de-registered, with 10,800 patients removed.

The Thames Valley Primary Care Agency, responsible for carrying out the drive, had projected a removal rate of just 10%.

Dr Paul Roblin, chief executive of Berkshire, Buckinghamshire and Oxfordshire LMCs, said patients whose first language is not English were being de-registered, and that students who remained in the area had been knocked off lists after letters were sent to student halls where they no longer lived.

Dr Roblin said: 'The DH sends down diktats that the local NHS has to follow, and there are unforeseen consequences.'

Dr Harry Yorall, medical secretary of Somerset LMC, told Pulse there were concerns in his area that members of the Polish and Portuguese communities

would not respond to letters sent out by the PCF: 'The formal letter is written in quite complex and bureaucratic English.'

Dr Marine Ullah, a GP in Maidenhead, Berkshire, claimed a number of current patients had been de-registered, and two such patients had left her practice as they were angry at their GP.

'Understandably, we're not very happy about this,' she said. 'Patients come back in quite angry with GPs. It reflects badly on the practice.'

A spokesperson for the Thames Valley Primary Care Agency said it worked 'closely' with GP practices 'to ensure the right people remain on lists'.

'Patients are written to and if they fail to respond within two months the practice has to show they are still registered and using services, or they are removed from the list after six months,' the spokesperson said.

▶ @maellendavies



# GPs denied dementia options

Limited fall in antipsychotic prescribing as investigation reveals patchy access to treatment alternatives

## EXCLUSIVE

By Pat Anderson


The Government's dementia drive has had little effect on antipsychotic prescribing, with GPs continuing to lack access to treatment alternatives, a Pulse investigation has found.

One in 10 PCTs does not commission any alternative dementia treatments for GPs to refer to, while in other areas waits can be up to six months.

Figures obtained by Pulse reveal that since the Government issued a call to reduce NHS prescribing of antipsychotics in dementia patients by two-thirds, there has been only a 16% reduction in GP prescribing of the drugs.

Prescribing figures extrapolated by healthcare market research agency Cegedim Strategic Data from 150 practices show an estimated 43,584 patients with a dementia diagnosis received a GP prescription for an antipsychotic in May.

This is a reduction from a peak of 55,616 patients taking



Antipsychotic prescribing has fallen, but not to target levels

the drugs in March 2009. But since November 2010, when the Government set its target of reducing prescribing by two-thirds, the fall has been just 16% in primary care.

As part of the 'Prime Minister's challenge on dementia', launched last year, GPs were asked to review all patients on antipsychotics and explore NICE-approved alternatives, such as aromatherapy, multisensory stimulation or massage.


But a Pulse survey of 82 PCTs in England shows 11% do not commission any alternative therapies.

Of those who do, only 13% allow GP referrals and waiting times ranged from three weeks to six months.

Responding to Pulse's investigation, RCGP chair Dr Clare Gerada said although GPs should be cutting down on antipsychotic use, it was essential the provision of memory clinics and community psychiatric services was expanded.

She said: 'We are going to end up with patients, families and carers without support, and

## GP antipsychotic prescribing



that's the worst possible scenario.'

Professor Steve Iliffe, a GP in north-west London and professor of primary care for older people at University College London, said GPs were often faced with an urgent situation as the ability of care home staff and carers at home to deal with behavioural problems was 'limited', and added: 'It makes no sense to say "stop using this

treatment" if alternatives are not available.'

Dr Simon Ruffe, a GP in Twyford, Berkshire, said: 'Some [patients] are terrified, see things and smear faeces on the wall - we are supposed to stand back and allow this?'

A spokesperson for the DH said it remained committed to reducing inappropriate prescribing.

feedback@pulsetoday.co.uk

## ANALYSIS

### The whole system needs to change



**Nigel Praetis**  
Acting deputy editor

A call to reduce the prescribing of any drug in the NHS by two-thirds is ambitious, but the case for doing this with antipsychotics in dementia is overwhelming.

Study after study has shown a substantially raised risk of mortality in dementia patients taking the drugs, and in a report published in 2009 the drugs were linked with an extra 1,800 deaths a year in the NHS.

On the back of this, the Government issued an

immediate review of care home prescribing, and followed this up with a 'call to action' in 2010 and the 'Prime Minister's challenge on dementia' last year to ensure all patients were reviewed and alternatives to antipsychotics were considered.

A health minister even made a threat of legal action under the Mental Capacity Act for prescribers who did not seek special permission to use the drugs.

Has all of this activity made a difference? Our investigation shows levels of antipsychotic prescribing by GPs are coming down slowly, which should be welcomed, but the overall rate

remains relatively high.

Speak to GPs and they will tell you the system is struggling to cope. Care homes and carers have very little capacity to handle aggression in a patient with dementia. GPs are often called only when the situation is urgent and, as our investigation reveals, their access to alternative treatments is, at best, patchy.

Antipsychotic prescribing in dementia is a rare example of experts, NICE, ministers and GP leaders agreeing what needs to be done. But institutional barriers continue to prevent the rapid improvement everyone wants to see.

## GPs hit by benefits overhaul

The GPC has complained to the Government over its drive to reassess everyone on incapacity benefit, warning practices are facing rising numbers of patients requesting 'fit notes' while their cases are reviewed.

The move comes as BMA leaders voted to scrap the Work Capability Assessment scheme, which they said 'has little regard for the nature or complexity of the needs of the long-term sick and disabled'.

Dr Deborah Colvin, chair of City and Hackney LMC, said each of the 10 GPs at her practice now sees three to four patients a week requesting a sick note while they appeal the decision to withdraw

their benefits, when it used to be an occasional occurrence: 'I can't bear seeing patients with major disabilities being told they can go to work when there are no jobs to be had. What do [the

**I can't bear seeing disabled patients being told they can go to work**

Dr Deborah Colvin

Department for Work and Pensions) expect us to do? Are we supposed to leave people with nothing?'

Dr John Canning, chair of the

GPC's Professional Fees Committee, said he had raised the rise in fit note requests with the DWP: 'The DWP have undertaken to address the issue. I will not let this rest.'

The BMA's Annual Representative Meeting in Bournemouth last week voted for the scheme to be replaced with a 'rigorous and safe' system that 'does not cause unavoidable harm' to the weakest in society.

A DWP spokesperson said: 'GPs should only issue a fit note if a patient has a health condition that impacts on their fitness for work, whether they are appealing any DWP decision or not.'

## For Seasonal & Perennial Allergic Rhinitis

# rhinolast®

azelastine hydrochloride 0.1%

A fast acting nasal spray that delivers symptom relief within 15 minutes



Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Meda Pharmaceuticals Ltd.

Prescribers are recommended to consult the summary of product characteristics before prescribing, particularly in relation to side-effects, precautions and contraindications. Legal category: POM. Further information is available from the Marketing Authorisation Holder: Meda Pharmaceuticals Ltd, Skyway House, Pennington Road, Tulseke, Bishop's Cleeve CM22 6PU.

**MEDA**



# Calm skin. Peaceful night.

Applied regularly, the patient friendly formula of Diprobaze will hydrate, soothe and calm eczematous skin<sup>1</sup>, helping to reduce night-time itching and scratching.



## Diprobaze Prescribing Information

**Uses:** Diprobaze Cream and Ointment are emollients, with moisturising and protective properties, indicated for follow-up treatment with topical steroids or in spacing such treatments. They may also be used as diluents for topical steroids. Diprobaze products are recommended for the symptomatic relief of red, inflamed, damaged, dry or chapped skin, the protection of raw skin areas and as a pre-bathing emollient for dry/eczematous skin to alleviate drying effects. **Dosage:** The cream or ointment should be thinly applied to cover the affected area completely, massaging gently and thoroughly into the skin. Frequency of application should be established by the physician. Generally, Diprobaze Cream and Ointment can be used as often as required.

Please refer to the full SPC text before prescribing this product.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to MSD Pharmacovigilance UK on +44 (0)1992 467272.

Code: C09/14 DERM-1032326-0001. Date of preparation: March 2012. Reference: 1. Diprobaze SPC. © Merck Sharp & Dohme Limited, 2012. All rights reserved.

**Contra-indications:** Hypersensitivity to any of the ingredients. **Side-effects:** Skin reactions including pruritus, rash, erythema, skin exfoliation, burning sensation, hypersensitivity, pain, dry skin and bullous dermatitis have been reported with product use. **Package Quantities:** Cream: 50g tubes, 500g pump dispensers; Ointment: 50g tubes, 500g jar. **Basic NHS Costs:** Cream: £1.28 (50g), £5.32 (500g); Ointment: £1.28 (50g), £5.99 (500g). **Legal Category:** GSL. **Marketing Authorisation Numbers:** Cream: PL 000250575; Ointment: PL 000250574. **Marketing Authorisation Holder:** Merck Sharp & Dohme Limited, Hertford Road, Huddersfield, Hertfordshire, BA11 9BU, UK. **Date of Revision:** February 2012.



## Diprobaze®

Emollient

Tried. Trusted. Diprotected.



[www.diprobaze.co.uk](http://www.diprobaze.co.uk)



# Cancer drive 'has no impact on diagnoses'

Pilots of DH awareness campaign find no significant rise in detections

By Emma Wilkinson

A major Department of Health publicity campaign urging patients to see their GP earlier if they have symptoms of breast, lung or bowel cancer is unlikely

to have any significant impact on the number of cancer referrals or diagnoses, official figures suggest.

A DH evaluation reveals its £9m national awareness campaign was based on pilots

that showed no significant increase in the numbers of cancers detected, compared with areas where there was no campaign.

The 'Be Clear on Cancer' awareness campaign was

launched by the DH in January, and includes adverts running on billboards, buses and in local newspapers urging patients to present to their GP if they have symptoms including a cough lasting three weeks or 'loose poo', but has been criticised by some cancer leads as unhelpful.

Data from pilots taking place in 76 PCTs in 2010/11 showed a non-significant 9% increase in two-week wait referrals for lung cancer, compared with a 7% rise in referrals over the same period in 73 'control' areas where the publicity campaign was not run.

With bowel cancer, there was a non-significant 16% rise in the 77 PCTs with local awareness campaigns, compared with a 13% rise in the 74 control areas.

The awareness campaigns also had no significant effect on the number of cancers detected.

There was a 6% rise in bowel cancers and a 4% rise in lung cancers detected in areas with the awareness campaign, but these were not statistically significant increases compared




The campaign had little effect on bowel cancer referrals

Xarelto®

## One tablet, once daily, simple.

NOW  
RECOMMENDED BY  
NICE<sup>1</sup>



**Xarelto®: Oral anticoagulation for the prevention of stroke and systemic embolism in eligible adult patients with non-valvular atrial fibrillation**

For further information on this NICE guidance please visit:  
<http://guidance.nice.org.uk/TA256/Guidance/pdf/English>



1. National Institute for Health and Clinical Excellence. Technology appraisal guidance 256. May 2012.

**Xarelto® 15 and 20mg film-coated tablets (rivaroxaban)** Prescribing information (Refer to full Summary of Product Characteristics (SmPC) before prescribing) Presentation: 15mg tablet: Red, round, biconvex film-coated tablets containing 15mg rivaroxaban. 20mg tablet: Brown-red, round, biconvex film-coated tablets containing 20mg rivaroxaban. Indication: Prevention of stroke & systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors such as congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischaemic attack. Parology & method of administration: Dosage: 20mg orally od with food. Continue therapy long term provided benefit of prevention of stroke & systemic embolism outweighs risk of bleeding. Refer to SmPC for information on converting to/from Vitamin K antagonists (VKA) or parenteral anticoagulants. Renal impairment: mild (creatinine clearance 30-49ml/min) - no dose adjustment necessary; moderate (creatinine clearance 15-29ml/min) - reduce dose to 15mg od; severe (creatinine clearance <15ml/min) - limited data indicates rivaroxaban plasma concentrations are significantly increased, reduce dose to 15mg od & use with caution. Patients with creatinine clearance <15ml/min - use not recommended. Hepatic impairment: Do not use in patients with hepatic disease associated with coagulopathy & clinically relevant bleeding risk (including cirrhotic patients with Child Pugh B & C patients). Elderly: Body weight & gender: No dose adjustment. Renal/hepatic: Not recommended below 18 years of age. Contra-indications: Hypersensitivity to active substance or any excipient; difficulty significant active bleeding; hepatic disease associated with coagulopathy & clinically relevant bleeding risk (including cirrhotic patients with Child Pugh B & C); pregnancy &

breast feeding. Warnings & precautions: Clinical surveillance in line with anticoagulant practice is recommended throughout the treatment period. Instability/mucosal bleeding & anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment - haemoglobin/haematocrit testing may be of value to detect occult bleeding. Following sub-groups of patients are at increased risk of bleeding & should be carefully monitored after treatment initiation. Use with caution - in patients with severe renal impairment (creatinine clearance 15-29ml/min) or in patients with renal impairment concomitantly receiving other medicines that are potent inhibitors of CYP3A4 (PK models show increased rivaroxaban concentrations in these patients); in patients treated concomitantly with medicines affecting haemostasis; in patients with an increased bleeding risk such as congenital or acquired bleeding disorders, uncontrolled severe arterial hypertension, active ulcerative gastrointestinal disease (consider appropriate prophylactic treatment for at risk patients), recent gastrointestinal ulcerations, vascular retinopathy; recent intracranial or intracerebral haemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain / spinal / ophthalmological surgery, brachytherapy or history of pulmonary bleeding. Use is not recommended in patients with creatinine clearance <15ml/min; receiving concomitant systemic treatment with azole-antimycotics or HIV protease inhibitors; with prosthetic heart valves; for treatment of acute pulmonary embolism. If invasive procedures or surgical intervention are required, stop Xarelto use at least 24 hours beforehand. Restart use as soon as possible provided adequate haemostasis has been established. See SmPC for full details. Xarelto contains lactose. Interactions: Concomitant use with strong inhibitors of both CYP3A4 & P-gp

(e.g. ketoconazole, itraconazole, voriconazole, posaconazole, rifampin) is not recommended as increased rivaroxaban plasma concentrations to a clinically relevant degree are observed (may increase risk of bleeding). Avoid co-administration with dronedarone. Use with caution in patients concomitantly receiving other anticoagulants (e.g. enoxaparin), NSAIDs (including acetylsalicylic acid) or platelet aggregation inhibitors due to the increased bleeding risk. Strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) should be used concomitantly with caution as they may reduce rivaroxaban plasma concentrations. Pregnancy & breast feeding: Contra-indicated. Effects on ability to drive and use machines: Adverse reactions like syncope & dizziness are common. Patients experiencing these effects should not drive or use machines. Undesirable effects: Common: anaemia, dizziness, headache, syncope, eye haemorrhage, tachycardia, hypotension, haematoma, epistaxis, GI tract haemorrhage, GI & abdominal pain, dyspepsia, nausea, constipation, diarrhoea, vomiting, pruritus, rash, ecchymosis, pain in extremity, urogenital tract haemorrhage, fever, peripheral oedema, decreased general strength & energy, increase in transaminases, post-procedural haemorrhage, confusion. Uncommon: thrombocytopenia, allergic reaction, allergic dermatitis, cerebral & intracranial haemorrhage, haemoptysis, dry mouth, abnormal hepatic function, urticaria, cutaneous & subcutaneous haemorrhage, haemarthrosis, renal impairment, feeling unwell, localised oedema, increased bilirubin, blood alkaline phosphatase, LDH, lipase, amylase, GGT, wound secretion. Rare: jaundice, muscle haemorrhage, increased conjugated bilirubin. Frequency not known: pseudoaneurysm formation following percutaneous intervention, compartment syndrome secondary to a bleeding,

renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion. Occult or overt bleeding from any tissue or organ which may result in post-haemorrhagic anaemia and complications with variable severity (including fatal outcome). Prescribers should consult SmPC in relation to full side effect information. Overdose: Rare cases of overdose up to 600mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect is expected at supratherapeutic doses of 50mg rivaroxaban or above. No specific antidote is available. Use of activated charcoal to reduce absorption may be considered. For management of bleeding complication associated with rivaroxaban please refer to the SmPC. Legal Category: POM. Package Quantities and Basic NHS Costs: 15mg - 28 tablets: £58.80, 42 tablets: £88.20, 100 tablets: £210.00; 20mg - 28 tablets: £58.80, 100 tablets: £210.00. MA Number(s): EUP108472011-21. Further information available from: Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire RG14 1JA, U.K. Telephone: 01635 563500. Date of preparation: November 2011.

Xarelto® is a trademark of the Bayer Group.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Bayer plc. Tel: 01635 563500, Fax: 01635 563703, Email: [phds@bayer.co.uk](mailto:phds@bayer.co.uk)

### Does the cancer campaign work?

#### Lung cancer

● Non-significant 4% rise in cancer diagnoses in campaign areas, compared with a 1% rise in control areas.

#### Bowel cancer

● Non-significant 6% rise in cancer diagnoses in campaign areas, compared with a 0.6% rise in control areas.

with control areas. Figures for the breast cancer awareness campaign were not calculated.

The report concluded: 'The data appear to show no significant impact on the number of cancers diagnosed via the two-week wait or the percentage conversions.'

Dr Kiran Singh, GP cancer lead for NHS Warwickshire - one of the areas that trialled the publicity campaign - said: 'I am surprised it didn't make a difference [to cancer referrals]. The general feeling among clinicians is that we do see an increase after such campaigns.'

But Dr Dermot Ryan, a GPST in endoscopy in Loughborough, Leicestershire, said: 'I have patients who are referred with absolutely no likelihood of cancer, and all it does is clog up the two-week wait.'

A DH spokesperson said: 'This initial evaluation is from only the first year of the programme, and we have always anticipated that full impact will be seen after a few years.'

[feedback@pulsetoday.co.uk](mailto:feedback@pulsetoday.co.uk)

UK: RH-GMA-XAR 2012.0256 June 2012


Bayer HealthCare

© Bayer HealthCare BPH

First in ORAL Direct Factor Xa Inhibition

**Xarelto**  
rivaroxaban  
Simple, proven, predictable anticoagulation





**Simplify the data.  
Complete the picture.**

**Bayer's new CONTOUR® NEXT USB meter helps patients organise their diabetes information quickly and easily**

- Captures blood glucose results, with optional carbohydrate and insulin logging, for a more complete picture of control
- Helps patients make the connection between actions and results, for better self-management
- No set-up requirements – easy-to-use and learn, and easy for you to teach
- Data is simple to see and share, directly on the meter, or plugged into any computer
- Uses Bayer's new CONTOUR® NEXT test strip to deliver advanced accuracy<sup>1</sup>



**High-performance accuracy and precision**  
– "Second chance" technology allows blood to be reapplied to the same test strip, if necessary



**Contour  
next**  
Blood Glucose Test Strips

**Speak to your Bayer representative to find out more**

Reference: 1. Harrison B, Schachner HC, Brown D. Accurate assessment of the blood glucose meter CONTOUR® NEXT USB. Poster presented at: Annual Meeting of the German Diabetes Association; May 16-19, 2012; Stuttgart, Germany (n=600). Bayer, the Bayer cross, CONTOUR, No Coding, and simplewins are trademarks of Bayer. © 2012 Bayer plc. All rights reserved. 06/12 V1 0612NUSBAD



**Contour  
next** **USB**  
Blood Glucose  
Monitoring System





A world of knowledge about allergy **MEDA**

**MEDA is one of the fastest growing Pharmaceutical companies in the world, with a global presence in over 120 countries and a current UK portfolio of over 70 products.**

With a team of dedicated specialists, we are committed to supporting healthcare professionals and patients in the treatment of allergy - now and for years to come.

**So as you can see we are covering a lot of ground.**



**Yorkshire GPs told to expect £19m debt despite ministers' assurances**
**DEBTS**

# PCT warns CCGs they will inherit deficits

By Gareth Iacobucci

NHS managers have admitted GP commissioners will inherit multimillion-pound PCT deficits from next April - despite repeated assurances from ministers that 'no legacy debts' will be passed on to CCGs.

NHS North Yorkshire and York said it had notified the Department of Health of its intention to pass on £19m debt to CCGs from next April because of the 'significant financial challenges' facing the PCT.

The disclosure comes despite ministers continuing to insist that debts will not be passed on to CCGs - a key demand of Pulse's *A Clean Slate* campaign last year.

Health secretary Andrew Lansley told CCG leaders at the Commissioning Show in London last week: 'As we have said before, we are still intending for CCGs to start in April 2013 with no legacy debts. It won't be true in the provider sector - it will be true for you as commissioners.'

NHS North Yorkshire and York, which will be superseded by four CCGs from next April, warned in its latest financial board report that it risked 'running out of money' this year.

The report said: 'We have formally notified the DH of our



Dr Vicky Pleydell: this year there will be no bail-out

projected deficit (overspend) of £19m for 2012/13.

'This means that on our current projections, we do not believe we will be able to meet our statutory duty to break even in financial terms.'

The report added: 'Without significant changes to patterns of expenditure, NHS commissioners in North Yorkshire and York risk running out of money this year.'

'This means they will be unable to pay providers for services to patients, which in turn means providers will be forced to take drastic actions in order to cut their costs. This kind of unplanned cost-cutting must be avoided.'

Dr Vicky Pleydell, a GP in Catterick, North Yorkshire, and shadow accountable officer for Hambleton, Richmondshire and Whitby CCG, said there was 'no

easy solution' to the historical financial problem.

Writing on her personal blog, Dr Pleydell said: 'The financial problem has been there for years and years, but in the past it has been temporarily sorted with loans from the SHA and made up of money from other PCTs who have underspent. This year there is no bail out and so we will probably finish the year in deficit too.'

Dr Pleydell said the CCG would need to 're-engineer our system' to tackle the deficit, by shifting more care into the community.

'That means fewer beds in hospital and the money that used to pay for those beds can be used to employ community staff,' she said.

A DH spokesperson confirmed CCGs would inherit any debts incurred during 2011/12 and 2012/13, adding: 'The NHS is delivering excellent results for patients, but we know that a small number of organisations have financial problems.'

@garethiacobucci

**NAPC 2012**  
 Hear how to develop a good working relationship with your CCG  
[napcannual.co.uk](http://napcannual.co.uk)

## RECONFIGURATION

### CCG leaders back major hospital re-jig

CCG leaders have lent their backing to one of the largest reconfigurations of hospital services to date, in a move that will radically reshape NHS services for two million patients.

NHS North West London this week revealed details of its *Shaping a healthier future* consultation, which proposes closing three A&E units in a bid to tackle both financial and clinical challenges.

The plans have received back-

ing from acute providers and all eight CCGs in north-west London, who said the changes were necessary.

NHS chief executive Sir David Nicholson last month cited the plans as a blueprint for CCGs looking to reconfigure services, in his keynote speech at the NHS Confederation conference.

The preferred option outlined in the consultation, which will run for 14 weeks, would close A&E departments at Ealing, Charing

Cross and Central Middlesex hospitals, and consolidate services into five major hospitals.

Dr Ruth O'Hare, chair of Central London CCG, said it supported the consultation: 'The CCG will take forward the resulting plans given adequate resources.'

**DOWNLOAD**  
 Read the full consultation  
[pulsetoday.co.uk/downloads](http://pulsetoday.co.uk/downloads)

## AQP

### LES competition welcomed

Private companies have welcomed the drive to open up local enhanced service funding under any qualified provider.

Last week the NHS Commissioning Board urged CCGs to remove some LESs from practices and commission 'wraparound' community services.

Leading private providers told Pulse they were keen to take advantage of the more competitive market. Dr Jeremy Rose, clinical director of the Practice Plc, said it was preparing to take on more primary care services: 'CCGs should be commissioning on behalf of patients, not member GPs.' Care UK said it was 'working to understand the needs and priorities of local commissioners', while Virgin Care said: 'Where we think services can make a difference to health outcomes and improve patient experience, we'll take a look.'

But Dr Simon Poole, deputy chair of the GPC's commissioning and service development subcommittee, warned CCGs to ensure services were not fragmented.

## REFERRALS

### Consultants 'educate' GPs on referrals

GP commissioners are planning to bring in hospital consultants to 'educate' practices and troubleshoot spiralling outpatient referral rates.

CCGs in Buckinghamshire decided to take action in May following data suggesting that GP outpatient referrals were 7% above the planned level and 8% above the same period last year.

They are now collaborating with local consultants to identify specialties where unnecessary hospital follow-up appointments are taking place

and to provide feedback to GPs on referrals. The work will focus on areas with high levels of follow-up appointments, such as haematology and trauma.

Board papers from NHS Buckinghamshire and Oxfordshire



'Anything that improves the efficiency of the system is beneficial'  
 Dr Prit Buttar

Cluster said: 'There is an ongoing consultant-led programme of education designed to stimulate change.'

A spokesperson for NHS Buckinghamshire and Oxfordshire Cluster said the move came after Aylesbury Vale CCG and Chiltern CCG took responsibility for £20.6m of QIPP efficiency savings.

Dr Prit Buttar, chair of Oxfordshire LMC, said: 'Anything that improves the efficiency of the system and improves care for patients is beneficial.'



## BAYER DIABETES CARE PRODUCT COMPATIBILITY CHART from 18 June 2012

### The next-generation of Bayer's CONTOUR® family

For Bayer's CONTOUR® XT and CONTOUR® NEXT USB meters, please prescribe new CONTOUR® NEXT test strips only.

Bayer's CONTOUR® XT and CONTOUR® NEXT USB meters are not compatible with original CONTOUR® test strips.



To find out more about Bayer's next-generation CONTOUR® family, [speak to your Bayer representative today, or call 01635 566381](http://www.bayer.co.uk/diabetes).



Reprint: The Bayer Group, 2011. CONTOUR, CONTOUR XT and CONTOUR NEXT are trademarks of Bayer. © 2012 Bayer plc. All rights reserved. 06/12 V1 761200 MFW/8



# Child maltreatment 'not coded'

Study recommends GPs use 'non-stigmatising' codes to record niggling concerns over child maltreatment

By Emma Wilkinson

Children suffering maltreatment may be missed due to concerns over recording information that relates to other family members in GP notes, an RCGP-funded study has warned.

The analysis found low levels of recording child maltreatment among GPs and recommended non-stigmatising codes indicating a 'cause for concern' should be used more widely.

The study comes just two weeks before the launch of new

GMC guidance on child protection, which is expected to say that every doctor has a responsibility to protect children, including if they are treating parents for a condition that could affect their ability to care for a child, and should record even minor concerns.

Analysis of the THIN database of 876,000 children showed eight in every 1,000 children were assigned a maltreatment-related code each year - much lower than the expected rate of 47 per 1,000 suggested by epi-



A study has found low levels of GPs recording maltreatment

demological studies. In a further detailed analysis of data from 11 practices - published in the July issue of the *British Journal of General Practice* - 25 children had known maltreatment, but six had no maltreatment-related codes recorded in their notes. GPs instead often wrote worries in free text or attached other documents.

In a series of interviews with a GP from each practice, researchers found GPs were wary of coding concerns because of worries about potential harm to the child or parents from seeing documented concerns, fears over recording third-party information in a child's notes and uncertainty over which codes to use.

The researchers concluded that although primary care would not know of every case, GPs should record any niggling concerns using 'non-stigmatising' codes (see box, above).

Dr Janice Allister, a GP in Peterborough and co-author of the study, said recording third-party information was allowed in Cal-

## What codes should GPs use?

**131F Child is cause for concern**  
**8C05 Child in need**  
**131F.11 Vulnerable child**  
**63CA.1w Mother not managing well**  
**ZV61300 Other parent-child problems**

Sources: *Br J Gen Pract* 2012, online 25 June

dicott information governance guidelines, but GPs tended to feel 'very under-confident' about it: 'The main thing is to flag up "child is a cause for concern", but you need to have that discussion with the parent or carer.'

Dr Brian Balmer, chief executive of Essex LMCs and a GP in Chelmsford, welcomed the recommendations and said: 'We take this very seriously and would certainly welcome any guidance from the GMC or the college.'

feedback@pulsetoday.co.uk

## What's inside?



Activia is a probiotic yogurt containing the exclusive probiotic strain *Bifidobacterium lactis* DN-173 010. Activia has been researched for more than 15 years with 17 publications of clinical studies. Studies have shown Activia may help reduce IBS-related digestive discomfort including bloating\* and distension\*, and improve GI well-being in women reporting minor digestive disorders.\* NICE guidelines state, "There is fair evidence to show that some probiotics (single or combination) give a significantly greater improvement in global symptoms of IBS than placebo\*\* and Map of Medicine states, "Some specific strains, such as *Bifidobacterium lactis* DN-173 010... have clinical trial evidence of efficacy for bloating (and) distension".†



Review the published evidence at [www.probioticsinpractice.co.uk](http://www.probioticsinpractice.co.uk)  
Information for Healthcare Professionals.



## ANALYSIS

### GPs must record concerns



This is not about criticising GPs. Quietly, behind the scenes, we do an enormous amount of work to support families. But what we have to do now is say we are doing it.

GPs often see multiple family members and can detect stressors - such as violence, parental depression and drug or alcohol abuse - that put children at risk of maltreatment. We hold the continuous health record and are a key resource for sharing information about maltreatment-related concerns.

Yet, from our research, we found GPs have worries about writing something in the notes that could cause argument or offence later on. GPs do sometimes feel

under-confident about the legal aspects of recording information about third parties in records, but this is covered by the Caldicott guidelines on information governance. New GMC guidance will be published next month and will address the ethical questions over this. The key thing is to develop a relationship with the patient to keep them engaged with services and get them the help they need.

It is about a balance of benefit and harm, and feeling confident in saying to a parent or carer: 'We will do all we can to support you and your family - what arrangements shall we make to check how you (and the child or young person) are getting on?'

**Dr Janice Allister is the RCGP clinical champion for child health and a GP in Peterborough**

## IN BRIEF

### NHS change urged

Sir David Nicholson has warned the NHS is 'not delivering' on service change.

Full story ▶ [pulsetoday.co.uk/commissioning-news](http://pulsetoday.co.uk/commissioning-news)

### CCGs not GPs' 'creatures'

The NHS reforms are being driven from the top, the GPC has claimed.

Full story ▶ [pulsetoday.co.uk/commissioning-news](http://pulsetoday.co.uk/commissioning-news)

### Anti-NHS reforms party

A new political party will field 50 candidates to campaign against the NHS reforms.

Full story ▶ [pulsetoday.co.uk/politicalnews](http://pulsetoday.co.uk/politicalnews)

References: 1. Dapunt D et al. *Aliment Pharmacol Ther* 2002;26:475-480. 2. Agovino A et al. *Aliment Pharmacol Ther* 2009;29:104-114. 3. Baxevier D et al. *Br J Nutr* 2008;103(11):1554-1562. 4. Mabea G. Collaborative Centre for Nausea and Vomiting (CCNV) on behalf of the National Institute for Health and Clinical Excellence (NICE). Irritable bowel syndrome in adults: Diagnosis and management of irritable bowel syndrome in primary care (2005). 5. Contributors representing the Royal College of Physicians. 2011. Available online at: [http://www.rcp.ac.uk/evidence/ibc/ibc\\_evidence/ibc\\_evidence\\_low\\_download\\_box\\_2.html](http://www.rcp.ac.uk/evidence/ibc/ibc_evidence/ibc_evidence_low_download_box_2.html) (accessed April 2012). \*Based on studies using two pots consumed daily. Enjoy as part of a healthy diet and lifestyle. Bloating and distension are part of digestive discomfort. ACTV034 May 2012.



# ONCE-DAILY ONBREZ BREEZHALER FOR COPD PATIENTS WHO REMAIN SHORT OF BREATH DESPITE SHORT-ACTING THERAPIES



## ONCE-DAILY ONBREZ BREEZHALER HELPS TO:

- RELIEVE YOUR PATIENTS' SHORTNESS OF BREATH<sup>1,2</sup>
- REDUCE YOUR PATIENTS' USE OF RELIEVER MEDICATION<sup>1,2</sup>
- IMPROVE YOUR PATIENTS' QUALITY OF LIFE<sup>2,3</sup>

VISIT [WWW.ONBREZ.CO.UK](http://WWW.ONBREZ.CO.UK) TO FIND OUT MORE

ONBREZ BREEZHALER IS INDICATED FOR MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN ADULT PATIENTS WITH COPD<sup>4</sup>. ONBREZ BREEZHALER SHOULD NOT BE USED IN ASTHMA DUE TO THE ABSENCE OF LONG-TERM OUTCOME DATA IN ASTHMA WITH ONBREZ BREEZHALER<sup>4</sup>. THE RECOMMENDED DOSE IS THE INHALATION OF THE CONTENT OF ONE 150µg CAPSULE ONCE A DAY, USING THE ONBREZ BREEZHALER INHALER. THE DOSE SHOULD ONLY BE INCREASED ON MEDICAL ADVICE<sup>4</sup>.

#### References:

1. Donohue JF, et al. *Am J Respir Crit Care Med* 2010;**182**:155-162.
2. Buhl R, et al. *Eur Respir J* 2011;**38**:797-803.
3. Yorgancıoğlu A, et al. Poster presentation at European Respiratory Society Annual Congress, Vienna, September 2009.
4. Onbrez Breezhaler, Summary of Product Characteristics, July 2011.



## Concerns over older risk score suggest GPs should switch to QRISK2

CVD

Framingham has  
'no clinical utility'

By David Swan

GPs should no longer use the Framingham risk score to assess patients for statin treatment, as the algorithm has 'no clinical utility' compared with the latest version of QRISK, according to researchers.

The damning conclusions of the study provide solid evidence for GPs to switch to use of the QRISK2 equation, as it identified up to five more cases per 1,000 patients than Framingham.

Current NICE guidance leaves it open to GPs to decide which cardiovascular risk score they wish to use - either a modified version of Framingham or QRISK2.

UK researchers looked at over two million patients, aged between 30 and 74 years and with no previous diagnosis of cardiovascular disease, recorded on The Health Improvement Network (THIN) database. Each patient's first diagnosis of cardiovascular disease was recorded in the five-year follow-up.

The independent analysis found the 2011 version of QRISK2 identified five more cases of pa-



Framingham should be updated for UK patients

tients at high risk of cardiovascular disease per 1,000 in males, compared with the NICE version of the Framingham equation. For women, QRISK2 identified two more cases of patients at high risk per 1,000.

This suggested an increased accuracy in estimating cardio-

vascular risk in UK patients, and did not come with any significant increase in the number of patients treated unnecessarily.

When predicted risk was compared with observed risk, QRISK2 showed good agreement across all age groups.

But Framingham showed a

near-constant over-prediction of around 5% across all age groups in men. Figures were not calculated for women.

The authors, from the University of Oxford, concluded: 'If the Framingham equation is to continue to be used and doctors advised to treat patients if their predicted risk is 20% or higher, it is necessary for it to be recalibrated and updated.'

Dr John Ashcroft, a GP in Derbyshire and member of the Derbyshire CHD committee, said a switch to QRISK2 would be a wise choice: 'It includes risk factors that are important and often overlooked or difficult to factor in, including family history and atrial fibrillation.'

But he added it may have implications for the NICE threshold for primary prevention, currently set at a 20% 10-year risk of CVD, which may be set too high.

BMJ 2012, online 21 June  
david.swan@pulsetoday.co.uk

**SEMINAR**  
Diabetes and CVD  
Update 2012  
pulse-seminars.com

## CANCER

GPs told not to rely on  
'red flags' in child cancer

GPs should not rely on 'red flag' symptoms for cancer in children as only one in five cases will present with them, according to Danish researchers.

The retrospective analysis used data from GP questionnaires looking at the symptoms in children who had subsequently been diagnosed with cancer. Of the 315 children whose symptoms were included in the study, only 20% had symptoms that were interpreted by

GPs as red flags, such as weight loss, or a lump or swelling.

The proportion of red flags was highest in those with leukaemia, at 44%, and lowest in those with bone tumours, at 6%. There was also evidence that red-flag symptoms increased in frequency as children got older.

The authors, from Aarhus University, Denmark, said: 'This shows the need to take a detailed medical history in children presenting with vague symptoms.'

Br J Gen Pract 2012, online 25 June

## DEPRESSION

Mental health 'worse  
with depressed parent'

Almost a quarter of children with a parent suffering from depression meet the criteria for a diagnosis of a psychiatric disorder themselves, according to UK research.

The study looked at 333 children aged between nine and 17 years who had a parent with a history of recurrent depression. Parents with bipolar depression or a psychosis were excluded. Data were gathered using structured interviews, with trained

interviewers used to assess the child's mental health over the preceding three months. Any child meeting criteria for a diagnosis was then reviewed by two senior psychiatrists. They found 24% of the children identified had a psychiatric disorder.

The authors, from Cardiff University, concluded: 'This highlights the need for GPs who are seeing parents with depression to be aware of the risk of problems in their children.'

Br J Gen Pract 2012, online 25 June

## HEART FAILURE

BNP and clinical features  
best for predicting HF

GPs should use BNP testing and a list of clinical features rather than ECGs to determine whether a patient with suspected heart failure needs to be referred for an echocardiogram, concludes a UK analysis.

The authors looked at five primary care studies that evaluated clinical features and investigations predictive of heart failure, and then formed different models of predicting heart failure.

They found that using clinical features of a myocardial infarction - crepitations and ankle oedema - plus a measure of BNP or NT-pro BNP was most sensitive (between 90-96%).

The study authors, from the University of Birmingham, concluded: 'Natriuretic peptide testing should be recommended over ECG. Some patients could be referred for early echocardiography without undergoing preliminary investigation.'

Eur J Heart Fail 2012, online 19 June

CPD  
TIP OF  
THE  
WEEKConsider psychogenic  
cough in children

If a child presents with a chronic cough that does not wake them at night, you should consider psychogenic cough as a potential cause, say the authors of a new case-based learning module. A psychogenic cough is usually a dry, repetitive cough that persists after an upper respiratory infection has cleared. It is less prominent at night and when the child is distracted. Hot topics in childhood cough - available to premium members of Pulse Learning and Worth a suggested 2 CPD hours - covers both acute and chronic cough, community-acquired pneumonia, pertussis and when to refer children for chest X-ray.

**ONLINE CPD**  
Hot topics in childhood cough  
pulse-learning.co.uk

Onbrez® Breezhaler® ▼150 and 300 microgram inhalation powder, hard capsules (indacaterol)

**Indications:** Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD). **Presentation:** Clear colourless capsules for inhalation containing indacaterol maleate equivalent to 150 or 300 micrograms of indacaterol. **Dose and administration:** The recommended dose is the inhalation of the content of one 150 microgram capsule once a day using the Onbrez Breezhaler device. The dose should be increased only on medical advice. The inhalation of the content of one 300 microgram capsule once a day using the Onbrez Breezhaler device has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD. The maximum dose is 300 micrograms once daily. Onbrez Breezhaler should be administered at the same time of day each day. No dose adjustment is required for elderly patients or patients with renal or mild-to-moderate hepatic impairment. There are no data on patients with severe hepatic impairment. Onbrez Breezhaler capsules are for inhalation use only and must not be swallowed. There is no relevant use of Onbrez Breezhaler in patients under 18 years. **Contraindications:** Hypersensitivity to the active substance, lactose or gelatin. **Precautions:** Onbrez Breezhaler is not for use in asthma due to the absence of long-term data. As with other inhalation therapy, administration of Onbrez Breezhaler may result in paradoxical bronchospasm that may be life-threatening. In this event Onbrez Breezhaler should be discontinued immediately. Onbrez Breezhaler is not indicated for the treatment of acute episodes of bronchospasm. In the event of deterioration of COPD during treatment, re-evaluation of the patient should be undertaken. Indacaterol should be used with caution in patients with cardiovascular disorders, patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta<sub>2</sub>-adrenergic agonists. Indacaterol may produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure and/or symptoms. Beta<sub>2</sub>-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Inhalation of high doses of beta<sub>2</sub>-adrenergic agonists may produce increases in plasma glucose. Diabetic patients should be monitored more closely upon initiation of Onbrez Breezhaler. **Drug Interactions:** Concomitant administration of other sympathomimetic agents may potentiate the undesirable effects of Onbrez Breezhaler. Onbrez Breezhaler should not be used in conjunction with other long-acting beta<sub>2</sub>-adrenergic agonists. Methylxanthine derivatives, steroids or non-potassium-sparing diuretics may potentiate the possible hypokalaemic effect of beta<sub>2</sub>-adrenergic agonists. Beta-adrenergic blockers may weaken or antagonise the effect of beta<sub>2</sub>-adrenergic agonists. Onbrez Breezhaler should not be given together with beta-adrenergic blockers. In those situations, cardioselective beta-adrenergic blockers are preferred. Inhibition of CYP3A4 and p-glycoprotein raises the systemic exposure of Onbrez Breezhaler, though the magnitude of exposure in clinical studies up to one year does not raise any safety concerns. **Undesirable effects:** Common (≥1/100 to <1/10) Nasopharyngitis, upper respiratory tract infection, sinusitis, cough, pharyngolaryngeal pain, rhinorrhoea, respiratory tract congestion, diabetes mellitus, hyperglycaemia, headache, ischaemic heart disease, muscle spasm, peripheral oedema. Uncommon (≥1/1000 to <1/100) Paraesthesia, atrial fibrillation, non-cardiac chest pain. **Cough:** In clinical studies 17-20% of patients experienced a sporadic cough that occurred usually within 15 seconds of inhalation and typically lasted 5 seconds. This cough was generally well tolerated and there is no evidence that cough experienced post-inhalation is associated with bronchospasm, exacerbations, deteriorations of disease or loss of efficacy. **Quantities and based NHS price (excl. VAT):** Onbrez Breezhaler with 30 day supply of capsules: 150 micrograms £29.26, 300 micrograms £29.26. **Marketing authorisation number** 150 micrograms: EU/1/09/593/001-005. 300 micrograms: EU/1/09/593/006-010. **Legal category:** POM. **Date of last revision of prescribing information:** August 2011

Full prescribing information is available from: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR. Telephone (01276) 698370, e-mail: medinfo.uk@novartis.com

Adverse events should be reported.  
Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis (01276) 698370.



NEW  
**Trajenta**<sup>®</sup>  
(linagliptin) 5mg film-coated tablets



# Control and care matter

**Trajenta<sup>®</sup> (linagliptin)** is suitable for your hyperglycaemic adult type 2 diabetes patients as monotherapy in metformin-inappropriate patients and add-on to metformin alone or metformin + a sulphonylurea<sup>1</sup>

## Efficacy

- significant HbA<sub>1c</sub> reductions vs placebo<sup>2-4</sup>
- HbA<sub>1c</sub> reduction sustained over 102 weeks as add-on to metformin + a sulphonylurea in the completer population (319 patients out of 544 enrolled patients)<sup>5</sup>

## Generally well tolerated

- Trajenta<sup>®</sup> (linagliptin) has an overall incidence of adverse events that is similar to placebo<sup>1</sup>

## Different

- the first one dose, once-daily DPP-4 inhibitor excreted primarily via the bile requiring no dose adjustment<sup>1,6-11</sup>

### Prescribing Information (PI)

### Trajeta<sup>®</sup> 5mg film-coated tablets

Film-coated tablets containing 5 mg linagliptin. **Indications:** Trajeta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults: as monotherapy; in patients inadequately controlled by diet and exercise alone or for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; as combination therapy: - in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control; - in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. **Dose and Administration:** 5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia. Patients with renal impairment: no dose adjustment required. Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. **Warnings and Precautions:** Trajeta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Caution is advised when linagliptin is used in combination with a sulphonylurea; a dose reduction of the sulphonylurea may be considered. **Interactions:** Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. It is not an inducer of CYP isozymes. Linagliptin is a P-glycoprotein substrate and inhibits P-glycoprotein-mediated transport of digoxin with low potency. Based on these results and *in vivo* interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glimepiride, simvastatin, warfarin, digoxin or oral contraceptives (please refer to Summary of Product Characteristics for information on clinical data). **Fertility, pregnancy and lactation:** Avoid use during pregnancy. A risk to the breast-fed child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Trajeta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No studies on the effect on human fertility have been conducted for Trajeta. **Undesirable effects:** Adverse reactions reported in patients who received linagliptin 5 mg daily as monotherapy or as add-on to therapies (pooled analysis of placebo-controlled studies). The adverse reactions are listed by absolute frequency. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/100), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), or very rare (<1/10,000), not known (cannot be estimated from the available data).

Very common: hypoglycaemia (combination with add-on to metformin and sulphonylurea); Uncommon: nasopharyngitis (monotherapy; combination with add-on to metformin); hypersensitivity (combination with add-on to metformin); cough (monotherapy; combination with add-on to metformin). Not known: nasopharyngitis (combination with add-on to metformin and sulphonylurea); hypersensitivity (monotherapy; combination with add-on to metformin and sulphonylurea); cough (combination with add-on to metformin and sulphonylurea); pancreatitis (monotherapy; combination with add-on to metformin; combination with add-on to metformin and sulphonylurea). Prescribers should consult the Summary of Product Characteristics for further information on side effects. **Pack sizes and NHS price:** 28 tablets £33.26. **Legal category:** POM. **MA number:** 001/11/707/003. **Marketing Authorisation Holder:** Boehringer Ingelheim International GmbH, D-68269 Ingelheim am Rhein, Germany. Prescribers should consult the Summary of Product Characteristics for full prescribing information. Prepared in September 2011.

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk/>. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (toll-free).

**References:** 1. Trajeta<sup>®</sup> Summary of Product Characteristics, August 2011. 2. Barnett AH et al. *Post Med*, 1023-4. The European Association for the Study of Diabetes. 40th Annual Meeting, 20-24 September 2010, Stockholm, Sweden. 3. Taskiran M-R et al. *Diabetes Obes Metab* 2011; 13:15-24. 4. Owens DR et al. *Diabet Med* 2011;28:1252-61. 5. Boehringer Ingelheim, data on file UM11-06a. 6. Vincent SR et al. *Drug Metab Dispos* 2007;35:533-538. 7. Januska (linagliptin) Summary of Product Characteristics. Available at: <http://www.medicines.org.uk/EMC/medicines/19609/SPC/JANUSKA-100mg-film-coated-tablets/> (accessed May 2012). 8. Gahleitner (linagliptin) Summary of Product Characteristics. Available at: <http://www.medicines.org.uk/EMC/medicines/22754/SPC/Gahleitner-50-mg-tablets/> (accessed May 2012). 9. Gahleitner (linagliptin) Summary of Product Characteristics. Available at: <http://www.medicines.org.uk/EMC/medicines/22754/SPC/Gahleitner-50-mg-tablets/> (accessed May 2012). 10. Deacon CF. *Diabetes Obes Metab* 2011;13:7-18. 11. Glech S et al. *Drug Metab Dispos* 2010;38:667-678. 12/11/10/003a. Date of preparation: May 2012



# BMA chair must listen, then lead

As Dr Mark Porter woke up last Friday morning, to begin his first day as the newly elected chair of the BMA, he could have been forgiven for pausing a second, looking in the mirror and wondering what exactly he had got himself into.

Representing the association's 150,000 members is no easy job at the best of times, but these are not the best of times.

The NHS is gearing up for the biggest reorganisation in its history, eye-watering efficiency targets are increasingly forcing doctors into an unpalatable rationing role – and then, of course, there's pensions.

The man Dr Porter is replacing, Dr Hamish Meldrum, drew a standing ovation from delegates at his farewell speech,



**Steve Nowotny**  
Acting editor

and rightly so. He has been a distinguished servant of the BMA, and represented doctors with dignity, gravitas and authority over the past five years.

And yet there remain real questions over some of the BMA's recent decisions – questions which will inevitably shape Dr Porter's thoughts as he looks to put his own stamp on the association's strategy.

On the NHS reforms, the policy of 'critical engagement' initially appeared statesmanlike, but then increasingly exposed as doctors' views on the health bill hardened. Ultimately the policy became more 'critical' than 'engagement', but many rank-and-file GPs felt it was too little, too late.

The vote at last week's Annual Representative Meeting instructing the BMA to campaign for the health act to be repealed, against Dr Meldrum's bidding, suggested lingering discontent.

On pensions, the BMA has been much more robust. But with the benefit of hindsight, its refusal to join other health unions in NHS-wide industrial action last November left it exposed when going it alone this year, and its handling of the day of action itself was politically tone-deaf.

The decision to target patient care rather than paperwork was curious, and the BMA invested so much energy in averting a possible legal challenge and running a media campaign to reassure the public

**Laxido Orange, powder for oral solution: Please refer to the Summary of Product Characteristics (SPC) before prescribing. Abbreviated Prescribing Information: Presentation:** Single dose sachet, each containing a white powder composed of: Macrogol 3350 13.125g, sodium chloride 950 mg, sodium hydrogen carbonate 170 mg, and potassium chloride 46 mg. **Indications:** Treatment of chronic constipation and fecal impaction. **Dosage:** **Chronic constipation:** A course of treatment for chronic constipation with Laxido Orange does not normally exceed 5 days. **Adults, adolescents and the elderly:** 1-3 sachets daily, all of which should be consumed within a 10 hour period. **Children below 12 years old:** Not recommended. **Faecal impaction:** A course of treatment for faecal impaction with Laxido Orange does not normally exceed 5 days. **Adults, adolescents and the elderly:** 1-3 sachets daily, all of which should be consumed within a 10 hour period. **Children below 12 years old:** Not recommended. **Patients with impaired cardiovascular function:** For the treatment of faecal impaction the dose should be reduced so that not more than 2 sachets are taken in any one hour. **Administration:** Each sachet should be dissolved in 125 ml water. For use in faecal impaction, dissolved sachets may be observed in 1-2 days. The sachet should be stored in a cool, dry place (20°C to 25°C) for up to 6 months. **Contraindications:** Intestinal obstruction or perforation caused by functional or structural disorder of the gut wall, fecal impaction in patients with severe inflammatory conditions of the intestine (e.g. ulcerative colitis, Crohn's disease) and toxic megacolon. Hypersensitivity to the active substances or any of the excipients contained in Laxido Orange. **Warnings and Precautions:** The faecal impaction diagnosis should be confirmed by appropriate physical and radiological examination of the abdomen. **Interactions:** If a patient develops any symptoms indicating a change in the absorption of Laxido Orange, the dose should be reduced. The absorption of other medicinal products could transiently be reduced due to an increase in gastric fluid volume induced by Laxido Orange. **Effects on ability to drive and use machines:** Laxido Orange has no influence on the ability to drive and use machines. **Undesirable effects:** Reactions related to the gastrointestinal tract are the most common and include abdominal pain, vomiting, nausea, dyspepsia, abdominal distension, flatulence, belching and anal discomfort. Diarrhoea may also occur, and cases of which usually respond to dose reduction. Allergic reactions, including anaphylaxis, angioedema, dyspnoea and skin reactions can occur. Other effects can include electrolyte disturbances, headache and peripheral oedema. **Overdose:** Refer to SPC. **Legal Category:** P. **NHS Price:** Each sachet 20 sachets: £3.50; 30 sachets: £5.24. **MA Number:** PL 21993/01/07. **Full prescribing information available from the MA Holder:** Galen Limited, Seagrove Industrial Estate, Oatridge, BT65 5UR, United Kingdom. **Date of Preparation:** June 2012.

#### RHINOCEPT® AQUA 64 micrograms (budesonide)

**General Summary of Product Characteristics before prescribing. Use:** Seasonal and perennial allergic rhinitis and vasomotor rhinitis. **Treatment of nasal polyps.** **Presentation:** Nasal spray, suspension. Each actuation contains 64 mcg budesonide. **Dosage and administration:** **Rhinitis:** 2 sprays into each nostril once daily in the morning or 4 sprays twice daily morning and evening. When good effect has been achieved, reduce dose. **Nasal polyps:** 4 sprays into each nostril once daily morning. Can be continued for up to 3 months. **Children:** Not normally recommended. Full effect not achieved until after a few days treatment. Treatment of seasonal rhinitis should start, if possible, before exposure to the allergen. Remind patients of importance of taking regularly. The minimum dose should be used at which effective control of symptoms is maintained. **Contraindications:** Hypersensitivity to budesonide or to any of the excipients. **Precautions:** Special care should be taken when treating patients transferred from oral steroids, where disturbances of hypothalamic-pituitary-adrenal (HPA) axis could be expected. Special care should be taken in patients with fungal and viral infections in the sinuses, or with active or quiescent pulmonary tuberculosis. Concurrent treatment of nasal rhinitis may sometimes be necessary to treat eye symptoms caused by the allergy. In children and long-term treatment, the nasal mucosa should be inspected regularly. Reduced liver function affects the elimination of corticosteroids, may lead to higher systemic exposure and possible systemic side effects. Long-term effects of Rhinocort use in children are limited. Growth of children taking Rhinocort should be monitored and benefit of treatment against possible growth suppression should be weighed. Treatment with higher than recommended doses may cause clinically significant adrenal suppression. Ketogenic and lipogenic diet can increase systemic exposure to budesonide several times. Concurrent treatment with Rhinocort should be avoided. If needed, period between treatments should be as long as possible and consider reduction to Rhinocort dose. No interaction has been observed with any drug used in nasal rhinitis. Raised plasma concentrations and enhanced effects of corticosteroids observed in women treated with oestrogens and contraceptive steroids. No effect observed during concomitant intake of low dose oral contraceptives. An adrenal function may be suppressed this may lead to false results in ACTH stimulation test for diagnosing pituitary dysfunction. **RHINOCEPT** does not affect ability to drive and operate machinery. Acid during pregnancy. No effects on foetal foetal and expected of therapeutic doses. **Undesirable events:** **Common:** Haemorrhagic secretion and epistaxis. Nasal irritation such as sneezing, stinging and dryness. **Uncommon:** Irritation and delayed hypersensitivity reactions including urticaria, rash, dermatitis, angioedema and pruritus. **Rare:** Signs and symptoms of systemic corticosteroid effects, including adrenal suppression and growth retardation. **Very rare:** Nasal septum perforation, atrophy of mucous membrane, ankyloblepharodactylosis. **Not known:** Raised intraocular pressure or glaucoma, cataract. Systemic

effects of nasal corticosteroids may occur, particularly when prescribed at high doses for prolonged periods. These may include Cushing's syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely a range of psychological or behavioural effects including psychiatric hypochlorid, sleep disorders, anxiety, depression or aggression particularly in children. Acute overdoses even in excessive doses, is not expected to be a clinical problem. **Legal category:** POM. **Marketing authorisation number:** 17901/0074. **Basic NHS cost:** 150 actuations: £3.49. **Further information is available from the Marketing Authorisation holder:** AstraZeneca UK Limited, 690, Garsfield Road, Luton, LU1 3LU, UK. **RHINOCEPT** is a trade mark of the AstraZeneca group of companies. AZ 05/2012 RSP 12/2012

**Calceos® Chewable Tablets Prescribing Information:** Please refer to the Summary of Product Characteristics (SPC) before prescribing Calceos®. **Presentation:** Chewable tablets containing calcium carbonate 1250mg (i.e. 500mg of elemental calcium) and vitamin D<sub>3</sub> 10 micrograms (equivalent to 400 IU of vitamin D<sub>3</sub> for oral use). **Indications:** Correction of vitamin D and calcium deficiency in the elderly. Vitamin and calcium supplement as an adjunct to specific therapy for osteoporosis. **Dosage:** Adults: One tablet to be chewed and taken with a glass of water, twice per day. **Children:** Not recommended. **Contraindications:** Calceos® is contra-indicated in patients with hypercalcaemia, hypercalcaemia, calcium lithiasis, tissue calcification, vitamin D overdose, myeloma and bone metastases, renal insufficiency and hypercalcaemia. **Effects on ability to drive and use machines:** None known. **Side effects:** Nausea, hypercalcaemia, hypophosphataemia, hypercalcaemia and mild gastro-intestinal disturbances such as constipation. **Overdose:** Please refer to SPC. **Basic NHS cost:** Packs containing 4 tablets at 15 tablets: £3.58. **Legal classification:** P. **Marketing Authorisation Holder:** Laboratoire International, 22 Avenue Aristide Briand, 94710 Arcueil, France. **Marketing Authorisation Number:** PL 19162/0001. **Full prescribing information available from:** Galen Limited, Seagrove Industrial Estate, Oatridge, BT65 5UR, UK. **Date of Preparation:** December 2011.

FUR-LUR-2012-0375  
1639405

Date of preparation: June 2012

This advertisement is intended for healthcare professionals only

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Galen Limited on 020 3833 4574 and select the customer services option, or email [info@galen.co.uk](mailto:info@galen.co.uk). Medical information enquiries should also be directed to Galen Limited. Adverse events and medical information enquiries concerning Rhinocort Aqua should be reported to AstraZeneca on 0800 783 0355.

**GALEN**





that somewhere along the way it forgot to sell the whole idea to its own members.

The result was a lacklustre turnout, which fatally undermined the first industrial action by doctors in a generation – and a nagging fear that on pensions the BMA may have shot its bolt, with nowhere left to go.

All of which adds up to a daunting to-do list for the new BMA chair – and a profession which, in the coming months, will need strong, sure-footed direction.

To have any hope of influencing the NHS reforms, winning concessions on pensions, getting members on side and restoring the BMA's credibility with the Government and the national media, Dr Porter will need to listen carefully, and then lead decisively.

A little luck wouldn't go amiss either.



**Do you agree? Let us know by emailing Steve at editor@pulsetoday.co.uk**

## How to contact Pulse

**General editorial enquiries**  
020 7332 2904

**News desk**  
020 7332 2904

**Classified advertising**  
020 7332 2924

**Display advertising**  
020 7332 2928

**pulsetoday.co.uk**  
020 7332 2938

**Email** pulse@pulsetoday.co.uk

**Address (editorial)**  
Pulse, Briefing Media, 3rd Floor  
Mermaid House, 2 Puddle Dock,  
London EC4V 3DB

**Delivery and subscription**  
Medical Reader, c/o BHP, 2-3  
Commercial Way, Christy Close,  
Southfields, Basingdon SS15 6EF  
Free circulation: Call 0845 1369316  
or email medicalreader@bnp.co.uk  
Paid subscription:  
Call 01852 438893

**Group editor** Jo Haynes

**Acting editor** Steve Nowotny

**Group clinical editor** Adam Legge

**Acting deputy editor**  
Nigel Praeger

**Chief reporter** Gareth Jacobucci

**Reporter** Sofia Lind

**News intern** Madlan Davies

**Online producer** Jessica Baron

**Online intern** Hannah Bass

**Deputy clinical editor**  
Rhannon Smith

**Assistant clinical editor** David Swan

**Assistant features editor**  
Ellie Broughton

**Art director** Ravi Naideo

**Art editor** James Depina

**Senior sub editor** Brooke Balza

**Events and business editor**  
Lisa Thomlinson

**Editorial adviser** Dr Keith Hopcroft

**General practice adviser**  
Dr Alistair Moulds

**Production controller** Phil Taylor

**Advertising executive** Cliff Brown

**Head of events** Stephen Knowles

**Projects director** Paul Bernasconi

**Associate publisher**  
Sanjay Chudasama

**CEO, Briefing Media** Neil Thackray

**CMO, Briefing Media** Rory Brown

Registered office: Briefing Media, 2nd Floor Mermaid House, 2 Puddle Dock, London EC4V 3DB. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or by any information storage or retrieval system without the express prior written consent of the publisher. The contents of Pulse are subject to reproduction in information storage and retrieval systems. Pulse is available on subscription at £100 per year (single copy £10).

Overseas subscriptions, including Europe, £127 per year (single copy £14). Pulse is available on subscription, will only be provided at the Publisher's discretion, unless specifically guaranteed within the terms of subscription offer. Briefing Media may provide suitable reader addresses to other relevant suppliers. Please do not wish to receive sales information from other companies, please write to Pulse, Briefing Media, 2nd Floor Mermaid House, 2 Puddle Dock, London EC4V 3DB. Originated by TMI Publishing Services, London. Printed by Pulse Ltd. 024 0046000

**PULSE**

**BriefingMedia**

**Recycle**  
a new standard of  
the paper your trust in



## Trusted drugs at a low price? It's an art.

Keeping an eye on budgets has never been more important.

Galen Limited is committed to providing a range of tried and trusted medicines at a low price; so when prescribing from the trustsaver collection you can be sure you're getting value for money.

Estimate your potential savings using the trustsaver savings calculator at [www.trustsaver.co.uk](http://www.trustsaver.co.uk)

Galen trustsaver collection  
The art of saving

[www.trustsaver.co.uk](http://www.trustsaver.co.uk)



# Free at the point of abuse

**Phil** only really got one thing out of the day of action – an object lesson in just how ridiculous it is to allow patients to decide what is 'urgent'

Well, thank heavens that's all over. It wasn't too bad, was it?

Thanks to our prompt, decisive and above all unanimous and co-ordinated industrial action, the Government has rolled over like the pussies we always knew they were and restored our promised pension agreements, just like we knew they would.

The worst thing we could have done would



have been to present a disunited front, put up a few token Uncle Toms for the popular press – who would parrot the idea that we do this job out of liberal guilt and not for any sort of living wage – and then, despite displaying a shamefully small percentage of participating doctors, back out of this even further on the day and offer to the public, as some sort of desperate half-assed child's attempt at a strike, two doctors in Penge who flatly refuse to remove ingrowing toenails until tomorrow.

Lucky that we didn't do that, eh?

Or maybe you don't care that our employment contract was theoretically in some way binding on both parties. It appears now that it wasn't, certainly.

If our Government can unilaterally piss my pension and retirement age away into the ether, then presumably I can also tear up the same contract and, say, refuse to treat any ailment from mid-thigh

downwards. Nobody would die as a result. Let's see just how far I get with that idea, shall we?

However, this was never going to be an easy gig, frankly, and I can hardly hold my own practice up as a beacon of excellence when it comes to Citizen Smith-style, bandana-wearing, fist-waving popular protest.

I'm the only one who insisted on taking any industrial action at all.

I refused to see anything but emergencies on the day, but as my partners insisted on working as normal, and as it is our patients who define the word 'emergency', then all that happened is that I saw all the 'urgent extras' that would have otherwise been (and are, on any other day) distributed among the lot of us.

And what an utterly depressing day of unrelenting crap it was.

Nobody likes to contemplate their own insignificance, or indeed have the bald fact of it thrust in their faces, but for heaven's sake, are we not here to deal with more important stuff than this?

This is urgent? For this, we cost the nation £25 per appointment? (And I'm well aware that this is a bargain compared with anyone else.)

I had intended to use this article to demonstrate the pathetic nature of most urgent requests to see a GP, and I kept a list of the utter rubbish that I saw on the day of action – the lost sick notes, the prescription queries, the requests for advice about

**This is urgent? For this we cost £25 per appointment?**

a parent who isn't actually a patient of yours, it goes on and on.

But what's the point? You've heard it all before. You all get it, every single day.

This profession deeply depresses me at times, and it always comes back to the fact that our services are free at the point of use (or abuse, if you will).

Some 90% of my time, or rather 100% on the day of supposed industrial action, is taken up by about 5% of our patients, and there is no evidence to suggest that they are the 5% that need it most.

Sometimes I can barely tolerate what I do for a living, and I'm in one of those periods now. During these times there seems only one realistic solution: charge them.

The type of patient who makes another appointment on the way out of the last one, on the grounds that they are bound to think of something else to moan about before then has to be... well, I was going to say discouraged, but I am actually tempted to say they should be socked on the back of the head with a baseball bat.

The patients we are actually here for cannot get easily accessible appointments because of the tedious minority who spend far too much of our time indulging their hobby of free, self-indulgent self-aggrandisement.

I honestly believe that the time for free access to medical care is over; ruined by the selfish few.

**Dr Phil Peverley** is a GP in Sunderland



**Blends proven efficacy  
with fast-mix convenience**

For the treatment of chronic constipation

**MOVICOL<sup>®</sup>  
LIQUID**

macrogol 3350, sodium hydrogen carbonate,  
sodium chloride, potassium chloride



www.movicol.co.uk

Please consult Summary of Product Characteristics before prescribing, particularly in relation to side effects, precautions and contra-indications. Further information is available on request from Norgine Pharmaceuticals Limited, Moorhall Road, Harefield, Middlesex, UB9 5NS. Legal category: P. MO/2851/MAR/12

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk>. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01 895 826606.



# Don't settle science in court

Doctors must be able to have a full and open debate about the evidence behind the science without being afraid they will be sued for libel, says **Margaret**

If one thing is clear, it is that robust discussion is essential when it comes to disputes about evidence. This is what makes us grown-up – this is what protects our patients.

I feel proud when I hear the rough and tumble of Prime Minister's Question Time in parliamentary session on Wednesdays – our democracy can take the free-for-all.

I feel glad that we have *Private Eye*, rude and cynical and so often completely correct. We need to be able to poke fun, vigorously question, slate, annoy, demand and push for debate and talk and chide. Personal attack is not so good, but free speech is sacrosanct.

This is what makes our country great – this is the kind of Britain I want to live in. It is good for medicine and good for patients. We should not be hemmed in by fear about libelling someone and prevented from debating the data.

This is why doctors should be supporting Sense about Science's attempts to make good the poor libel laws in the UK.

Most doctors are likely to have heard of Simon Singh's travails after the British Chiropractic Association attempted to sue him for libel, or when cardiologist Dr Peter Wilmshurst was threatened with libel after speaking out about trial data of a heart device.

Then there is plastic surgeon Mrs Dalia Nield, who contested claims about 'Boob Job' cream, and the Burzynski Clinic, which threatened bloggers who wanted to dispute their claims about antineoplastic treatments for cancer.

And now a new possible libel action is looming after a long-running dispute between a private GP and a scientist, over their differing views on the evidence base for the therapies the GP was offering to patients with chronic fatigue syndrome.

GPs are often the first contact for people who have read about miracle cures.

It's part of our job to help people reach good decisions about their health – and as the internet becomes our debating ground, it's essential that doctors can freely talk about the shortcomings and problems with evidence.

It would be even better if patients – or potential patients – could read these debates for themselves, and that's only possible if we are unafraid of being sued just because we disagree.

**We should not be hemmed in by fears about libel**



The Defamation Bill is currently going through the House of Commons. While it has cross-parliamentary support, there is substantive concern that as it stands, it will be ineffective where it counts.

I support Sense about Science's efforts to make the bill effective, and would urge GPs to consider supporting them. We need freedom to call out for evidence, and we need to be assured that debate will not end with a demand for libel damages.

It's clear that in the UK, defamation proceedings cost more than in other European countries.

As it stands, patients lose out where their

doctors cannot challenge and debate openly matters of evidence.

The court is not the place to settle science. Everywhere else is.

**Dr Margaret McCartney** is a GP in Glasgow

## More online

**Copperfield** returns next week, but if you can't wait until then to get your regular blast of the world according to Copperfield, you can read his blog at [pulsetoday.co.uk/copperfield](http://pulsetoday.co.uk/copperfield), or following him on Twitter @doccopperfield.

## Medication case file #4

# Adding value

In the latest in a series of real-life cases, find out how GP Lionel Dean has solved repeat prescription problems for a variety of his patients.



*"Pharmacy2U is one of the many ways we are providing 'added value' for patients. I've found the electronic requests quick and easy to handle."*

**Dr Lionel Dean**

## The practice

The Melrose surgery in Reading is a busy two-partner urban practice with a list size of 5,200. Caring for a mix of patients from the elderly and housebound to busy London commuters, Dr Lionel Dean recognised that the traditional way of ordering and collecting a prescription was not suitable for all.

## The problem

With limited mobility and access to transport, many of Dr Dean's elderly patients found it difficult to make regular trips to pick up repeats. Nor could his 'time-poor' working patients easily fit visits to the doctor and chemist round long days away from home. Dr Dean wanted to reduce the number of last-minute repeat requests coming in, to improve practice efficiency.

## The resolution

He offered his patients the option of a free NHS repeat prescription service from Pharmacy2U. It enables them to have scripts dispensed without having to contact the practice directly or collect a paper prescription. Pharmacy2U delivers medicines free of charge and the service includes telephone or email reminders when a prescription is due.

## The benefits – for GPs and patients

The repeat prescription service has proved extremely popular. "It has been particularly well-received by the elderly, housebound and commuters – who can have their medications delivered direct to their home or workplace," said Dr Dean. "It's also been useful for QOF reviews, as a message can be sent along with the medication, encouraging patients to attend."

There are other advantages to the service for GPs. The electronic link with Pharmacy2U enables speedy communication to update the pharmacist of changes to repeat prescriptions, and for the pharmacist to give reasons for early or unusual requests from patients.

GPs are also reassured by the reliability and clinical safety of the service, which only ever requests medication that is current for your patient. Quicker repeat prescribing means you can maximise your other QOF points, too.

**'Patients tend to prefer a reasonably fast service for their repeat prescriptions.'**

*Medicines 8.1 QOF practice guidance (BMA).*

[www.pharmacy2u.co.uk/practice](http://www.pharmacy2u.co.uk/practice)

**Pharmacy  
2U**



# Telehealth shows enormous potential for the NHS

Trial data proves telehealth can improve care, but done right it can also cut costs, writes **Dr Julian Neal**

The first of five detailed papers from the Whole Systems Demonstrator (WSD) trial, published last month in the *BMJ*, found that, over the course of a year, patients provided

with telehealth had 19% fewer emergency admissions than the control group, who were cared for 'in the usual way'. More significantly, over the same 12-month period only 4.6% of those provided with telehealth died, compared with 8.3% of the control group.

Both these findings are statistically significant and are consistent with the results from a study my practice undertook two winters ago, when 100 patients with COPD were provided with telehealth monitoring and 11 hospital admissions were prevented in just three months.



The study in the *BMJ*, which covered 3,154 patients, also concluded that for those patients with telehealth the overall costs of hospital care were £188 per patient less than those for control patients (though this was not thought to be a statistically significant difference).

Telehealth is clearly good for patients: clinical outcomes are improved, lives saved and admissions prevented. But more detailed research needs to be done to prove the benefits to patients can be achieved at a lower cost.

My own experience of telehealth suggests that significant cost savings can only be generated by having nurse-led triage at the heart of the service.

Much of the WSD trial imposed technology on community and primary care staff with no significant service redesign.

Opportunities for economies of scale were lost – for example, one specialist nurse could cost-effectively monitor several hundred patients.

Too often telehealth became an additional cumbersome layer rather than a focused cost-effective improvement.

A wealth of overseas data exists that confirms the clinical and financial benefits of telehealth.

Reproducing these gains in the NHS will require more than just technology – sensitive patient selection and large-scale integrated implementations are essential prerequisites.

The Department of Health also needs to do its bit by providing incentives. A new 'telehealth tariff' should encourage rollout of services to practices and CCGs, which in turn should drive down costs and encourage provision under any qualified provider.

It should also encourage the adoption of cheaper and smarter technological solutions, including mobile phone apps.


My own practice is currently four months into a two-year observational study of the effects of telehealth on hundreds of patients with COPD, chronic heart failure and diabetes.

As well as recording clinical outcomes and a large range of socioeconomic factors, we will analyse total NHS use for two years before and after deployment of telehealth.

The potential to reduce demand on both GPs and the out-of-hours services is enormous.

**Dr Julian Neal** is a GP in Portsmouth and clinical adviser to Telehealth Solutions

For stroke prevention in your moderate to high risk Atrial Fibrillation patients



Oral anticoagulation is three times more effective at preventing stroke than aspirin<sup>1</sup>  
It is estimated that there are over 230,000 AF patients treated with aspirin<sup>2</sup>

Discover how the new AF QOF Indicators benefit your patients  
and your practice – go to the website for further information



**www.stopstart.org.uk**

An online resource for stroke prevention in atrial fibrillation for UK Healthcare Professionals



References: 1. Neal et al. *Practical Use of Anticoagulation in Atrial Fibrillation*. *BMJ Open* 2012;12:e001427. 2. NHS Guidelines. *Aspirin*. *BMJ Open* 2012;12:e001427.

**MORE ONLINE**  
**Dr Mark McCarthy** argues that the WSD trial leaves a number of questions unanswered. Read his side of the debate and have your say at [pulsetoday.co.uk/opinion](http://pulsetoday.co.uk/opinion)



# Pathology variation down to poor practice

From Dr John Orchard

Alfreton, Derbyshire

Dr Robert Morley is severely misinformed when he seeks to justify wide variation in pathology tests ('Yet another stick to beat us with', [pulsetoday.co.uk/opinion](http://pulsetoday.co.uk/opinion)). The truth is that variation is down to poor practice.

When one individual in a multi-partner practice has investigation rates four times those of his peers, he has a problem.

When the phlebotomist expresses surprise the locum is requesting so many tests, the locum has a problem. When the number of tests requested by general practice has increased enormously, the profession has a problem.

My observation is that defensive medical practice is driving the desire to exclude everything at the expense of rational practice.

The time-honoured practice of history taking leading to a differential diagnosis,

investigated by appropriate examination and then clarified by targeted testing and imaging, has been replaced by minimal history taking, differential diagnoses from an undergraduate textbook, blanket laboratory screening and unnecessary referral.

The fault lies in the failure to deal with uncertainty, which results from insufficient clinical exposure in training caused by restricted working hours, part-time training and a reluctance to accept responsibility for dealing with patients' anxieties.

The result of the QOF and internet misinformation is a belief in the infallibility of tests and the dumbing down of clinical acumen.

What is needed are competent doctors with the courage to practise the skills they have learned who do not bow to the demand for every test because it can be done.

LETTER  
OF THE  
WEEK



Is wide variation in use of lab tests linked GPs 'dumbing down'?

## Just what do we mean by 'telehealth'?

From Dr Stuart Berry

Nelson, Lancashire

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

Telehealth, like other health interventions, is most useful if the patient develops greater understanding about their own self-care by the end of episode ('Telehealth cuts admissions, but not costs', [pulsetoday.co.uk/news](http://pulsetoday.co.uk/news)).

But the term is too inclusive and has the potential mess up some innovative ideas. After all, the telephone is probably the simplest 'telehealth' device used in healthcare today.

## Show us the evidence, not the spin

From Dr George Farrelly

Bow, east London

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

Policy development on telehealth must be guided by robust evidence and seeing how things actually work ('Data does not support the DH's extraordinary claims for telehealth', [pulsetoday.co.uk/margaret-mccartney](http://pulsetoday.co.uk/margaret-mccartney)).

Dr McCartney is very right to push the Department of Health to produce evidence, and not spin. It seems to me that there are parts of the DH which are driven by spin, in a sort of evidence denial.

This is no way to develop and implement policies - indeed, it is actually damaging.

## Maynard is wrong on the QOF

From Dr Mary Church

Glasgow

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

I wanted to respond to Professor Maynard's remarks about incentivising GPs ('NHS should use 'reputational threats' to keep GPs in line, says expert', [pulsetoday.co.uk/news](http://pulsetoday.co.uk/news)).

Because of incentives like the QOF, GPs took on work that should have been done in hospital, did it better and should be paid for it. Plenty of evidence supports the improvement in care of those with long-term illnesses that resulted from our work. Business markers also improved overall practice performance.

I believe Professor Maynard is talking out of a lack of understanding of what GPs do.

## For the record

Pulse's priority is accuracy. However, in the busy process of preparing a weekly publication, mistakes can occur. To draw our attention to an error, email [letters@pulsetoday.co.uk](mailto:letters@pulsetoday.co.uk)

## Drop the CQC? I'm with Copperfield

From Dr Kevin D'Mello

Hucknall, Nottinghamshire

Copperfield was on the ball with his article on CQC registration ('Standardised into submission', [pulsetoday.co.uk/copperfield](http://pulsetoday.co.uk/copperfield)). How has the BMA colluded on such rubbish?

It will not make any real difference, as the CQC regulating body has proved its incompetence time and again. They regularly bury their heads in the piles of information collected so that, when alerted to misdemeanours and poor practice, they are unable - or unwilling - to respond. Surely if the majority of us refuse to engage in this task, we will not have to pay for the privilege.

● From Dr Robert Cullen

Romney, Kent

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

Dr Copperfield is right, CQC registration will be a complete waste of time. I have tried to encourage my local practices to boycott the process. If we all did, then there is no way we could all be closed down.

● From Dr John Derounian

Glenilvet, Banffshire

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

Nobody else has realised yet, but I think you'll find that CQC actually stands for Can't Quite Comply. That will probably apply to me anyway. Anybody else?

## Will the BMA commit to more action?

From Dr Peter Budden

Manchester

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

As numerous commentators and jolting GPs keep telling our 'representatives', we have three powerful options available right now to effect change ('Change tack on industrial action, says GP candidate for BMA chair', [pulsetoday.co.uk/news](http://pulsetoday.co.uk/news)).

These are no co-operation with the CQC, no co-operation with revalidation and ultimately refusal to apply for CCG authorisation.

None of these affect patients. Will the BMA now kindly step up to the mark?

Hell, I may even re-join if they did.

## Targeting the CQC won't hurt patients

From Dr Ian King

Redhill, Surrey

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

The BMA has made a poor choice for action and it hurt patients.

Let's refuse to co-operate with the CQC until the Government backs off. No patients get hurt that way. We don't have to worry about lots of box-ticking.

The Government will, however, have to justify that it is still safe for patients to go to primary care, even if nobody is CQC-accredited. What can go wrong if we all stand united?

● From Dr Steve Hirst

Preston

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

I agree with Dr Gary Taylor ('Above all, we must protect our patients', [pulsetoday.co.uk/letters](http://pulsetoday.co.uk/letters)).

Will someone at the GPC please listen to us for once?

We should start a campaign now of non-cooperation, targeting the Government (and

not patients) and starting with CQC registration - before it is too late.

## For once, I agree with the Government

From Dr C John McHenry

York

As a semi-retired GP who worked nights and weekends, I am sickened by the action of GPs ('Third of GPs taking industrial action', [pulsetoday.co.uk/news](http://pulsetoday.co.uk/news)).

I thought we were members of what used to be a profession. For a change, I endorse the Government's response.

## We need psychiatry support

From Dr Thomas Caldwell

Worcester

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

While I welcome the calls for training in psychiatry, it is the access to psychiatrists and therapies that I see as the major problem ('GPs must make sure that mental health doesn't lose out', [pulsetoday.co.uk/opinion](http://pulsetoday.co.uk/opinion)).

I did psychiatry as part of my rotation, and would start medications and try to start therapies.

However, access to acute psychiatry is appalling and moves at a glacial pace - access to counselling or talking therapies is almost impossible.

No amount of training compensates for the fact that when you see a clinical need you can access so little, and what you can access seems hopelessly slow.

## Choose and Book's locality divide

From Dr Peter McEvedy

Blyth, Northumberland

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

The figures for Choose and Book use make interesting reading ('Choose and Book usage dips below 50%', [pulsetoday.co.uk/news](http://pulsetoday.co.uk/news)).

Coming from the North East, we have a high usage figure, but Choose and Book is an illusion here as there is very little choice. At best, it's a choice between two trusts.

Booking is a boon though - that is, when the system actually works.

I imagine the choice element is far greater in the south and east of England where there is the lowest adherence - the plethora of choices makes the system far more unwieldy.

## All doctors should have CSA training

From Dr Rob Fletcher

Croydon, south London

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

I was a hospital doctor for 11 years before taking the MRCGP last year, largely working in orthopaedics and A&E, and I came to the same conclusion as Dr Anudeep Chakrabarti when I was doing my VTS ('GPs love all that tree-hugging stuff, don't they?', [pulsetoday.co.uk/gpnote](http://pulsetoday.co.uk/gpnote)).

It is laughable that the consultation models, training and assessment are considered specific to general practice as a specialty - these should be mandatory for all trainees,

students and junior doctors alike. I suspect there is an inversely proportional relationship between years spent as a hospital doctor and CSA pass rates.

The problem is that in hospital, the doctor doesn't want the patient to elaborate and expand - they just want to deal with the most pressing issue.

Performing an ideas, concerns and expectations consultation on a patient in A&E can be the kiss of death for timekeeping.

Remember that almost all junior hospital doctors work on the principle that they will never see the patient again, so his leaving satisfied is far less important to them than the GP who must establish a totally different relationship with the patient, who's going to keep coming back until they get satisfaction.

## Useful joint injection guidance

From Dr Samia Bushra

Dagenham

[via pulsetoday.co.uk](mailto:via.pulsetoday.co.uk)

I don't administer joint injections myself, though Dr Ted Willis's article on NICE's current approach to osteoarthritis was interesting ('Why NICE is wrong on OA', [pulsetoday.co.uk/clinicalwriting](http://pulsetoday.co.uk/clinicalwriting)).

However, my colleague does, and as usual, it is the steroid injection rather than the hyaluronan injections Dr Willis discusses.

I have known about the hyaluronan injections for some time, and would imagine that, as he says, physiologically it would be the better injection.



# Pulse Clinical

## In this issue

**Key questions** 1.5 CPD hours

HIV

page 20

**ENT clinic**

Otosclerosis

page 24

Stapedectomy restores hearing in 95% of cases



**Ten top tips**

Bronchiectasis

page 25

**Post-operative problems**

1 CPD hour

Gastrointestinal surgery complications

page 26

## More online



**Pulse Learning**

► pulse-learning.co.uk

**Hot topics in women's health** 2 CPD hours

Includes mastitis and pointers to ovarian cancer

**Key questions: rhinitis and nasal congestion** 1.5 CPD hours

A sponsored module on allergic and vasomotor rhinitis and polyps

**Photofile: external eye conditions** 1.5 CPD hours

Our latest picture module



**Pulse Today**

► pulsetoday.co.uk

**Resource of the week** NICE has launched a new BNF app, which can be downloaded for free

## KEY QUESTIONS

# HIV

**Dr Michael Brady,** consultant in sexual health and HIV, tackles questions from GP **Dr Pam Brown** on HIV testing, pre-test counselling and antiretrovirals

### 1 What presentations should prompt us to suggest HIV testing?

HIV seroconversion illness is the first prompt to test for HIV. The symptoms are non-specific and typically mimic a flu-like illness such as glandular fever.

Common symptoms include fever, sore throat, rash and lymphadenopathy – severity of symptoms varies, but most patients will experience them.


A recent study in south London showed that 1.3% of glandular fever screening samples were positive for HIV.<sup>1</sup>

This highlights the need to include HIV testing in investigations of flu-like illnesses, especially in high-risk groups (gay men and black African people).

Following seroconversion, patients enter a period of asymptomatic infection that can last for many years.

During this time there will be nothing clinical to indicate they have HIV. Routine testing of high-risk groups is the only way to detect undiagnosed infection at this stage. In 2011, NICE produced guidance to support this.<sup>2,3</sup>

As HIV disease progresses and immune function worsens, patients may present with a wide range of signs and symptoms. Suspect HIV in any patient with unusual presentations or conditions that are more severe, or harder to treat, than you would expect.



HIV viruses budding from a lymphocyte

### Clinical indicator diseases for adult HIV infection

System	AIDS-defining conditions	Other conditions where HIV testing should be offered
Respiratory	Pneumocystis	Bacterial pneumonia Tuberculosis
Dermatology	Kaposi's sarcoma	Severe or recalcitrant seborrhoeic dermatitis or psoriasis Multi-dermatomal or recurrent herpes zoster
Neurology	Cerebral toxoplasmosis Primary cerebral lymphoma	Cerebral abscess Peripheral neuropathy Dementia
Gastroenterology	Persistent cryptosporidiosis	Oral candidiasis Oral hairy leukoplakia Chronic diarrhoea Weight loss Hepatitis B or C
Haematology		Unexplained blood dyscrasia (anaemia, neutropaenia, lymphopaenia, thrombocytopaenia)
Other		Glandular fever-like illness Lymphadenopathy (unknown cause) Any sexually transmitted infection

### 2 What are the common presentations of long-standing HIV infection which we should be aware of in primary care?

The UK National Guidelines for HIV testing<sup>4</sup> includes a useful table describing the clinical indicator diseases for adult HIV infection. It lists both AIDS-defining illnesses and conditions that are more common in people with HIV. The table (below left), which doesn't include every condition, is taken from those guidelines.

### 3 When is it appropriate for HIV testing to be undertaken in a general practice setting, and do we need to document consent?

It is always appropriate for HIV testing to be undertaken in general practice. There are two approaches – routine opt-out screening (which is recommended in high-prevalence areas) or targeted testing of patients at highest risk and those presenting with symptoms suggestive of HIV.

Opt-out testing of all new GP registrants is recommended in areas where diagnosed HIV prevalence is greater than 0.2%. You can find details of your local HIV prevalence and information supporting opt-out testing on the Health Protection Agency website.<sup>5</sup> In areas of low prevalence, opt-out screening is unlikely to be cost effective – so here, targeted testing of patients at highest risk should be undertaken. There is no need for written consent for an HIV test – verbal consent is sufficient. Ensure that the patient is aware they are having an HIV test and what the benefits and implications are and note that you have done so.

### 4 What is the specificity and sensitivity of point-of-care tests? If it's negative, should we recommend laboratory testing?

The sensitivity and specificity of point-of-care tests is very good. The tests available in the UK have reported sensitivities of 99-100% and specificities of 96-99.6%.

The key thing to know with any HIV test is the window period – the time it takes from acquiring infection to it being detectable by the test. Third-generation HIV tests only detect HIV antibodies and have a window period of three months. Fourth-generation HIV tests detect both HIV antibodies and HIV p24 antigen, and have a window period of just one month. Most UK labs use fourth-



# Relax, Urgency controlled



**Vesicare®**  
solifenacin

## ABBREVIATED PRESCRIBING INFORMATION

**Presentation:** Vesicare® film-coated tablets containing 5 mg or 10 mg solifenacin succinate. **Indication:** Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome. **Dosage:** Adults: Recommended dose: 5 mg once daily. If needed, the dose may be increased to 10 mg once daily. Children and adolescents: Should not be used. **Contraindications:** Urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and its patients at risk for these conditions. Patients hypersensitive to the active substance or to any of the excipients, or undergoing haemodialysis, or with severe hepatic impairment, or with severe renal or moderate hepatic impairment and on treatment with a potent CYP3A4 inhibitor. **Warnings and Precautions:** No clinical data are available from women who became pregnant while taking solifenacin. Caution should be exercised when prescribing to pregnant women. The use of Vesicare® should be avoided during breast-feeding. Assess other causes of frequent urination before prescribing. Use with caution in patients with clinically significant bladder outflow obstruction at risk of urinary retention, gastrointestinal obstructive disorders, risk of decreased gastrointestinal motility, autonomic neuropathy, severe renal or moderate hepatic impairment (doses not to exceed 5 mg), concomitant use of a potent CYP3A4 inhibitor, hiatal hernia/gastroesophageal reflux and/or patients currently taking

medicines that can cause or exacerbate oesophagitis. Angioedema with airway obstruction has been reported with some patients on Vesicare®. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. **Interactions:** Concomitant medication with other medicinal products with anticholinergic properties may result in more pronounced therapeutic effects and undesirable effects. Allow one week after stopping Vesicare® before commencing other anticholinergic therapy. Therapeutic effect may be reduced by concomitant administration of cholinergic receptor agonists. Can reduce effects of stimulants of gastrointestinal tract motility. If used concomitantly with ketoconazole or other CYP3A4 potent inhibitor, maximum dose should be 5 mg due to 2-3 fold increase in AUC of Vesicare®. Pharmacokinetic Interactions are possible with other CYP3A4 substrates with higher affinity and CYP3A4 inducers. **Adverse Effects:** Dry mouth, blurred vision, constipation, nausea, dyspepsia, abdominal pain, urinary tract infection, peripheral oedema, colonic obstruction, rash, urinary retention, hallucinations, confusional state, angioedema. In worldwide postmarketing experience, QT prolongation and Torsade de Pointes have been reported in association with Vesicare® use, but the frequency of events and the role of Vesicare® in their causation cannot be reliably determined. Prescribers should consult the Summary of Product

Characteristics in relation to other side effects. Basic NHS Cost: Vesicare® 5 mg blister packs of 30 tablets £27.62; Vesicare® 10 mg blister packs of 30 tablets £35.91. Legal Category: POM. Product Licence Number: Vesicare® 5 mg PL 00166/0197; Vesicare® 10 mg PL 00166/0198. Date of Revision: October 2011. Further information available from: Astellas Pharma Ltd, 3rd Floor, Future House, The Gantry, Egham, Surrey, TW20 9AH. Vesicare® is a Registered Trademark. For full prescribing information please refer to the Summary of Product Characteristics. For medical information phone 0800 783 5018.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) Adverse events should also be reported to Astellas Pharma Ltd. Tel: 0800 783 5018.

Date of preparation: April 2012  
VES12142UCb

 **astellas**  
Leading Light for Life



20 generation tests. Most point-of-care tests are third-generation tests.

If you are concerned that a patient may have been infected within the last three months, it is best to do a fourth-generation laboratory test. All positive results on point-of-care tests need to be confirmed with a serological test because false positives do occur, particularly in low-prevalence populations. But if a point-of-care test is negative and the patient is beyond the window period for that test, there is no need to recommend laboratory testing as well.

### 5 What pre-test counselling should we give?

A pre-test discussion with the patient is recommended, to give them information about the test. This can be given in written form if that helps to save time. Pre-test discussion should focus on the benefits of a diagnosis - explain that HIV is now

## PULSE Learning

### 1.5 CPD hours

Go online to complete this CPD module for a suggested 1.5 credits. This module will be available free to all members of Pulse Learning until 18 July 2012  
► [pulse-learning.co.uk](http://pulse-learning.co.uk)

an easily treatable long-term condition. Access to treatment means patients stay well and should live long and healthy lives. Treatment also dramatically reduces the risk

of transmission to others and enables women to have normal pregnancies, labour and uninfected children.

The pre-test discussion should also include information about the window period and advice about the timing of a re-test if needed, and clear information about how and when they will get the test result. More detailed pre-test discussion or counselling may be necessary for patients whose first language isn't English, patients at higher risk or patients who are particularly anxious about the result.

### 6 What are the important interactions with antiretroviral medication? How can we find out that our patient is taking these drugs, as they are prescribed by specialist clinics?

Most antiretroviral drugs are metabolised via cytochrome p450 in the liver and so can cause, or be affected by, alterations in the activity of

this enzyme system. It's impossible to list all potential interactions here, but the University of Liverpool has an excellent website where you can look up potential antiretroviral drug interactions - go to [pulsetoday.co.uk/tools-and-resources](http://pulsetoday.co.uk/tools-and-resources) for a link to the site.

Some of the drugs that can interact with antiretroviral medications include:

- tuberculosis medications
- some antidepressants
- PPIs and H<sub>2</sub>-antagonists
- statins
- oral contraceptive pill
- warfarin
- antiepileptics
- methadone
- herbal medicines such as St John's wort and milk thistle.

Specialists generally encourage patients to disclose their HIV status to their GP so details of their medications and recent blood test results can be provided. If you know one

# Don't let a single moment of weakness undo all of a patient's hard work

## Prescribe combination therapy from quit day

NiQuitin Minis 4 mg are proven to improve NiQuitin Clear 21 mg Patch quit rates when used in combination from quit day.<sup>1</sup>

Prescribe the continuous protection of NiQuitin Clear 21 mg Patch with NiQuitin Minis 4 mg, a fast response to cravings.



**Prescribing information:** NiQuitin 2 mg / 4 mg Lozenges, NiQuitin 2 mg / 4 mg Mint Lozenges, NiQuitin Pre-Quit 4 mg Mint Lozenges, NiQuitin Minis Mint 1.5 mg / 4 mg Lozenges and NiQuitin Minis Cherry Flavour 1.5 mg Lozenges (nicotine). For relief of nicotine withdrawal symptoms during abrupt / gradual / temporary smoking cessation and to aid reduction in smoking. **Dosage: Adults (18 and over):** Maximum 15 lozenges / day. Cessation to be encouraged, professional advice if no quit attempt after 6 months / difficulty discontinuing after quitting. **Lozenges & Mint Lozenges:** 4 mg if smoke within 30 minutes of waking, otherwise 2 mg. **Pre-Quit Lozenges:** for those who smoke within 30 minutes of waking only. **Mint Lozenges:** 4 mg strength if smoke > 20/day, otherwise 1.5 mg. **Abrupt cessation:** Lozenges: 3 Mint Lozenges: Weeks 1 to 6, 1 lozenge every 1 to 2 hours (min. 8/day). Weeks 7 to 8, 1 lozenge every 2 to 4 hours. Weeks 10 to 12, 1 lozenge every 4 to 8 hours. Beyond 12 weeks, 1 to 2 lozenges per day if strongly tempted to smoke. **Mint Lozenges:** 8 - 12 lozenges/day, use a lozenge when urge to smoke. **Super use after 6 weeks:** After treatment, use a lozenge if strongly tempted to smoke. **Gradual cessation & Pre-Quit:** Prior to schedule above use when strong urge to smoke to reduce cigarette consumption. Professional advice if no reduction after 6 weeks. **Reduction in smoking:** Use when strong urge to smoke to reduce cigarette consumption as much as possible. **Temporary cessation:** 1 lozenge every 1 to 2 hours. **Adolescents (12-17 years):** Abrupt cessation only. Dosing as for adults. Seek professional advice if unable to quit abruptly. **Contraindications:** Hypersensitivity, non-smokers, children under 12 years. **Precautions:** Risk of NRI substantially outweighed by risks of continued smoking in virtually all circumstances. Supervise use in those hospitalised for MI, severe dysrhythmia or CVA who are haemodynamically unstable. Once discharged, can use NiQuitin as normal. Susceptibility to angioedema, urticaria. Renal/hepatic

impairment, hyperthyroidism, diabetes, pheochromocytoma. **Overdosed nicotine** may exacerbate nasopharyngitis, gastric / peptic ulcer. **Lozenges, Mint Lozenges & Pre-Quit Lozenges:** low sodium diet, phenylethanolamine. **Pregnancy / lactation:** For those unable to quit unaided the risk of continued smoking is greater than the risk of using NRI. Start treatment as early as possible in pregnancy. Lozenge/gum preferable to patches unless nauseous. **Side effects:** At recommended doses, NiQuitin has not been found to cause any serious adverse effects. See SPC for full details. Dizziness, anaphylaxis, sleep disorders, anxiety irritability, headache, cough, GI disturbances, oral irritation/ulceration. **Lozenges, 4 mg Lozenges, 4 mg Mint Lozenges & Pre-Quit Lozenges only:** Sore throat, chest pain/tightness. **Lozenges, Mint Lozenges & Pre-Quit Lozenges only:** Appetite change, pharyngitis, lower respiratory tract infection, respiratory disorders, dysphagia, aggravated asthma (2 mg only), throat swelling (4 mg only). **Mint Lozenges only:** Nervousness, depression. **SSL PL numbers:** PL 00079/0606, 0607, 0389, 0370, 0610, 0611 & 0658. **PL holder:** GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, U.K. **Pack sizes & NHS cost:** Lozenges & Mint Lozenges: 36's £5.12, 72's £9.07. **Pre-Quit Lozenges:** 36's only, £5.12. **Mint Lozenges:** 20's £3.18, 60's £8.93. **Date of preparation:** February 2012.

**NiQuitin 21, 14, 7 mg Transdermal Patches:** NiQuitin Clear 21, 14, 7 mg (nicotine). Opaque or transparent transdermal patches 21 mg, 14 mg, 7 mg nicotine (Step 1, 2, 3) for relief of nicotine withdrawal symptoms during abrupt/gradual/temporary smoking cessation and to aid reduction in smoking. **Dosage: Adults (18 and over):** Once daily, ≥ 10 cigarettes a day start with step 1, otherwise step 2. Cessation to be encouraged, professional advice if no quit attempt after 6 months/difficulty discontinuing use after quitting. **Abrupt cessation:** ≥ 10 cigarettes/day, Step



of your patients is HIV positive and have not heard from their specialist centre, I would advise contacting them for details of any medication the patient is taking.

### 7 Very rarely, GPs might find themselves having to explain the implications of a positive HIV result. What areas should the GP cover in this initial post-test consultation?

Everyone reacts differently, so be flexible - some patients will want a lot of information and some will want none. The focus should be on supporting the patient to deal with the diagnosis. How are they feeling? Was it a surprise? Who will they tell?

The key thing is to explain that HIV is a treatable condition and life expectancy for patients living with HIV and accessing treatment is expected to be much the same as the non-HIV positive population. This doesn't

## Supporting you with CPD

► [pulse-learning.co.uk](http://pulse-learning.co.uk)

Go online to read an extended version of this article, with Dr Brady answering questions on completing insurance forms, managing intercurrent illness, prophylaxis and palliative care for patients with AIDS.

diminish the impact an HIV diagnosis can have on an individual, and it is important to be able to help patients cope with, and come to terms with, an HIV diagnosis. Organisations such as the Terrence Higgins Trust are useful sources of support in these early days and I always give patients their contact details ([tht.org.uk](http://tht.org.uk) and THT Direct: 0800 802 1221).

Rapid referral to your local HIV service is essential, so ensure you have an agreed referral pathway in place.

**Dr Michael Brady** is a consultant in sexual health and HIV at King's College Hospital and medical director of the Terrence Higgins Trust

**Dr Pam Brown** is a GP in Swansea

The Terrence Higgins Trust is the UK's leading HIV and sexual health charity. Wednesday 4 July marks 30 years since the death of Terry Higgins, the first person publicly identified as dying with AIDS in the UK. To view the charity's 30th anniversary campaign 'Thanks Terry', visit [tht.org.uk](http://tht.org.uk).

### References

1. Ruf M, Hsu D, O'Shea S et al. Diagnosing HIV infection in patients presenting with glandular fever-like illness in primary care: are we missing primary HIV infection? *HIV Med* 2012, online 20 May
2. NICE. Increasing the uptake of HIV testing among men who have sex with men. 2011;PH34
3. NICE. Increasing the uptake of HIV testing among black Africans in England. 2011;PH33
4. British HIV Association, British Association of Sexual Health and HIV, British Infection Society. UK National Guidelines for HIV Testing. 2008
5. HPA. Evidence and resources to commission expanded HIV testing in priority medical services in high prevalence areas. April 2012. [hpa.org.uk](http://hpa.org.uk) (accessed 14 June 2012)

## PULSE Learning

Our most popular CPD modules over the last week

What's new in... **1 CPD hour**  
Cardiology

Key questions **1.5 CPD hours**  
COPD

Ten new generics to look out for in 2012/13 **1 CPD hour**

PulsePlus: Neurology **3 CPD hours**

Key questions **1.5 CPD hours**  
Smoking cessation

► [pulse-learning.co.uk](http://pulse-learning.co.uk)

## Relieve breakthrough cravings fast with NiQuitin Minis

Sometimes cravings that strike at trigger moments, like whilst enjoying that glass of wine, can be tough to resist. In fact, these acute, breakthrough cravings can lead to smoking in just 11 minutes.<sup>2</sup>

**Prescribe NiQuitin Minis 4 mg Lozenges for fast relief from breakthrough cravings<sup>3,4</sup>, whenever your patient needs it.**

Studies carried out using standard **NiQuitin** Lozenge



1 for 6 weeks, then Step 2 for 2 weeks, then Step 3 for 2 weeks, < 10 cigarettes/day; Step 2 for 6 weeks then Step 3 for 2 weeks. Pre-quit gradual cessation (2mg only). Use patch and continue to smoke as needed for 2-4 weeks before starting abrupt quit as above. Reduction in smoking: Use patch whilst smoking as needed. Reduce cigarette consumption as much as possible. Temporary abstinence: Use patch for period during which smoking is to be avoided. Adolescents (12-17 years): Abrupt cessation only. Dosing as for adults. Seek professional advice if unable to quit abruptly. Contraindications: Hypersensitivity, occasional/non-smokers, children under 12 years. Precautions: Risk of NRT substantially outweighed by risks of continued smoking in virtually all circumstances. Supervise use in those hospitalised for MI, severe dysrhythmia or CVA who are haemodynamically unstable. Once discharged, can use NiQuitin as normal. Susceptibility to angioedema, urticaria. Discontinue use if severe/persistent skin reactions. Renal/hepatic impairment, hyperthyroidism, diabetes, pheochromocytoma. Pregnancy/lactation: For those unable to quit unaided the risk of continued smoking is greater than the risk of using NRT. Start treatment as early as possible in pregnancy. Lozenge/gum preferable to patches unless nausea. Remove patches at bedtime. Side effects: At recommended doses, NiQuitin patches have not been found to cause any serious adverse effects. Local rash, itching, burning, tingling, numbness, swelling, pain, urticaria, heaviness, hypersensitivity reactions. Headache, dizziness, tremor, sleep disorders, nervousness, palpitations, tachycardia, dyspnoea, pharyngitis, cough, GI disturbance, sore throat, arthralgia, myalgia, malaise, anaphylaxis. See SPC for full details. GSK PL 03679/0368, 0367, 0366, 0356, 0355 & 0354. PL holder: GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, U.K. Pack sizes and NHS Cost: 7 patches £0.97; Step 1 only 14 patches £18.79. Date of preparation: February 2012.

## Celebrate every win with NiQuitin<sup>®</sup> nicotine

References: 1. Piper ME et al. A Randomized Placebo-Controlled Clinical Trial of 6 Smoking Cessation Pharmacotherapies. *Arch Gen Psychiatry* 2009; 66: 1250-62. 2. Fergusson SG and Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. *Journal of Substance Abuse Treatment* 2008; 36: 235-43. 3. Durcan MJ et al. Efficacy of the nicotine lozenge in relieving cue-induced cravings. Presented at the 5th European SANC. Parma, Italy, 2003. 4. GSK data on file, 2007.


Adverse events should be reported. Reporting forms and information can be found at <http://www.mhra.gov.uk/yellowcard>. Adverse events should also be reported to GlaxoSmithKline Consumer Healthcare 0500 100 222

NiQuitin and the MHHS device are registered trade marks of the GlaxoSmithKline group of companies

Date of preparation: June 2012: CHG/CMQ/0055/12

**gsk** GlaxoSmithKline Consumer Healthcare





**OMACOR<sup>®</sup>**

Omega-3-acid ethyl esters 90

You can't control life.  
You can control hypertriglyceridaemia.

Please consult the Summary of Product Characteristics before prescribing, particularly in relation to side effects, precautions and contraindications. Legal Category: P.


Full prescribing information is available on request from: Abbott Healthcare Products Ltd, Marlowe Road, West End, Southampton, SO18 3JQ.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Abbott by phone: 0800 121 8267.

Date of preparation: April 2012

AHOMA120160

**Abbott**  
A Promise for Life



## ENT CLINIC

# Otosclerosis

## ENT GPST

**Dr Raj Singh**  
on a common  
cause of  
progressive  
hearing loss in  
young adults

### CASE

A 19-year-old student presented to his GP shortly after starting his first term at the local university.

He described a five-year history of gradually progressive hearing loss, originally in his right ear but bilateral for around two years. He had never presented with the problem before as he found he could compensate at school – for example, by sitting near the front in class.

But he was finding it more difficult to cope at university – with loud social situations particularly stressful – and he felt the problem had recently got much worse. He also described the recent development of mild, intermittent tinnitus. There was no family history of hearing problems and he was otherwise healthy.

Auroscopy was normal, but Weber and Rinne testing revealed conductive hearing loss in his right ear and was inconclusive in his left. He was referred to ENT, where pure-tone audiometry confirmed purely conductive, predominantly low-tone hearing loss in both ears and he was diagnosed with otosclerosis.

Three months later he had a stapedectomy in his right ear, which almost totally restored his hearing in that ear. He is currently being monitored for possible surgery on his left ear.

### The problem

- Otosclerosis is a failure in sound conduction caused by a pathological increase in bone turnover, leading to sclerosis and ankylosis of the stapes footplate in the fenestra ovalis.
- The process sometimes extends to the cochlea itself.

- There is an autosomal dominant inheritance pattern, but variable penetrance – so often there is no family history – and environmental factors have also been implicated, including oestrogens and measles infection.<sup>1</sup>

- European prevalence estimates range from around 1.4% to 2.1% – seen in one UK study<sup>2</sup> – but there are suggestions the incidence has declined with fewer measles infections.<sup>1</sup>

- It typically presents between the ages of 15 and 35, is more common in women than men and most common in Asian and Caucasian populations.

- If untreated, otosclerosis leads to significant hearing loss of about 50–60dB – though total deafness is uncommon.

### Features

- The main symptoms are progressive hearing loss – bilateral in around 70% of cases – and tinnitus.
- The hearing loss is usually in the lower range and particular difficulty hearing deep, male voices is a characteristic sign.
- There are usually no vestibular symptoms, but some patients might also experience mild dizziness and in rare cases there is severe rotatory nystagmus as in Ménière's disease.

### Diagnosis

- Auroscopy is usually normal, although increased vascularity of the promontory will cause a reddish-blue discoloration behind the tympanic membrane in about 10% of cases – Schwartz's sign.
- Weber and Rinne testing usually shows a conductive pattern deafness.
- If the cochlea has become involved, there may be a mixed conductive/sensory pattern of hearing loss.

- Page's disease – which shares some pathophysiological similarities – can present with exactly the same pattern of hearing loss, but usually also with other features of the disease such as bone pain. This usually affects older age groups.

- Audiometry is the primary investigation of choice and will usually reveal a purely conductive, mostly low-tone loss.

- Characteristic audiogram patterns can seal the diagnosis if there is the mixed conductive/sensorineural loss seen with cochlea involvement.

- In a few cases, CT scanning will be used to look for abnormal bone deposition in the temporal bone.

### Management

- Hearing aids can be very effective, but advances in surgical treatment over the past 20 years make this the most popular management option.

- There are two surgical options, both with the aim of enhancing the vibration of fluid within the cochlear canal. Stapedectomy involves the extraction of the stapes footplate, while stapedotomy involves small holes being made in the footplate. Both are done as day cases.<sup>3</sup>

- Restoration of normal hearing loss is seen in up to 95% of cases for both procedures, but total hearing loss occurs after about 1% of procedures for unknown reasons and does not seem to be linked to surgical skill.

**Dr Raj Singh** is an ENT GPST in Manchester

### References

- Schrauwen I and Van Camp G. The aetiology of otosclerosis: a combination of genes and environment. *Laryngoscope* 2010; 120:1155–202.
- Vartiainen E and Vartiainen T. Effect of drinking water fluoridation on the prevalence of otosclerosis. *J Laryngol Otol* 1997; 111:20–2.
- Niedermeyer HP and Arnold W. Otosclerosis and measles virus – association or causation? *J Otolaryngol Head Neck Surg* 2008; 129:63–70.



## TEN TOP TIPS

## Bronchiectasis

Respiratory GPSI **Dr Tarek Bakht** outlines 10 key points in managing bronchiectasis



In bronchiectasis the bronchi are thickened and dilated

- 1 Consider bronchiectasis in persistent productive cough.**  
Think of bronchiectasis in patients who have a persistent productive cough for many years with increased sputum production or recurrent chest infections, especially younger patients with no smoking history. Other symptoms include dyspnoea, wheezing, haemoptysis and chest pain.
- 2 Do baseline investigations before referral.**  
In most regions you need to refer for confirmation of diagnosis and further assessment. It is useful for GPs to request a baseline chest X-ray, spirometry and sputum culture and sensitivity. Chest X-ray is often normal in bronchiectasis but advanced cases may show thickened dilated bronchi with 'tram lines', cystic spaces and ring opacities. Tests for cystic fibrosis should be done if indicated – especially in patients younger than 40.
- 3 Vaccinate against influenza and pneumococcal pneumonia.**  
Make sure patients with bronchiectasis have their annual flu vaccine and also have had the pneumococcal vaccine.
- 4 Refer for chest physiotherapy.**  
All patients with bronchiectasis should see a chest physiotherapist. This can help improve sputum clearance from the lungs, which reduces symptoms and exacerbations and improves quality of life.
- 5 Be aware of chronic colonisation.**  
Two-thirds of bronchiectasis patients chronically colonise bacteria in their lungs – commonly *Pseudomonas aeruginosa*, *Haemophilus influenzae*, *Staphylococcus aureus*, *Moraxella catarrhalis* and occasionally opportunistic mycobacterium. Sputum culture and sensitivity will help guide antibiotic treatments and identify patients with pseudomonas colonisation, who often have poor disease progression, increased hospital admissions and poor quality of life.

6

**Assess for airway obstruction.**

Some bronchiectasis patients have airway obstruction related to the disease, asthma or COPD. Do spirometry on all bronchiectasis patients to detect related airway obstruction and assess for reversibility. Patients with co-existing asthma or COPD should be managed according to the relevant guidelines. There is insufficient evidence to determine whether mucolytics are useful in bronchiectasis.

7

**Don't delay antibiotics in exacerbations.**

Exacerbations are characterised by worsening cough, purulent sputum production, increasing wheeze, breathlessness and haemoptysis or systemic upset. Don't wait for the results of a sputum sample – start empirical treatment with amoxicillin 500mg TDS or clarithromycin 500mg BD (in penicillin-allergic patients) for 14 days. Where previous sputum bacteriology is known, antibiotic treatment can be guided by this. Ciprofloxacin should be used in patients known to have pseudomonas colonisation.

8

**Consider long-term antibiotics for frequent exacerbations.**

Long-term oral antibiotics can be considered in patients with three or more exacerbations a year, or fewer exacerbations if there is significant morbidity. Long-term nebulised antibiotics can also be considered in similar patients if they chronically colonise *Pseudomonas aeruginosa*. Refer to a specialist if you are considering long-term antibiotics.

9

**Do annual spirometry.**

It is useful to do annual spirometry in patients with bronchiectosis to detect and monitor obstructive airway disease.

10

**Refer patients with deterioration, chronic colonisation or comorbidities.**


Consider specialist referral in patients who have three or more exacerbations a year, deteriorating bronchiectasis with declining lung function, chronic pseudomonas, opportunistic mycobacteria or MRSA colonisation, or who are on long-term antibiotics. Also consider referring patients who have comorbidities, advanced disease and those considering transplantation or surgery.

**Dr Tarek Bakht is a GPSI in respiratory medicine in Bolton, Greater Manchester, and executive board member of the Primary Care Respiratory Society UK**

The Primary Care Respiratory Society UK (PCRS-UK) is the UK-wide professional society committed to improving respiratory care in primary care. PCRS-UK is a registered charity, led by its members through a range of committees and faculties dedicated to meeting the vision of 'optimal respiratory care for all', providing education, policy support and research. As a member you'll have unlimited access to a wealth of specialist respiratory care information, expertise and resources, plus practical everyday tools to help you make a difference in respiratory care. For more information about PCRS-UK and how to join, go to [pcrs-uk.org/join](http://pcrs-uk.org/join).

**Further reading**

- 1 Mandal P and Hill A. Bronchiectasis Opinion Sheet. Primary Care Respiratory Society UK, 2011.
- 2 Pasteur MC, Hilton D and Hill AJ. British Thoracic Society guideline for non-CF bronchiectasis. *Thorax* 2010;65:11-58.
- 3 Hill A, Pasteur M, Cornford C et al. Primary care summary of the British Thoracic Society Guideline on the management of non-cystic fibrosis bronchiectasis. *Prim Care Respir J* 2011; 20:135-40.



**OMACOR<sup>®</sup>**  
Omega-3-acid ethyl esters 90

Significantly reduces sudden death after MI

Please consult the Summary of Product Characteristics before prescribing, particularly in relation to side effects, precautions and contraindications. Legal Category: IT.

Full prescribing information is available on request from: Abbott Healthcare Products Ltd, Mansbridge Road, West End, Southampton, SO16 3JD.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Abbott by phone: 0800 121 8267.

Date of prescription: April 2012

AKOMA 120160

**Abbott**  
A Promise for Life



## POST-OP PROBLEMS

# Gastrointestinal surgery

Consultant surgeon

**Mr Mike Parker**

continues our series with a discussion of complications after GI surgery

In this article I will cover the post-operative complications of some common gastrointestinal (GI) operations which are usually done as day cases - hopefully helping GPs to deal with these complications in the community where possible, and to know when referral should be considered.

## Classification

In GI surgery, complications can be classified as immediate (within 24 hours), early (24 hours to one week) or late (after one week).<sup>1</sup>

## Oesophago-gastro-duodenoscopy

Oesophago-gastro-duodenoscopy (OGD) is one of the most common investigations performed for GI problems.

Most patients will go home the same day perfectly well. Intravenous sedatives wear off after about 45 minutes, but may stay in the system for up to 24 hours, and patients are usually advised not to drive, operate heavy machinery or sign legal documents during this time.

### Immediate and early

- **Bleeding** occurs rarely post-OGD, and this nearly always stops spontaneously - unless the reason for the endoscopy was upper GI bleeding.
- **Perforation of the upper GI tract** occurs very rarely - the incidence is about one in 25,000 cases. This is an absolute emergency. The patient will be unwell, possibly with crepitus in the neck and sometimes with early signs of mediastinitis - for example, pyrexia, tachycardia, dyspnoea, nausea and vomiting. If any patient presents

within 24 hours (or even longer) with such symptoms, they must be taken to hospital immediately. If possible inform the clinician concerned at the hospital, as emergency surgery may be required.

- **Aspiration** may occur at the time of OGD, and this will usually be treated by keeping the patient in hospital. But occasionally it may not be recognised and the patient may present over the next few days with a cough, temperature, tachycardia and signs of a chest infection. The diagnosis is actually a chemical pneumonitis (inflammatory) and any infection is secondary, but patients do need to be treated aggressively with antibiotics,

physiotherapy and possibly steroids. If the patient does not respond rapidly to treatment, consider semi-emergency referral to the endoscopy team or to a respiratory physician.

## Colonoscopy

Colonoscopy is also usually performed under intravenous sedation, and so the same advice about driving and operating machinery is given as for OGD.

### Immediate and early

- **Perforation** is more common in colonoscopy than OGD, with about a one in 2,000 incidence in the UK. Any patient with signs

suggesting perforation - such as abdominal pain or tenderness, tachycardia and a temperature - should be referred back to the endoscopy unit immediately. Onset of severe pain after discharge means something untoward might have occurred, because no patient should be discharged from hospital after a colonoscopy if they are still in pain.

- **Bleeding** sometimes occurs because of the colonoscope chafing the wall of the bowel, but in my experience this always stops spontaneously and does not need referral unless catastrophic in volume, which I have never seen.



## Did you know that the nose is one of the dirtiest organs in the human body?

Stérimar<sup>®</sup>, the 100% natural seawater nasal spray, is giving you the opportunity to learn more about nasal conditions and complete 1.5 CPD hours for free at [www.pulse-learning.co.uk](http://www.pulse-learning.co.uk)

You can also find out more about the nose and how Stérimar can help your patients at [www.sterimaracademy.co.uk](http://www.sterimaracademy.co.uk)

**For a cleaner, healthier nose, naturally**

Stérimar is a trademark of SOFIBEL SAS. Rev. 06-12

**STÉRIMAR<sup>®</sup>**  
Natural Sea Water Nasal Spray



# complications



Haematoma is a common complication after hernia repair

## Liver biopsy

Liver biopsy is a common diagnostic investigation for liver disease.

### Immediate

● **Bleeding or biliary leakage** into the peritoneal cavity will usually settle if treated conservatively, but any patient with spreading peritoneal signs in the hours after a liver biopsy should be referred back to the unit where it took place for observation and ultrasound to assess the volume of leakage or bleeding. Occasionally surgical intervention will be required.

### Early

● **Pneumothorax** occurs rarely, if the biopsy needle accidentally enters the pleural cavity. The patient may present with dyspnoea, tachycardia and classical physical signs of diminished breath sounds and hyper-resonance to percussion. Referral back to the hospital is necessary on the day of diagnosis for further assessment, observation and occasionally chest drainage. Pneumothorax may also present as an immediate complication, but would probably have been treated in hospital.

● **Tension pneumothorax with mediastinal shift** may occur very rarely. The patient will be extremely unwell, verging on unconscious, and cyanosed with the trachea deviated to the contra-lateral side. Immediate aspiration of the right chest is necessary to keep the patient alive. If you are familiar with this technique, it may have to be performed at the scene - a cannula placed in the mid axillary line in the fourth intercostal interspace or the mid clavicular line is the safest approach and will likely be rewarded with a hiss of air released, which will be sufficient to keep the patient alive until they

reach A&E. Failing this, blue light transfer to A&E is necessary.

### Late

● **A sub-phrenic or liver abscess** usually occurs about a week after surgery. Patients will present with a swinging temperature, tachycardia and rising white cell count and elevated LFTs, but often there will be remarkably few clinical symptoms and signs except that the patient feels generally unwell and may be mildly jaundiced. These patients need to be referred back to hospital fairly quickly for a surgical opinion.

## Cholecystectomy

Cholecystectomy is carried out laparoscopically in the UK in 95% of cases, so most patients go home within 24-48 hours.

### Immediate

● **Respiratory problems**, such as atelectasis, lobar collapse, mucus plug or pneumothorax, would usually be noted before the patient leaves hospital. But if the patient has any symptoms and signs worse than a simple cough - and certainly if they are dyspnoeic at rest - consider referral back to hospital.

● **Secondary haemorrhage** is unusual but not impossible, and will present with increasing abdominal pain and swelling with a tachycardia and eventually hypotension if untreated. Immediate referral back to the hospital is required.

● **Biliary leak** is also unusual and tends to present subtly, with abdominal swelling initially, and eventually pain that becomes progressively more severe over the next couple of days. A high index of suspicion is often necessary to diagnose this complication and an abdominal ultrasound, if available, will show a lot of fluid in the peritoneal cavity. Immediate referral back to the hospital is necessary.

### Early

● **Obstructive jaundice** is usually because of a surgical error, but could be because of a retained bile duct stone. Either way, the patient needs immediate referral back to the surgical unit for investigation and treatment.

● **A sub-hepatic or sub-phrenic abscess** should be managed as described above, after liver biopsy.

● **Respiratory infection** can often be treated at home with physiotherapy and, if necessary, antibiotics. Failure to improve might require a non-emergency referral.

● **Urinary tract infection** can almost always be investigated and treated in the community.

● **Wound infections** are quite rare in laparoscopic surgery, and most can be dealt with at home with release of pus from the wound. Antibiotics are only necessary if there are signs of cellulitis or systemic illness.

● **Port site hernia** is a rare complication of laparoscopic surgery in which a loop of small bowel may become incarcerated in a port site. It is rare, with an incidence of less than 1%. Patients will present with symptoms and signs of small bowel obstruction, usually with a painful tender lump at one of the port sites, pyrexia, tachycardia and rarely hypotension. They need emergency referral for re-laparoscopy to release the hernia and repair the defect.

● **Deep vein thrombosis or pulmonary embolus** is rare after laparoscopic surgery, with an

incidence of less than 1%. If you suspect this, urgent referral is necessary.

### Late

● **Keloid scarring** of the port site wounds can be referred non-urgently to the surgeon concerned if necessary.

● **Chronic intermittent small bowel adhesion obstruction** occurs in fewer than 5% of cases and needs non-urgent referral to the surgeon, unless it occurs suddenly and with severe abdominal pain, distension, vomiting and tachycardia with or without hypotension - in which case, emergency referral may be needed.

● **Diarrhoea**, caused by bile salt depletion, can be treated with either cholestyramine or constipating agents, but if this fails refer the patient non-urgently.

● **Post-cholecystectomy syndrome** presents with virtually the same symptoms as the patient had prior to surgery - likely to be irritable bowel syndrome or right sub-costal nerve entrapment. Re-referral to the specialist is necessary.

## Hernia repair

Hernia repair is still carried out by open surgery in most hospitals, but is increasingly being done laparoscopically - which results in fewer complications and more rapid recovery.

### Immediate

● **Primary haemorrhage** presents with tachycardia and hypotension, sometimes with obvious signs of bleeding in the wound - but in laparoscopic surgery this may be more difficult to determine. A high index of suspicion is required. If you suspect bleeding, contact the surgeon and immediately refer back to the hospital.

● **Urinary retention** may require urgent catheterisation followed by referral back to the hospital at a later stage.

● **Respiratory problems** range from atelectasis, to pneumothorax, lung collapse or mucus plug obstruction. If the clinical signs are worrying - for example, cyanosis, tachycardia and hyperventilation - immediate referral back to the hospital is recommended.

### Early

● **Seroma/haematoma** is the most common complication of hernia repair, and seroma is seen in about 10% of laparoscopic repairs. It is simply serum collecting in the remnant sac and does not require referral or any intervention. Reassurance that this is likely to resolve spontaneously is all that is required. Sometimes patients and clinicians think this represents an early local recurrence, but it is easy to differentiate as there is never a cough impulse and it is always cystic with signs of fluctuance.

● **Wound infection** is more common in open surgery than laparoscopic, but still only occurs in about 5% of cases after open surgery. Antibiotics will sometimes settle the problem - although if there is spreading cellulitis and signs of a localised abscess, the wound may need to be opened to release pus.

● **Wound dehiscence** only occurs after open surgery and is very rare. Patients should be referred back to the surgeon.

● **Secondary haemorrhage** is also rare - but if it happens, it requires referral back to the surgeon.

● **Port site hernia** presents, and should be managed, as above.

● **Chest infection** can usually be treated in primary care with antibiotics and physiotherapy. Very rarely pulmonary embolus may occur, requiring immediate referral.

● **Deep vein thrombosis** is a rare complication, as these operations rarely take more than an hour to complete - but occasionally it may be seen, and will require referral.

● **Urinary tract infection** can be treated with antibiotics.

### Late

● **Seroma** can be differentiated from a seroma or haematoma as described above, and needs re-referral.

● **Keloid scarring** should be managed as above.

## PULSE Learning

### 1 CPD hour

Go online to complete this CPD module for a suggested 1 credit. This module will be available free to all members of Pulse Learning until 18 July 2012  
► [pulse-learning.co.uk](http://pulse-learning.co.uk)

● **Mesh infection** requires all, or part of, the mesh to be removed.

● **Chronic groin pain** requires non-urgent referral if the patient requires advice and treatment.

● **Adhesional small bowel obstruction** is very rare and should be managed as described above.

**Mr Mike Parker** is a consultant general surgeon with a special interest in gastrointestinal disease at Pembury Hospital, Fawkham Manor Hospital and Chelsfield Park Hospital, Kent

This series was produced in collaboration with The Royal College of Surgeons - a professional body that sets the highest possible standards for surgical practice and training, leading to the delivery of safe and high quality patient care. The Royal College of Surgeons has expertise, authority and independence, allowing it to act in the best interests of patients and in support of those providing their care. Go to [rcseng.ac.uk](http://rcseng.ac.uk) for more information.

### References

1 Ellis H, Culne R and Watson C. *Lecture notes on general surgery* (10th edition). Blackwell Publishing, 2002

### Coming up in this series

Surgical complications of cardiology, orthopaedics, gynaecology and ophthalmology

## PULSE Learning

### Case-based learning Dyspepsia 2 CPD hours

A brilliant case-based module.

Dr Peter Kureya

► [pulse-learning.co.uk](http://pulse-learning.co.uk)



Destination	Hepatitis A	Cholera	Typhoid	Tuberculosis	Hepatitis B	Yellow fever	Meningococcal	Japanese encephalitis	Rabies	Malaria	Risk areas	Recommended regimen	Alternative regimen
Abu Dhabi	S	R	S	S	S	S	S	S	S	S	No	W	Le
Albania	S	R	S	S	S	S	S	S	S	S	No	W	Le
Algeria	S	R	S	S	S	S	S	S	S	S	No	W	Le
Angola	S	R	S	S	S	S	S	S	S	S	Yes, high risk	W	Sh Ta
Antigua & Barbuda	S	R	S	S	S	S	S	S	S	S	No	W	Le
Argentina	S	R	S	S	S	S	S	S	S	S	Yes, rural areas near NE border with Brazil and Paraguay. Other areas very low risk.	W	Le
Armenia	S	R	S	S	S	S	S	S	S	S	Variable risk. Aerial Valley Jun-Oct.	W	Le
Australia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Austria	S	R	S	S	S	S	S	S	S	S	No	W	Le
Azerbaijan	S	R	S	S	S	S	S	S	S	S	Variable risk. NW border Jan-Oct.	W	Le
Bahamas	S	R	S	S	S	S	S	S	S	S	No	W	Le
Bahrain	S	R	S	S	S	S	S	S	S	S	No	W	Le
Bali	S	R	S	S	S	S	S	S	S	S	Yes, low risk.	W	Le
Bangladesh	S	R	S	S	S	S	S	S	S	S	Yes, V and Chittagong Hill Tracts. Elsewhere, low risk.	W	Le
Barbados	S	R	S	S	S	S	S	S	S	S	No	W	Le
Belarus	S	R	S	S	S	S	S	S	S	S	No	W	Le
Belize	S	R	S	S	S	S	S	S	S	S	Variable risk in south, low risk Belize City.	W	Le
Benin Republic	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Bermuda	S	R	S	S	S	S	S	S	S	S	No	W	Le
Bhutan	S	R	S	S	S	S	S	S	S	S	Yes, southern districts.	W	Le
Bolivia	S	R	S	S	S	S	S	S	S	S	Yes, high risk in Amazon basin. Variable risk on Paraguan and Argentinian borders.	W	Sh Ta
Borneo	S	R	S	S	S	S	S	S	S	S	Low risk, coastal areas of Malaysian Sabah and Sarawak and Sabah Indonesian Kalimantan, high risk all areas.	W	Sh Ta
Bosnia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Botswana	S	R	S	S	S	S	S	S	S	S	Yes, northern half only Nov-June.	W	Sh Ta
Brazil	S	R	S	S	S	S	S	S	S	S	High risk in Mato Grosso do Sul. Elsewhere, very low risk.	W	Sh Ta
Brunei	S	R	S	S	S	S	S	S	S	S	No	W	Le
Bulgaria	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Burkina Faso	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Burundi	S	R	S	S	S	S	S	S	S	S	Yes, significant risk elsewhere.	W	Sh Ta
Cambodia	S	R	S	S	S	S	S	S	S	S	Meningitis risk. Phnom Penh, Angkor Wat, Siem Reap.	W	Sh Ta
Cameroon	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Canada	S	R	S	S	S	S	S	S	S	S	No	W	Le
Cape Verde Islands	S	R	S	S	S	S	S	S	S	S	Yes, low risk Aug-Mar.	W	Le
Cayman Islands	S	R	S	S	S	S	S	S	S	S	No	W	Le
Central African Rep.	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Chad	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Chile	S	R	S	S	S	S	S	S	S	S	No	W	Le
China (Mainland)	S	R	S	S	S	S	S	S	S	S	Yes, in Yunnan and inland Hainan. Elsewhere, very low risk.	W	Sh Ta
China (Hong Kong)	S	R	S	S	S	S	S	S	S	S	No	W	Le
China (Macao)	S	R	S	S	S	S	S	S	S	S	No	W	Le
Colombia	S	R	S	S	S	S	S	S	S	S	Yes, high risk. Eastern half. Variable risk elsewhere <1,000m. Very low around Medellin. Bogotá & Cartagena.	W	Sh Ta
Comoros	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Congo	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Congo-Dem. Rep.	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Cook Islands	S	R	S	S	S	S	S	S	S	S	No	W	Le
Costa Rica	S	R	S	S	S	S	S	S	S	S	Small variable risk area on west coast. Rest of country, low risk.	W	Le
Croatia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Cuba	S	R	S	S	S	S	S	S	S	S	No	W	Le
Cyprus	S	R	S	S	S	S	S	S	S	S	No	W	Le
Czech Republic	S	R	S	S	S	S	S	S	S	S	No	W	Le
Djibouti	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta

Destination	Hepatitis A	Cholera	Typhoid	Tuberculosis	Hepatitis B	Yellow fever	Meningococcal	Japanese encephalitis	Rabies	Malaria	Risk areas	Recommended regimen	Alternative regimen
Dominican Republic	S	R	S	S	S	S	S	S	S	S	Yes, high risk along Haitian border, variable risk elsewhere.	W	Sh Ta
Dubai	S	R	S	S	S	S	S	S	S	S	No	W	Le
East Timor (Timor Leste)	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Ecuador	S	R	S	S	S	S	S	S	S	S	Yes, high risk. Eastern and southern borders with Colombia and Peru. Elsewhere, low risk.	W	Sh Ta
Egypt	S	R	S	S	S	S	S	S	S	S	No	W	Le
El Salvador	S	R	S	S	S	S	S	S	S	S	Yes, low risk.	W	Sh Ta
Equatorial Guinea	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Eritrea	S	R	S	S	S	S	S	S	S	S	Yes, high risk (high risk in Asmara).	W	Sh Ta
Estonia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Ethiopia	S	R	S	S	S	S	S	S	S	S	Yes, high risk below 2,000m. (No risk in Arba Minch).	W	Sh Ta
Falklands (Tristan da C.)	S	R	S	S	S	S	S	S	S	S	No	W	Le
Fiji	S	R	S	S	S	S	S	S	S	S	No	W	Le
Finland	S	R	S	S	S	S	S	S	S	S	No	W	Le
France	S	R	S	S	S	S	S	S	S	S	No	W	Le
French Guiana	S	R	S	S	S	S	S	S	S	S	High risk inland and border areas. Coast and islands, low risk.	W	Sh Ta
French Polynesia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Gabon	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Gambia	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Georgia	S	R	S	S	S	S	S	S	S	S	Yes, low risk SE (July-Oct).	W	Sh Ta
Germany	S	R	S	S	S	S	S	S	S	S	No	W	Le
Ghana	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Goi	S	R	S	S	S	S	S	S	S	S	Yes, variable risk.	W	Sh Ta
Greece and Islands	S	R	S	S	S	S	S	S	S	S	No	W	Le
Greenland	S	R	S	S	S	S	S	S	S	S	No	W	Le
Grenada	S	R	S	S	S	S	S	S	S	S	No	W	Le
Guadeloupe	S	R	S	S	S	S	S	S	S	S	No	W	Le
Guam	S	R	S	S	S	S	S	S	S	S	No	W	Le
Guatemala	S	R	S	S	S	S	S	S	S	S	Yes, some risk below 1,500m.	W	Sh Ta
Guinea	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Guinea-Bissau	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Guyana	S	R	S	S	S	S	S	S	S	S	Yes, high risk. A few endemic rural areas.	W	Sh Ta
Haiti	S	R	S	S	S	S	S	S	S	S	Yes, high risk throughout country.	W	Sh Ta
Hawaii	S	R	S	S	S	S	S	S	S	S	No	W	Le
Honduras	S	R	S	S	S	S	S	S	S	S	Yes, risk variable.	W	Sh Ta
Hungary	S	R	S	S	S	S	S	S	S	S	No	W	Le
India	S	R	S	S	S	S	S	S	S	S	Yes, high risk. Assam. Yes, low risk in southern states, Delhi, Jaipur, Agra, Mumbai. Yes, elsewhere.	W	Sh Ta
Indonesia	S	R	S	S	S	S	S	S	S	S	Yes, high risk in Lombok. Very low in Bali and Borneo. Yes, variable elsewhere.	W	Sh Ta
Iran	S	R	S	S	S	S	S	S	S	S	Yes, high risk. SE provinces. Mar Mar.	W	Sh Ta
Iraq	S	R	S	S	S	S	S	S	S	S	Yes, v. low risk in north. Mar Mar.	W	Sh Ta
Israel	S	R	S	S	S	S	S	S	S	S	No	W	Le
Italy	S	R	S	S	S	S	S	S	S	S	No	W	Le
Ivory Coast	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta
Jamaica	S	R	S	S	S	S	S	S	S	S	No	W	Le
Japan	S	R	S	S	S	S	S	S	S	S	No	W	Le
Jordan	S	R	S	S	S	S	S	S	S	S	No	W	Le
Kazakhstan	S	R	S	S	S	S	S	S	S	S	No	W	Le
Kenya	S	R	S	S	S	S	S	S	S	S	Yes, high risk. (Mar Mar and highlands low risk).	W	Sh Ta
Kiribati	S	R	S	S	S	S	S	S	S	S	No	W	Le
Korea (North)	S	R	S	S	S	S	S	S	S	S	Yes, limited risk extreme south.	W	Sh Ta
Korea (South)	S	R	S	S	S	S	S	S	S	S	Yes, limited risk extreme north.	W	Sh Ta
Kosovo	S	R	S	S	S	S	S	S	S	S	No	W	Le
Kuwait	S	R	S	S	S	S	S	S	S	S	No	W	Le
Kyrgyzstan	S	R	S	S	S	S	S	S	S	S	Yes, low risk (some SE). W areas.	W	Sh Ta
Laos	S	R	S	S	S	S	S	S	S	S	Yes, high risk (minimal risk in Vientiane).	W	Sh Ta
Latvia	S	R	S	S	S	S	S	S	S	S	No	W	Le
Lebanon	S	R	S	S	S	S	S	S	S	S	No	W	Le
Lesotho	S	R	S	S	S	S	S	S	S	S	No	W	Le
Liberia	S	R	S	S	S	S	S	S	S	S	Yes, high risk.	W	Sh Ta

## Key

- M** = immunisation mandatory  
**R** = immunisation recommended as risk of infection is substantial  
**S** = immunisation sometimes recommended:  
 – for more than three visits in a one-year period  
 – a stay of more than three months in a rural area  
 – for high-risk occupational groups  
 – for backpackers staying more than one month  
 – when entering the limited geographical risk area for the target disease  
**C** = See Yellow fever, next column

Where **S** appears for cholera, it indicates that only high-risk travellers, usually healthcare workers in areas of known epidemics, should be immunised.

## Vaccinations information

**Tetanus**  
 Five tetanus doses are considered protective for life by the DH, although there is no evidence base for this. Travellers at risk of tetanus-prone wounds should be given 10-yearly boosters if they are going to poorer countries in Africa, Asia and South America where specific immunoglobulin may be unavailable.

**Polio**  
 All travellers should have completed the British vaccination schedule for polio immunisation in childhood or as adults.

**Yellow fever**  
 An International Certificate of Vaccination **C** is required for travellers from yellow fever zones who wish to enter countries bordering the margins of a yellow fever endemic area, or from more distant countries where a mosquito vector provides the potential for transmission. A certificate may also be required for travellers who have been in transit through yellow fever endemic zones.

An International Certificate of Vaccination may be required (**M**=Mandatory) for all entering travellers over the age of 12 months. For further details see International Travel and Health Requirements and Health Advice, WHO, Geneva 2008. [www.who.int/itih](http://www.who.int/itih)

**Information source and updates**  
 This chart is based on information from the UK TRAVAX website and other databases. TRAVAX is an information service provided by Health Protection Scotland ([www.travax.scot.nhs.uk](http://www.travax.scot.nhs.uk); telephone 0141 300 1130).

The chart is updated regularly. Readers are advised to use the latest chart only, to ensure that their practice reflects the most recent advice.

**Travel vaccinations and malaria information author**  
 Dr Michael Jones, consultant physician, Regional Infectious Disease Unit, Western General Hospital, Edinburgh

## Specialist advice

For advice on complex itineraries and other queries, use the following helplines:  
 Birmingham 0121 424 0357/3354/2357  
 Edinburgh, Western General Hospital 0131 537 2822  
 National Travel Health Network and Centre (Monday to Friday, 9am-12pm, 2pm-4.30pm) 0845 602 6762 (local call rate)

## Parasitic infections

Short-term travellers staying in good conditions are usually at low risk of acquiring parasitic infections. Schistosomiasis is common and potentially serious. Leishmaniasis and trypanosomiasis are less common but potentially lethal. Expatiation in remote areas at risk of other rare diseases are not shown in this chart.

**Sh** = schistosomiasis. Travellers should avoid swimming in freshwater lakes and rivers in endemic areas.

**Ta** = African trypanosomiasis (sleeping sickness). Transmitted by tsetse flies, and a risk in some African game parks and rural areas. Travellers should use insect repellents, close windows if fly swarms approach and seek medical attention for any signs of infection around bites one to three weeks later.

**Te** = South American trypanosomiasis (Chagas' disease). Transmitted by reduid bugs that feed at night and reside in the thatch and crevices of rural dwellings. Travellers should avoid sleeping in huts.

**Le** = leishmaniasis. Transmitted by sandflies in arid areas (including Mediterranean coastal areas), mostly at night. Travellers should use insecticide-impregnated mosquito nets and insect repellent.

## Travel medicine update

**Legionnaires' disease**  
 A cluster of Legionnaires' disease has been reported from the tourist resort of Alanya, Turkey, affecting four Danish tourists with the last case notified on 6 April. Although no UK tourists have been affected so far, Alanya is popular with British travellers. Legionnaires' disease should be suspected in any patients with pneumonia returning from Alanya and, if confirmed, notified to the appropriate national centre as soon as possible.

**Polio in Nigeria**  
 The goal of global eradication of polio remains elusive and six new cases were reported recently in Nigeria – five WPV1 and one WPV3. All six presented with paralysis this year, bringing the total number of cases in 2012 to 28. All travellers to Nigeria should have their protection checked and receive a booster where necessary. Other countries with a polio risk are listed in the vaccination chart.

**Dengue fever in South America**  
 The absence of a vaccine for this serious viral illness means that avoiding dengue tends not to be emphasised in travel medicine consultations. There is a large current epidemic in South America this year affecting Argentina (1,100 cases), Brazil (about 15,000 cases), Ecuador (over 4,000 cases) and Peru (about 7,000 cases). Avoiding mosquito bites is the only protection available to travellers, who should consider wearing long-sleeved clothing, and use repellents and bed nets.

**Measles**  
 Also often forgotten is the risk of measles. Uganda has just reported over 3,000 cases and the Democratic Republic of Congo over 10,000, but outbreaks have also been recently reported in the US, Canada, Japan, Israel and several European countries. Those born before 1970 are likely to have had measles as a childhood illness. Those born since 1970 may have deficits in immunity or vaccination, which can be corrected with the MMR vaccine.

**Source**  
[travax.nhs.uk](http://travax.nhs.uk)





Xifaxanta™ gets to work here  
...and only here<sup>1,2</sup>

The first and only virtually  
non-absorbed antibiotic licensed  
for the treatment of non invasive  
Travellers' Diarrhoea<sup>3</sup>



**Xifaxanta**™  
Rifaximin- $\alpha$

**XIFAXANTA™ Prescribing Information**

REFER TO FULL SUMMARY OF PRODUCT CHARACTERISTICS (SmPC) BEFORE PRESCRIBING.

**Presentation:** Film-coated tablet containing rifaximin 200 mg. **Uses:** Xifaxanta is indicated for the treatment of travellers' diarrhoea that is not associated with fever, bloody diarrhoea, eight or more unformed stools in the previous 24 h, occult blood or leucocytes in the stool. **Dosage and administration:** Adults over 18 years of age: 200 mg every 8 hours for three days (total 9 doses). Rifaximin must not be used for more than 3 days even if symptoms continue and a second course of treatment must not be taken. Not recommended in children under 18 years of age. **Contraindications:** Hypersensitivity to the active substance, to any rifamycin (e.g. rifampicin or rifabutin) or to any of the excipients. **Warnings and precautions for use:** Not recommended for the treatment of travellers' diarrhoea caused by invasive enteric pathogens. If symptoms worsen, treatment with rifaximin should be interrupted. If symptoms have not resolved after 3 days of treatment, or recur shortly afterwards, a second course is not recommended. The potential association of rifaximin treatment with *Clostridium difficile* associated diarrhoea and pseudomembranous colitis cannot be ruled out. **Interactions:** Due to the

negligible gastrointestinal absorption of orally administered rifaximin (less than 1%), the systemic drug interaction potential is low. Rifaximin should not be administered concomitantly with other rifamycins and the tablets should not be administered for at least two hours after the administration of charcoal. **Pregnancy and lactation:** Rifaximin is not recommended during pregnancy and in women of childbearing potential not using contraception. The benefits of rifaximin treatment should be assessed against the need to continue breastfeeding. **Undesirable effects:** Common effects reported in clinical trials are dizziness, headache, abdominal pain, constipation, defecation urgency, diarrhoea, flatulence, bloating, distension, nausea, vomiting, rectal tenesmus and pyrexia. Other effects that have been reported are candidiasis, herpes simplex infections, clostridial infections, palpitations, increased blood pressure, liver function test abnormalities, blood disorders (e.g. thrombocytopenia) and anaphylactic reactions, i.e. angioedema, hypersensitivity and skin reactions. **Licensing and legal category:** Legal category: POM. **Cost:** Basic NHS price £15.15 (9 tablets). **MA number:** PL 20011/0021. **For further information contact:** Norgine Pharmaceuticals Limited,

Norgine House, Moorhall Road, Harefield, Middlesex, UB9 6NS. 01895 826606. E-mail: [medinfo@norgine.com](mailto:medinfo@norgine.com).  
**Date of preparation/revision:** XIF/2553/AUG/11.

Adverse events should be reported. Reporting forms and information can be found at <http://yellowcard.mhra.gov.uk>. Adverse events should also be reported to Medical Information at Norgine Pharmaceuticals Ltd on 01895 826606.

**References**

1. Jiang ZD et al. *Antimicrob Agents Chemother* 2000;44 (8):2205-2206.
2. Descombe JJ et al. *Int J Clin Pharmacol Res* 1994;14 (2):51-56.
3. Xifaxanta™ Summary of Product Characteristics.



XIF/2620/SEP/11.

XIFAXANTA is a trademark of Alfa-Wasserhann Hungary KFT, exclusively licensed in the UK to the Norgine group of companies.

Date of preparation: September 2011.



# 30 PULSE SERVICES TRAVEL VACCINATIONS & MALARIA PROPHYLAXIS

Updated:  
May 2012

Destination	Typhoid	Hepatitis A	Cholera	Diphtheria	Tuberculosis	Hepatitis B	Yellow fever	Meningococcal	Rabies	Malaria	Tick-borne encephalitis	Japanese encephalitis	Risk areas	Recommended regimen	Alternative regimen	Main parasite hazards
Libya	S	R	S	S	S	S	S	S	S	C	S	S	No risk	ME or DO or MON	PC	Le
Liechtenstein	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Lithuania	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Macedonia	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Madagascar	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Madeira	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Malawi	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Malaysia	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk Sabah Yes, low risk deep coastal Malaysia Very low risk elsewhere	ME or DO or MON PC W	PC	Sh
Maldives	R	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Malta	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Malta and Gozo	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Martinique	S	R	S	S	S	S	S	S	S	C	S	S	No	ME or DO or MON	PC	Sh
Mauritania	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk all year in south Low risk in north	ME or DO or MON	PC	Sh
Mauritius	R	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Mayotte	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Mexico	R	R	S	S	S	S	S	S	S	C	S	S	Yes, southern states only Elsewhere and tourist areas	ME or DO or MON C W	PC P W	Sh
Moldova	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Mongolia	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Montenegro	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Montserrat	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Morocco	R	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Mozambique	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Myanmar (Burma)	R	R	S	S	S	S	S	S	S	C	S	S	Yes, west part of Shan State Yes, elsewhere	DO or MON ME or DO or MON	PC PC	Sh
Namibia	R	R	S	S	S	S	S	S	S	C	S	S	Yes, north-east coast only Yes, all year – along Karoo and Kunene Rivers	ME or DO or MON	PC	Sh
Nepal	R	R	S	S	S	S	S	S	S	C	S	S	Yes, below 1,500m (no risk in Kathmandu)	PC	SH	Le
Neth Antilles	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Netherlands	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
New Caledonia	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
New Zealand	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Nicaragua	R	R	S	S	S	S	S	S	S	C	S	S	Yes, variable risk in north Low risk in south	C	P	Le
Niger	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Nigeria	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk	ME or DO or MON	PC	Sh
Norway	S	R	S	S	S	S	S	S	S	C	S	S	No	W	W	Sh
Oman	S	R	S	S	S	S	S	S	S	C	S	S	Sp. risk, imported risk	W	W	Sh
Pakistan	R	R	S	S	S	S	S	S	S	C	S	S	Yes, significant below 2,000m Yes, high risk NE coast to Colombia border	ME or DO or MON	PC	Sh
Panama	R	R	S	S	S	S	S	S	S	C	S	S	Variable risk SE coast bordering Brazil and Bolivia	ME or DO or MON	PC	Sh
Papua New Guinea	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk below 1,500m	ME or DO or MON	PC	Sh
Paraguay	R	R	S	S	S	S	S	S	S	C	S	S	Yes, eastern border with Brazil	ME or DO or MON	PC	Sh
Peru	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Philippines	R	R	S	S	S	S	S	S	S	C	S	S	Variable risk SE coast bordering Brazil and Bolivia	ME or DO or MON	PC	Sh
Poland	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Portugal	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Puerto Rico	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Qatar	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Reunion	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Romania	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Russian Federation	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Rwanda	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Sabah	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Samoa	S	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh
Sao Tome	R	R	S	S	S	S	S	S	S	C	S	S	Yes, high risk in forest (esp. Amazon basin)	ME or DO or MON	PC	Sh

## Key to malaria prophylaxis regimens

### Regimen MON

Malarone (atovaquone/proguanil), one tablet daily. Begin 1-2 days before departure, continue while in malarious area and for 7 days after return. ACPMP suggest Malarone is safe for periods in continuous use of at least 1 year and possibly longer. Safety in pregnancy has not been established, and use in pregnancy should only be considered if benefit to the mother outweighs risk to fetus. Children use paediatric tablets.

### Regimen PC

Proguanil (Paludrine) 200mg daily plus chloroquine 300mg or 310mg base weekly (=Araldine 2x250mg). Begin 1 week before travel and continue for 4 weeks after return.

### Regimen ME

Mefloquine, 1x250mg tablet weekly. ACPMP suggest it is safe in continuous use for periods of at least 3 years. Begin at least 2 1/2 weeks before travel (at least 3 doses before arriving in malarious area). Avoid in first trimester of pregnancy and do not start pregnancy until 3 months after stopping mefloquine. Inadvertent use in first trimester is not an indication for termination. If pregnant women must travel to chloroquine-resistant falciparum area, seek expert advice and conduct careful risk-benefit analysis. Use in any trimester may be justified.

### Regimen C

Chloroquine 300mg or 310mg base

weekly (=Araldine 2x250mg). Begin 1 week before travel and continue for 4 weeks after return.

### Regimen P

Proguanil (Paludrine) 200mg daily. Begin 1-2 days before travel and continue for 4 weeks after return.

### Regimen W

No chemoprophylaxis but be aware of risk. Avoid mosquito bites and carry standby treatment if going to be far from medical facilities.

### Regimen DO

Doxycycline, 1 tablet of 100mg daily. Begin 1-2 days before travel and continue for 4 weeks after return. Not for children or pregnant women. Be aware of oesophageal ulceration, photosensitivity and very rare intracranial hypertension risk. Take with food or milk and avoid ingestion in late evening.

### Regimen DRF

In the alternative regimen column, DRF is Drug-Resistant Falciparum regimen. DRF = ME or DO or MON

### Primaquine

A causal prophylactic that may be used when G6PD deficiency has been excluded in travellers with contra-indications to other anti-malarials. Active against all species. Adult dose 90mg daily. Start 1-2 days before departure and continue for 7 days after return.

## Children's doses of antimalarial prophylactics

Weight in kg	Chloroquine Proguanil	Mefloquine	Age
Under 6.0	0.125 adult dose 1/4 tablet	not recommended	term to 12 weeks
6.0 to 9.9	0.25 adult dose 1/2 tablet	0.25 adult dose 1/4 tablet	3 months to 11 months
10.0 to 15.9	0.375 adult dose 3/4 tablet	0.25 adult dose 1/4 tablet	1 year to 3 years 11 months
16.0 to 24.9	0.5 adult dose 1 tablet	0.5 adult dose 1/2 tablet	4 years to 7 years 11 months
25.0 to 44.9	0.75 adult dose 1 1/2 tablets	0.75 adult dose 3/4 tablet	8 years to 12 years 11 months
45kg and over	Adult dose 2 tablets	Adult dose 1 tablet	13 years and over

## Children's doses

### Paediatric malarone for prophylaxis

Weight in kg	Number of tablets daily
11-20	1 paediatric tablet
21-30	2 paediatric tablets
31-40	3 paediatric tablets
Above 40	1 adult tablet

Although every effort is made to ensure that information in these pages is correct, the publishers and Pulse cannot accept responsibility for the consequences of error. © PULSE 2012

## TIP OF THE MONTH Imported malaria in the UK

An important survey recently published in the *BMJ* should be read by all travel medicine advisers.<sup>1</sup> Between 1987 and 2006, 791 malaria associated deaths were recorded in the UK out of 39,320 cases. Seven deaths occurred in non-falciparum species with a case fatality rate of 0.05%, while in 25,054 falciparum cases there were 181 deaths – giving a case fatality rate of 0.73%. Case fatality rates were higher, at 2.56%, in tourists than in those visiting friends and relatives (VFRs) at 0.32%. VFRs born in Africa had lower case fatality (0.4%) than those born outside of Africa (2.4%). Case fatality was particularly high in those visiting the Gambia, at 3.9%, and this difference increased to 6% for tourists. Although most malaria deaths in endemic areas occur in children, no deaths were reported in the zero-to-five years age group, but mortality increases with age and was 10 times more likely in those over 65 years of age than those aged 18-35 years. December is the most risky month to present with malaria, with an overall risk of dying of 2.55% compared with 0.58% for all other months.

Also recently released is the HPA report on malaria in the UK in 2011, showing a 5% decrease in malaria infections compared with 2010 but a 22% increase in cases from the Indian subcontinent, mostly due to a doubling of cases of *Plasmodium vivax* acquired in Pakistan.<sup>2</sup>

### References

- 1 Checkley AM, Smith A, Smith V et al. Risk factors for mortality from imported falciparum malaria in the UK over 20 years: an observational study. *BMJ* 2012;344:e2116
- 2 HPA. [hpa.org.uk/web/HPAwebGHPAwebStandard/HPAweb\\_C/131713806543](http://hpa.org.uk/web/HPAwebGHPAwebStandard/HPAweb_C/131713806543)



# NAPC Annual Conference

## and Vision Awards 2012

30-31 October – The NEC, Birmingham

A new era  
for the NHS

### What makes this the must-attend event for more than 700 health and social care professionals?

- The exceptional quality of the speakers
- A programme tailored to the crucial issues affecting your role
- Opportunities to influence policy in shaping a future sensitive to local needs

Free  
to attend  
Limited places  
available

#### Who should attend?

- GPs, nurses and practice managers
- Clinical commissioning leaders
- Secondary care clinicians
- Local authority and social care professionals
- Health managers and PCT cluster staff

#### Hear from:

**Andrew Lansley**

Secretary of state for health

**Sir David Nicholson**

Chief executive of the NHS and the NHS  
Commissioning Board

**Sir Stephen Bubb New**

Chief executive of AVECO

**Professor Steve Field**

Chair of the NHS Future Forum

**Professor Alan Maynard**

Co-director of the York Health Policy Group

**Viv Bennett New**

Director of Nursing in the Department of Health

**Jeremy Taylor New**

Chief executive of National Voices

**David Oliver New**

National clinical director for older people

#### Tracks targeted to meet your needs:

● **Track A - Practice business and finance**

Improve patient access and practice income

● **Track B - CCGs: Preparing for action**

Authorisation and beyond

● **Track C - Transforming health and social care**

Tackle the healthcare time-bomb

● **Track D - Innovating for efficiency**

Use technology to transform patient care

● **Track E Nursing in the new NHS**

Collaborative working and sharing best practice

Join colleagues from across the country and book your free place now at **napcannual.co.uk**

**Delegate Plus Pass**

Upgrade your complimentary place from just £60 + VAT



Organised by

**Practical  
Commissioning**

**PULSE**



# Pulse Business & Commissioning

## Practice Business

### IN THIS ISSUE

**Your countdown to CQC registration** Richard Banyard gives month-by-month advice on how practices should prepare [page 32](#)

### MORE ONLINE

[pulsetoday.co.uk/practice](http://pulsetoday.co.uk/practice)

**Could I benefit from an in-practice pharmacy?** A business guide to starting a new venture at your surgery

**A brief guide to pension changes** What are the benefits now and how might they change?

**Should I sign my CCG's constitution?** The GPC offers guidance, and a checklist before committing

## Commissioning

### IN THIS ISSUE

**Working with a charity** One GP commissioner's experience of partnering the third sector [page 35](#)



### MORE ONLINE

[pulsetoday.co.uk/commissioning](http://pulsetoday.co.uk/commissioning)

**Last step before authorisation** Dr James Kingsland looks at the bureaucracy of naming your CCG

**New NHS Commissioning Board guidance** On the future of commissioning primary care

**How mental illness loses out in the NHS** Download a report from the Centre for Economic Performance



## Your countdown to CQC registration

**Richard Banyard** walks practices month-by-month through the steps they should take to prepare

BY APRIL 2013, ALL ENGLISH GP PRACTICES will need to have registered with the CQC.

While some of the final details have yet to be decided, the key steps along the registration journey are already clear. The key messages in preparing for the CQC are:

- Start early.
- Recognise that this is a progressive process - and it is about much more than just filling

in the registration form in the autumn and then forgetting about it.

- Focus on the six key risk areas of non-compliance. Know what they are - for GPs, these are medicines management, staffing, records management, safeguarding, confidentiality and information control - and have clear action plans in place as necessary to deal with them.

- If in doubt, don't be afraid to ask the CQC for advice.

Below is a month-by-month timeline to help your practice prepare.

### Before July 2012

By now, you should have made sure that the practice is properly legally constituted. Partnerships, for example, will need to make

sure that the partnership agreement is up to date, as the CQC can only register a practice if it legally exists.

Lead management responsibilities also need to be sorted out. A crucial step will be to decide who the registered manager or managers will be, as this is the person who will be accountable in law for the services being operated. At least one GP partner will need to take the lead for CQC issues; it cannot all be left to the practice manager to sort out.

Key players in the practice will also need to have begun to learn more about the CQC itself and its powers. By now, practices should have started the process of assessing their compliance against the 250+ CQC standards. Don't underestimate how long this process might take. Some of the standards only apply to certain providers, so as an initial step practices will need to determine which 'service types' are offered before starting to assess compliance. The key to CQC compliance is working out where any key risks lie for patients and staff.

If you have a spare moment, make sure that your key policies - such as complaints,



safeguarding procedures and patient information leaflets – are up to date in order to save time later in the year.

### July 2012

Formal processes begin. The CQC will contact all practices to sort out the 28-day window during the autumn for each practice's registration application.

Look out for the CQC application form. This will be available online, so can be completed incrementally. Practices need to identify the questions that might cause the most difficulties, and then focus on these during the lead-up period to completing the application itself. Make sure that CQC issues appear regularly on practice meeting agendas throughout the application period.

Another important issue to decide early on is which 'locations' your practice is operating. For most practices, this will be straightforward – but if a practice is operating from more than one surgery or has a branch, you will have to decide whether separate applications are also needed.

By July, you will also need to decide which are the 'regulated activities' for which you will be seeking CQC registration. These are likely to be 'treatment of disease, disorder and injury' and 'diagnostic and screening procedures'. However, there are another 13 possible activities that are all to be registered with the CQC, so you will need to work through them just to check whether you also need to apply for these. For a full list, go to [pulsetoday.co.uk/gp-regulation-cqc](http://pulsetoday.co.uk/gp-regulation-cqc).

Finally, be absolutely clear about who will need to have a Criminal Records Bureau (CRB) check. GPs with current GMC registration

## Make sure CQC issues appear regularly on practice meeting agendas

should be exempt from this, but others – for example, non-clinicians in the partnership and non-medical registered managers – are almost certain to need enhanced checks.

This process needs to be started as early as possible. Most other staff in the practice may also need to have been CRB checked, especially those who work single-handed with patients and children.

### September 2012

From September, practices will begin submitting applications. Allow time for the application to be fully signed by all the partners, and also fully checked through before submission. If it is incomplete, it will just arrive back from the CQC in your in-tray.

It is important that you prepare an action plan for any areas you have assessed as being non-compliant or only partly compliant with the CQC standards. It is far better to have a remedial action plan in place than to feign compliance and be caught out later.

### December 2012

This is the latest deadline for CQC

applications to be submitted. If there are subsequent queries from the CQC, make sure that these are answered promptly and accurately in order to ensure your application is not delayed.

In addition, as soon as your application has gone in, there will be other CQC-related tasks to consider such as training and budgeting for the costs of compliance and registration. It will also be prudent to start working up the internal practice procedures that you will need to follow once registration commences. For example, any deaths or untoward incidents in the practice will need to be notified to the CQC from April.

A key member of the practice team and a deputy will need to be identified to co-ordinate such ongoing notifications to the CQC, which are a legal requirement.

### March 2013

Make sure you have notified the CQC of any substantive changes since your application was submitted. If your CQC registration letter has not arrived by now check where it has got to, and once it is available check that it is accurate – for example, does it include all the services that you offer?

### April 2013 onwards

Celebrate your CQC registration – but don't relax too much. Check the ongoing requirements that practices will need to follow once registered on the CQC website, and be aware that a CQC inspector can arrive at any time – announced or unannounced.

**Richard Banyard** is director of CQC registration consultants CQCassist

## PULSE Business Seminars



## Successful Practice Management

**Thursday 29 November, Birmingham**

Pulse brings together experts with real experience at the coalface of general practice to dissect the management theory and share workable solutions that have yielded results elsewhere, and can help your practice succeed.

**Book now at**  
► [pulse-seminars.com](http://pulse-seminars.com)

## You've got mail



The easiest way to keep up-to-date with latest NHS and GP news

Sign up to your free Pulse Daily email at [pulsetoday.co.uk/email-sign-up](http://pulsetoday.co.uk/email-sign-up)






Providing you with the widest range of medical goods & services

## 1 Propulse NG Electronic Ear Irrigator

The new Propulse NG Electronic Ear Irrigation System sets new standards in ear irrigation and simplifies the removal of cerumen, keratin and foreign bodies from the external auditory meatus.

### Features:

- Patented Quick release system
- Hygienic, single-use Qix Tips
- Contrapulse water delivery system
- Meets all EC safety requirements
- 12 month parts and labour warranty



**26% OFF**

**Now £126.00** Includes VAT  
Was £171.00 Code PW6267

## 2 Merlin Medical M-Pulse™ Lite Pulse Oximeter

This value for money product is reliable and easy to operate, making it an excellent choice for performing on-the-spot SpO<sub>2</sub> and Pulse Rate measurements.

### Specifications:

- Universal finger clip - suitable for adults, children, and neonatal patients
- SpO<sub>2</sub> Range: 70 - 99%
- SpO<sub>2</sub> Accuracy: 80 - 99%, ± 2%; 70-79, ± 3%
- Pulse Rate Range: 30 - 235bpm
- Pulse Rate Accuracy: ± 2% or 2bpm
- Dimensions: 58mm x 32mm x 34mm
- Requires 2x AAA batteries (supplied)
- FREE carry case

**24% OFF**  
FREE Case W6421



**Now £45.54** Includes VAT  
Was £59.94 Code PW32538

## 3 Omron M6 Upper Arm Blood Pressure Monitor

The M6 Upper Arm BPM from Omron boasts a range of enhancements. It has an innovative dual check system that checks the machine's calibration on start up, as well as irregular heartbeat detection and movement indicators.

### Features:

- Intellisense comfort inflation
- 90 memories with date and time stamp
- One button operation
- Arrhythmia detection and movement indicator
- Calibration checked on startup
- Display indicates that the cuff is wrapped correctly
- Supplied with a medium cuff, storage case, batteries and full instructions
- Clinically Validated

**44% OFF**



**Now £47.94** Includes VAT  
Was £85.74 Code PW4343

# July Special - at least 10% off all equipment

Stethoscopes, ABPM's, Oscopes and lots more - Quote 'July Special' when ordering

## How to order

Call **0800 212 855** E-mail **sales@pulsemedicalstore.co.uk**

Online **www.pulsemedicalstore.co.uk** (To find more products and offers)

Advertised deals cannot be used in conjunction with any other promotions unless otherwise agreed. Offers valid for 4 weeks.

**Order now**  
**Free delivery**  
**on orders**  
**over £100**

## PULSE Clinical Update

Free-to-attend half-day seminars

# Lower GI update

Focusing on accurate diagnosis and effective management of irritable bowel syndrome and lower gastrointestinal symptoms

Choose from two venues in 2012

27 September Crowne Plaza, Manchester

11 October King's Fund, London

Don't miss this essential afternoon seminar:

- Sharpen your diagnostic skills in lower GI disorders to avoid unnecessary testing and reduce costs
- Establish how to tailor first- and second-line management options to meet individual needs
- Hear expert insight on patient perspectives to maximise the effectiveness of your consultations

Register your free place online **pulsetoday.co.uk/lower-gi-2012**

**BOOK NOW**  
**LIMITED FREE**  
**PLACES**

Supported and initiated by



In association with



**PULSE**  
**3 CPD hours**

Attending this seminar is worth 3 CPD credits towards the 50 annual credits you must build up for appraisal



IN GATESHEAD, WE HAVE a 10% higher than average mortality rate for stroke and about 10% more admissions for stroke than the England average. The prevalence of strokes in Gateshead is 2.2%, compared with 1.7% in England as a whole.

We knew that one of the ways to tackle stroke death and emergencies was to focus on primary prevention. That meant better diagnosis of atrial fibrillation (AF) – notably we didn't use any risk scoring for stroke at that time – and addressing the fact that local GPs seemed reluctant to prescribe anticoagulants; it was often felt that warfarin prescribing was a specialist decision for secondary care to make.

For both of those problems we needed to improve education and confidence among primary care practitioners.

Gateshead CCG decided to focus on reducing stroke risk in patients with AF, with case finding and anticoagulant prescribing for patients at high risk.

### What we did

The CCG's initial contact with the Stroke Association arose from discussions on moving secondary prevention clinics from secondary to primary care, which laid the foundations for our future joint working. We were keen to collaborate with the charity to maximise the impact of their campaigns and to use their experience in working with the public to enhance our work on stroke prevention.

Our first step was to organise training on stroke awareness, and on how our local stroke services worked. We asked our local stroke team and the Stroke Association to lead an update session at one of our area's regular education half-days.

Education sessions happen around six times a year – every local practice shuts for an afternoon and the PCT pays for staff cover while we run a training session on a particular clinical area for GPs, nurses and practice staff.

We followed this initial session with regular updates on using CHADS<sub>2</sub> risk scores, safe prescribing of warfarin, ECG interpretation and risk stratification.

Throughout the year we encouraged practices to promote the Stroke Association campaigns including the Act Fast campaign, which educates the public on recognising and reacting to stroke symptoms. The charity provided campaign materials – namely posters – which were well designed and saved us time and money.

We also worked with the Stroke Association to ensure practices used its Ask First publicity materials, which highlighted the importance of identifying anyone with undiagnosed AF.

The charity helped us provide an education session at my practice's patient forum, which included a presentation on stroke prevention and services available to those affected by strokes.

Alongside our work with the Stroke Association, we developed a local enhanced service for practices to screen patients over the age of 65 for pulse irregularities when they attended for their flu jab – 30 out of 34 practices took part, and practices were paid £2 per patient screened.

We ran a local incentive scheme, which paid all 34 practices up to £2.05 per patient for taking part in risk stratification. This involved practice clinicians and staff attending our regular training half-days, taking part in audits and surveys and undertaking a wide variety of clinical improvement projects.

All 34 practices in our locality decided to use the Grasp AF toolkit to find patients at high risk of stroke.



## Working with a charity

**Dr Steve Kirk** explains how working with the third sector helped his CCG improve primary prevention for stroke

It works by searching for any Read codes that might indicate AF, such as 'pulse irregular', and produces a list of patients whose notes need to be reviewed.

The CCG provided IT support to enable each practice to download the toolkit and run the searches. We also gave our practice

managers training on using it.

The second stage of Grasp AF allocated a CHADS<sub>2</sub> stroke risk score to each patient. We reviewed the records of every patient who was at high risk of stroke to ensure they were receiving appropriate anticoagulation therapy.

Patients were then invited to attend an appointment with a GP to discuss their risk of stroke and the benefits of anticoagulant therapy.

### Lessons learned

Working with a charity in this way was a new experience for us as a CCG. We got fantastic support from the Stroke Association for our projects and access to high-quality educational and promotional materials.

The joint education programme with the Stroke Association for patients and clinicians

helped raise the profile of our prevention work, and we hope that the links made between individual practices and the Stroke Association will lead to more joint working in the future.

Working together with a charity helped both sides achieve their aims.

We have also worked with the British Heart Foundation, a much larger charity, which paid the salary of one of our heart failure nurses. It's a little different working with a charity who has given you funding, as it wants to be clear its funding is meeting its needs as well as yours.

We had to be adaptable to changing circumstances – midway through the project, we were asked to select contracts to be commissioned through any qualified provider. We chose anticoagulation services in order to increase capacity, to accommodate the expected increase in referrals.

Some of the work on stroke was more thanks to the NHS than the third sector. The local Cardiac Network, the North of England branch, was helpful on Grasp AF – providing experts to give education sessions and educational materials to support clinicians in prescribing warfarin. There are 28 Cardiac Networks across Britain, all run by NHS Improvement.

### Outcomes

At the end of nine months, the total number of patients with recorded AF had risen by 96 patients – from 3,235 to 3,331.

We think the true number of new patients identified was much higher, as many practices removed or put into past problems the AF diagnosis from patients where AF had resolved or had been an incorrect diagnosis.

The number of patients at high risk of stroke (CHADS<sub>2</sub> score >1) prescribed warfarin rose from 1,175 to 1,269, a rise of 8%, and referrals to the anticoagulation clinic rose by 11%. Many patients had previously not been prescribed warfarin or had any documented contraindication or record of declining warfarin, and this number reduced from 533 to 215 – a fall of 60%.

The Grasp AF toolkit does not remove patients who have AF that has resolved, meaning it is not possible to have for all patients at high risk to be prescribed warfarin or have a record of contraindication or declining warfarin.

Before our project 16 practices did their own ECGs, only six of which could send electronic copies for cardiologist interpretation. We now have 24 practices providing in-house ECGs with access to cardiologist interpretation of ECGs through 'advice and guidance' on Choose and Book.

The pulse irregularities LES was a success, with 15,504 patients having their pulse checked and 765 new irregular pulses identified.

Unfortunately, we were not able to say how many of these 765 patients went on to be diagnosed with AF – the LES did not ask practices to collect this data.

Lastly, in June, I accepted on behalf of the CCG the 2012 Life After Stroke award from the Stroke Association for our work.

Hopefully this award will help both patients and clinicians locally build on the good work we've started in this area.

### The future

While we know that working with bigger charities with more funding might entail more compromise or negotiation, we will look to increase the number of charities we work with as our experience with the Stroke Association has been very rewarding.

**Dr Steve Kirk** is a GP in Gateshead and vice chair of Gateshead CCG





**PULSE Clinical Seminars**

# Diabetes and CVD Update 2012

Extended  
early bird rate  
**Save £50**  
Book before  
24 August

A one-day seminar to bring you the latest clinical developments, guidelines and innovations of relevance to general practice

**Wednesday 26 September, Hotel Russell, Russell Square**

## Attend this event for

- The very latest NICE guidance on preventing type 2 diabetes - controversies and practical tips
- Realistic and cost-effective strategies to implement the NICE hypertension guidelines in your practice
- A masterclass on the pros and cons of new versus older diabetes drugs
- When and how to use the new anticoagulants in atrial fibrillation
- What's new in the QOF and how to boost income
- A case-based look at tackling diabetes complications

## Expert speakers include

**Professor Martin Stevens** Professor of medicine at the University of Birmingham and consultant diabetologist, Heart of England NHS Foundation Trust

**Dr Stephen Lawrence** GPSI in diabetes, executive member of the Primary Care Diabetes Society and clinical lead for diabetes, Diabetes UK and the RCGP

**Dr Ahmet Fuat** GP specialist in cardiology and chair of the GPSI Cardiology Forum

## Book Now

Register today at [www.pulse-seminars.com](http://www.pulse-seminars.com)

t 020 7332 2934

**6**  
CPD  
hours



In association with



Media partner



**99%**

of delegates who attended a recent Pulse Clinical Seminar left feeling more confident in diagnosing and treating patients. (based on 116 respondents at Pulse Dermatology Update, March 2012.)





## Contact

**Cliff Brown**  
Advertisement executive  
020 7332 2924  
For a quote send adverts to:  
clifford.brown@briefingmedia.com

## Rates

£18.00 - £26.00 per single column centimetre.  
Colour rates available on request

## Issue date/Copy deadline

Publication date Wednesday.  
Booking deadline Thursday 4pm preceding publication date.  
Copy deadline Friday noon preceding publication date

## By post

Briefing Media  
3rd Floor, Mermaid House  
Puddle Dock  
London, EC4V 3DB

## Website

pulsetoday.co.uk

## DOCTORS/GPs REQUIRED

### SALARIED GP

*With a view to Partnership*  
**8 sessions per week**  
**Salary Negotiable**

Mayfield Medical Centre, 4 Glenholme Park, Clayton, Bradford, BD14 6NF

We are a friendly, supportive and forward thinking training practice with an established team of Doctors, nursing and admin support.

The practice comprises of a wide reaching skill mix and we would welcome anyone who wishes to develop a special interest.

**Practice features:-** Teaching practice, list size is 6,700 approx, three Partners and 2 Advanced Nurse Practitioners, Patient Reference Group, Enhanced in house services, high QOF achievers, SystmOne clinical system, protected clinical meetings.

We have also recently achieved the RCGP Quality Practice Award.

**Our closing date for the application is Friday 27th July 2012**

Please send a CV with a covering letter to:  
Mrs Sharon Barracough, Business Development, Enterprise and Finance Manager, Mayfield Medical Centre, 4 Glenholme Park, Clayton, Bradford, BD14 6NF  
Email: Sharon.barracough@bradford.nhs.uk  
Website: www.mayfieldmedicalcentre.com

### CIRCUIT LANE SURGERY, READING

#### GENERAL PRACTITIONER

We are a long established, well-respected, busy practice. Due to the forthcoming departure of a full-time partner, and the imminent retirement of our senior partner, we are looking for full/part-time/job-share partners but would consider making salaried appointments.

- 7 partners, 5 Swt, with a list of 10,500
- 4wte salaried doctor
- Well organised, fully computerised and paper light using the iSoft Synergy package
- nPMS with high level of aspiration/ achievement
- Excellent nursing, reception and administrative support
- Located in an area which has an expanding local population
- Planned premises development
- Friendly and supportive PHCT
- Active member of North & West Reading Clinical Commissioning Group
- OOH cover provided by Westcall

Please visit our website:  
[www.circuitlanesurgery.co.uk](http://www.circuitlanesurgery.co.uk)

For further information please contact:  
Mrs Jenny Marnock, Practice Manager, 0118 9582537  
Or Email: jennymarnock@nhs.net

**Start dates: September 2012 and March 2013**



### Salaried GPs (Full Time / Part Time)

Aston Healthcare Ltd, Knowsley, Merseyside

Aston Healthcare Ltd is a forward thinking and highly motivated organisation, looking after approximately 28,000 patients across 7 sites in the Knowsley area. We are committed to achieving excellence in every aspect of Primary Care under the leadership of new management team.

We are looking for enthusiastic GPs to join our existing team from August 2012; however, we would be prepared to wait for the right candidate. We would also consider a candidate preferring to work part time.

The successful candidate will get up to £30,000.00 + NHS Pension + 6 weeks Annual Leave + Study Leave (as authorised).

- Excellent and well-organised Primary Care Team.
- 2 established training practices; 4 more will become training practices this year.
- PMS Plus Contract.
- High QOF achievement.
- Paper light Vision software
- Opportunity to provide Minor Surgery, Family Planning or other Specialist Interest Clinics

Applications in writing with an accompanying CV and references by post or e-mail to: Elaine Jackson, Aston Healthcare Ltd, Munir Farm Medical Centre, Munir Farm Road, Hayton, L36 0UB, Elaine.Jackson@knowsley.nhs.uk

Informal enquiry:

Dr Afrah Hossain,

Lead GP and Managing Director of Aston Healthcare Ltd,  
Tel: 0151 480 1244, E-mail: Afrah.hossain@knowsley.nhs.uk

### ST MARYS SURGERY, SOUTHAMPTON

#### GP VACANCY

We are a friendly and dynamic inner-city practice with an expanding patient list, and we are looking for an enthusiastic, hard-working salaried doctor to join our growing clinical team.

This new post is for 6 - 7 sessions per week and will include responsibility for a small patient list.

We are an innovative PMS training practice, working from two, purpose-built premises in the centre of Southampton City.

To find out more about our practice, you can visit our website at [www.StMarysHealth.co.uk](http://www.StMarysHealth.co.uk).

Please contact our practice manager on 023 8021 0292 or email to [barbara.clark1@nhs.uk](mailto:barbara.clark1@nhs.uk) for more information, or to arrange an informal visit.

Please send a letter of application and your C.V. to:  
Barbara Clark, St Marys Surgery, 1 Johnson Street, Southampton, SO14 1LT

### Salaried GP required

South East London/Kent borders

**We are seeking an enthusiastic GP with strong clinical and communication skills to join our forward thinking PMS practice**

- Well established practice with 11,200 patients over 4 sites
- 8 clinical sessions a week over 5 days
- Excellent administrative team and clinical support staff including district nurses
- Vision clinical system and paperlight
- High QOF achievement
- Easy access to London and transport networks

Informal visits welcome

Please apply with covering letter and CV to: Suzanne Gibbs, Practice Manager, 73 Upper Wickham Lane, Welling, Kent DA16 3AP or e-mail [suzanne.gibbs@nhs.net](mailto:suzanne.gibbs@nhs.net)

**Closing date 27th July 2012**

### Maternity Locum Required

#### with Possible View to Partnership

Bethesda Surgery, Gwynedd  
Tel: 01248 600212

Locum required between October 2012 and end of March 2013 to cover full time position, however, hours are negotiable.

Part time partner required from April 2013, hours between 0.5 and 0.75 FTE negotiable.

- List size 6,000
- 3 full time and one part time partners
- New premises

Informal visits and enquiries welcome for either position or send CV with covering letter to: Mr J Hayes  
Yr Hen Orsaf, Station Rd., Bethesda, Gwynedd LL57 3NE

Tel: 01248 600212  
email: [john.hayes@gp-w94028.wales.uk](mailto:john.hayes@gp-w94028.wales.uk)

**Closing date end of July 2012**

### BRYNTIRION SURGERY

#### BARGOED (SOUTH WALES)

#### FULL TIME SALARIED GP

(WITH POTENTIAL PARTNERSHIP OPPORTUNITY)

- Purpose built, well maintained premises
- Vision Computer Software
- List size 10,700 (operating from two sites)
- Consistently high QOF points
- Opportunity to develop special interests and roles
- Full complement of attached staff

Please apply in writing with CV to: Miss Jayne Billington, Bryntirion Surgery, West Street, Bargoed, Mid Glamorgan CF81 8SA.

Email: [Jayne.Billington@wales.nhs.uk](mailto:Jayne.Billington@wales.nhs.uk)

Closing date: Willing to wait for the appropriate candidate  
Region: South Wales  
Job Type: Salaried GP

### Salaried GP

Upton Road Surgery-Watford, Herts

- Diverse outer London Area
- Close to M1 M25
- EMIS LV Practice, looking to move to EMIS web
- Full time (8 sessions) or two part time Doctors wanted
- GMS Practice
- To start as soon as possible
- View to partnership for the right person

Contact: Denise Cooper, Practice Manager  
Upton Road Surgery, 30 Upton Road, Watford WD18 0JS  
Tel: 01923 226266

### sandylanesurgery

Rugeley, STAFFORDSHIRE  
SANDY LANE SURGERY

#### SALARIED GP

JUNE 2012

We are a friendly, innovative, dynamic and forward thinking Practice, having all the usual:

- ◆ New purpose built health centre (Jan 07)
- ◆ EMIS LV / Paperlight (moving to EMIS web)
- ◆ Training Practice
- ◆ Skilled Admin / Nursing Team
- ◆ GP Triage / Nurse Practitioner
- ◆ Member of Primary Care Research Network

We require a Salaried GP up to 7 sessions per week.

Application packs available from  
[stephanie.o'nion@nhs.net](mailto:stephanie.o'nion@nhs.net),  
or Stephanie on 01889 572058  
**Closing date: 6th July 2012**

### SALARIED GP

(with a view to partnership)  
7 SESSIONS PER WEEK

SAXON SPIRES PRACTICE  
NORTHAMPTONSHIRE

We are looking for an enthusiastic GP to join our friendly, rural practice on 2 sites in Northamptonshire.

Why join us:

- List size 14420
- Dispensing practice
- Training practice
- EMISweb
- Excellent nursing and admin team
- 5 GP partners and 3 salaried GPs
- High QOF achievers

Please apply with CV and covering letter to:

Kathryn Baines, Practice Manager,  
Saxon Spire Practice,  
West Haddon Road, Gillsborough,  
Northamptonshire NN6 8QE

Tel: 01604 740210 Email: [Kathryn.Baines@gp-KB3054.nhs.uk](mailto:Kathryn.Baines@gp-KB3054.nhs.uk)

Informal visits welcome.  
**Closing date 13th July 2012**



## DOCTORS/GPs REQUIRED

### PART TIME SALARIED GP KETTERING NORTHANTS

Due to an increasing patient list size, a vacancy has arisen for the post of salaried GP at Weavers Medical.

- 6 – 8 sessions per week
- Core working days Tuesday, Wednesday & Thursday
- To start as soon as possible
- 15,800 patients, town centre practice
- Long established training practice
- GMS, heavily involved with PBC & Nene Commissioning
- New purpose-built premises shared with one other practice & a range of ancillary services
- Full complement of staff including strong nurse team leading LTC clinics & minor illness clinics, multi-skilled 20+ strong admin team
- Team approach to workload, forward-thinking, friendly, inclusive, supportive, open & honest ethos, consistently high GQAQ survey results
- Dedicated time for peer-review of clinical work to support revalidation & best-practice, we consider ourselves a 'learning practice'
- Systemic, very paperlight & maximum use of IT within practice
- Consistently high achievements in QoF, full portfolio of ESC & full participation in other local contracts

[www.weaversmedical.co.uk](http://www.weaversmedical.co.uk)  
[www.prospect-house.co.uk](http://www.prospect-house.co.uk)

Please send full CV with covering letter and names of two referees (one from current place of work). Please include details of sickness absence in last two years and statement of health.

**Closing date for applications: 31.07.12**

For further information or an informal chat contact:  
Dr John McManus on 01536 513494.  
Previous applicants need not apply.

### EAST COWES MEDICAL CENTRE ISLE OF WIGHT

#### GP MATERNITY LOCUM (Up to 7 sessions per week)

We seek a GP Locum from 25 September 2012 until Friday 17th May 2013 for up to seven sessions per week to cover maternity leave. Salary and benefits are negotiable.

East Cowes is undergoing exciting regeneration and population growth. The town has excellent links to mainland and is close to fantastic sailing, beaches and countryside.

- New Purpose built Premises
- 8100 Patients
- Fully computerised Vision Practice
- Five Doctors (4.5 wte)
- Highly skilled Nursing Team
- Comprehensive PHCT

Application by CV and covering letter to:  
recruitment@gp-84004.nhs.uk  
**Closing date for applications 14th July 2012**

Informal visits welcomed. Please Telephone: 0844 477 3116  
Nicholas Emery, Practice Manager, East Cowes Health Centre,  
York Avenue, East Cowes, Isle of Wight PO32 6RR.

### Partner wanted for South Leeds Practice (Full Time)

The Whitfield Practice

Due to retirement of the senior partner, this long established, very friendly practice situated in Hunslet, South Leeds is looking for an enthusiastic and motivated GP to join 4 other partners. We can offer opportunities on both clinical and managerial aspects of general practice.

- Practice population – 7,500 and growing
- GMS
- EMIS LV computer system, upgrading to Emis Web shortly
- High QoF achievement
- Practice is based within a Health Centre

You are invited to make an appointment to visit us phone  
0113 2008837 or 0113 2705194  
and ask for Sue Coleman, Practice Manager.

Applications by letter or email with CV

Email: [susan.coleman@nhs.net](mailto:susan.coleman@nhs.net)

### SALARIED GP OR RETAINER 4 Sessions a week: Tuesday and Thursday preferred Starting ASAP

PRINCES GARDENS SURGERY, ALDERSHOT, HAMPSHIRE

We are a friendly, well established practice with a reputation for providing good patient care, with a strong, supportive team. We are a PMS practice in the centre of town in new purpose-built premises.

- 7,300 patients
- Isot PREMIERS (moving to Synergy)
- 4 partners and 2 salaried GPs
- Training practice
- Medical students
- High QoF achievement
- 6 month period of mutual assessment as salaried GP

Please send a CV and covering letter to Elaine Beverley,  
Practice Manager by email only to [elaine.beverley@nhs.net](mailto:elaine.beverley@nhs.net)

**Closing date for applications 13th July 2012**

### Preseli Peaks Practice Newport & Crymych Surgeries, Pembrokeshire Seeks Salaried GP with view to Partnership

- 2 - 4 days a week
- Friendly Training Practice
- Vision and Docman, paperlight
- 6300 patients
- Well organised team
- High QoF Achievement
- Pembrokeshire Coast National Park - Preseli

2012 + prepared to wait for right candidate  
enquiries to:  
Practice Manager, Surgery, Long Street, Newport,  
Pembrokeshire, SA42 0TJ  
Telephone 01239 - 820194 / 820397  
Email [julie.evans@gp-w92064.wales.nhs.uk](mailto:julie.evans@gp-w92064.wales.nhs.uk)

### WHETSTONE MEDICAL CENTRE BIRKENHEAD, WIRRAL

#### SALARIED GP REQUIRED FOR SIX SESSIONS PER WEEK

We are a six partner GMS urban practice with a vacancy due to retirement of a partner.

We are looking for an enthusiastic GP to join our friendly and supportive team, initially on a 12 month contract 8,900 patients.

EMIS LV due to move to EMIS web Oct12.

On site pharmacy, physiotherapy and counseling involved in undergraduate teaching.

**Starting date 1st September 2012**

**Closing date for applications 10th July**

Applications in writing with CV to:-

Mrs Anita Jones, Practice Manager,  
Whetstone Medical Centre,  
44 Whetstone Lane, Birkenhead, Wirral CH41 2TF  
e mail: [anjajones2@nhs.net](mailto:anjajones2@nhs.net)

### Summerville Medical Centre

#### GP PARTNER Opportunity 6 sessions per week From 1st October 2012 (Salaried GP considered)

We are a friendly, forward thinking, five partner GMS practice based in Ilminster, Somerset.

- 7100 patients
- Training practice
- EMIS LV clinical system
- High QoF achievement
- Dispensing practice
- Committed to delivering enhanced services and actively engaging in local commissioning
- New purpose built premises from 1st September 2012

Applications in writing, with CV, to Susan Harris, Practice Manager, Summerville Medical Centre, Wharf Lane, Ilminster, Somerset, TA19 0DT  
or [susan.harris@summervalleim.nhs.uk](mailto:susan.harris@summervalleim.nhs.uk)  
If you would like to arrange an informal visit or require further information please e mail or ring 01460 52354

SUFFOLK  
Framfield House Surgery, Woodbridge  
[www.framfieldhouse.com](http://www.framfieldhouse.com)

### FULL TIME PARTNER (eight sessions) (Retirement Vacancy)

We are seeking a committed and enthusiastic full time GP (or combination of part time GPs) to join our progressive semi-rural training practice.

- Eight sessions a week over four days
- 11,500 patients
- Fabulous partner owned new medical centre with further development potential
- In house separate pharmacy company which you will be invited to join subject to satisfactory mutual assessment period
- Excellent practice team including nurse practitioners
- High QoF achievers
- VTS training practice and University undergraduate teaching practice
- Beautiful area and excellent schools
- We aim for a good work/life balance
- London 1hr 10, Cambridge 1hr, Norwich 1hr

For an informal visit or to apply please contact Carole Edwards,  
Business Manager 01394 615500  
or email [carol.edwards@gp-d83057nhs.uk](mailto:carol.edwards@gp-d83057nhs.uk)

**Closing date for applications July 31st 2012**

NEW TYNEWYDD SURGERY  
TRENERBERT, RHONDDA

### LONG TERM LOCUM GP WITH A VIEW TO PARTNERSHIP to start within the next three months

- 7-9 sessions per week,  
Terms negotiable.
- 6,500 patients.
- VISION
- Purpose built Surgery and branch
- High QoF achievement.

Application with CV to:

Susan Williams, Practice Manager, New Tynewydd Surgery, William Street, Tynewydd, RCT. CF42  
SUN Tel: 01443 777485 or by email: [Susan.Williams@gp-w95071.wales.nhs.uk](mailto:Susan.Williams@gp-w95071.wales.nhs.uk)



**Doctors required UK-Wide  
for Insurance medicals.**

**dc life**

...is growing. Join our panel of doctors who provide Insurance Medicals.

- Adhoc or sessional work
- Training provided
- Excellent remuneration
- Full administrative support

This is a unique opportunity to be part of our team. If you are interested please send a copy of your CV to:

[info@dc.life.co.uk](mailto:info@dc.life.co.uk) Tel: 0845 140 3000

### HARLEY STREET DOCTORS LTD.

Doctors required UK-wide for mobile insurance medicals, especially in the following areas:  
London, Bournemouth, Southend, Chelmsford, Reading, Southampton, Leics., Lincs., Cambs., Herts., Dorset, Dundee, Aberdeen & Dublin  
Please email your CV to: [peter@harleystreetgroup.co.uk](mailto:peter@harleystreetgroup.co.uk)  
or call on 020 7224 0030

### Maternity Locum Required with Possible View to Partnership

Bethesda Surgery, Gwynedd  
Tel: 01248 600212

Locum required between October 2012 and end of March 2013 to cover full time position, however, hours are negotiable.

Part time partner required from April 2013, hours between 0.5 and 0.75 FTE negotiable.

- List size 6,000
- 3 full time and one part time partners
- New premises

Informal visits and enquiries welcome for either position or send CV with covering letter to: Mr J Hayes  
Yr Hen Orsaf, Station Rd., Bethesda, Gwynedd LL57 3NE

Tel: 01248 600212  
email: [john.hayes@gp-w94028.wales.nhs.uk](mailto:john.hayes@gp-w94028.wales.nhs.uk)

**Closing date end of July 2012**



## LOCUM AGENCIES

## Locum Staffing

Finding work doesn't have to be time consuming. Let the work come to you.

- Earn up to £100 p/hour
- Placements nationwide
- Newly qualified/experienced welcome
- Free e-mail and sms job alerts
- Excellent referral fees

Ongoing locum and salaried positions throughout the UK

We are providers of GPs to:

- PCTs
- Hospitals
- GP Practices
- Walk in Centres
- HM Prisons
- Out of Hours Services
- Medico - Legal

t. 08450 562 867 | f. 01582 345 355  
info@locumstaffing.co.uk | www.locumstaffing.co.uk

## Cimarron

Established and unique GP Locum Agency, offering a professional, efficient service for all GPs.

## URGENTLY REQUIRED

**Primary Care and Substance Misuse GPs required for prison work in; Chelmsford, Manchester, Peterborough and Middlesex**

Contact us today and see the Difference!  
Phone 01206 274174  
Email: enquiries@cimarron-uk.com



## PULSE Recruitment

To advertise your Locum Agency call Cliff now on 020 7921 8124

## dr-locums

Earn **£1000\*** per day

Recruiting across the UK :-

London \* Sussex \* Essex \* Suffolk \* Midlands \* North England \* Wales

Walk in Centres

Out of Hours

Prisons (RCGP1 trained)

GP surgeries

Call 020 7498 7999

www.drlocums.com

gp@drlocums.com

RELEASE YOUR SURGERY EQUITY  
OR  
DEVELOP YOUR NEW SURGERY  
Medical Centre Developments Ltd

We are specialist developers and funders.  
Talk to us about your requirements.

Contact: Christopher Holden  
54 Weymouth Street, London W1G 8NU  
020 7935 5042 - Email: jon.christ@medicalcentres.co.uk  
www.medicalcentres.co.uk

## OVERSEAS

## Life in New Zealand!

Friendly communities, spectacular scenery and an outdoor lifestyle culture. New Zealand truly is the ideal place to be.


NZLocums, New Zealand's only not-for-profit recruitment specialists.

We provide:

- Immigration assistance
- Three day orientation course
- Smooth, swift and recruitment service
- Wide choice of long-term and permanent opportunities

Contact us today!

enquiries@nzlocums.com | Freecall 0800 224 7822 | www.nzlocums.com



## COURSES &amp; CONFERENCES



5th - 9th October 2012  
POSTGRADUATE GP COURSE in  
Taormina, Sicily

Set 700 feet above the azure blue sea and dramatic cliffs on Sicily's Monte Tauro, is the medieval town of Taormina. Commanding breathtaking views over two rugged bays below, Taormina has captured the imagination of great travellers and writers for many decades. It is widely considered the most beautiful town in Sicily with its semi-tropical palms, bougainvillea and orange trees.

Experience our superb academic conference with high quality interactive teaching PLUS:

Direct flights from Gatwick to Catania on British Airways

4 nights on bed & breakfast at the 5\* Hotel Imperiale, Taormina

Superb optional tour programme

ACADEMIC FACULTY TO INCLUDE:

MR ROB POLLOCK, CONSULTANT ORTHOPAEDIC SURGEON

DR FAYE GISHEN, CONSULTANT IN PALLIATIVE MEDICINE



## CONFERENCES TO COME:

India & Britain  
10th - 11th October 2012  
19th - 20th June 2013  
2nd - 3rd Feb 2014

Cappadocia & Bodrum  
10th - 11th October 2012  
19th - 20th June 2013  
2nd - 3rd Feb 2014

May 2013  
October 2013  
October 2013



BOOK ONLINE AT: www.conferenceplus.co.uk  
OR EMAIL: info@conferenceplus.co.uk  
Tel: 01923 859163 Fax: 01923 465161



British Medical Acupuncture Society  
Foundation Courses in Western  
Medical Acupuncture

Are you interested in learning a technique that will enable you to treat 70% of musculoskeletal pain?

The BMAS runs Foundation Courses for healthcare professionals subject to obligatory registration and registration in the country in which they practice, and for whom acupuncture is within the scope of their professional practice.

Course venues: York, Bristol, Manchester, London, Newcastle, Glasgow, Birmingham

Book online: www.medical-acupuncture.co.uk  
or Tel: 01605 786782

Email: admin@medical-acupuncture.org.uk  
3 Wincanton Court, Northwich CW9 1AQ



Join the BMAS today

\* Discounted course fees

\* Recognition by health insurers

\* Free Acupuncture in Medicine Journal

## OVERSEAS

## Work in Australia

As a GP in Australia you can...

Escape the NHS reforms

Earn over **£200,000** a year

Have a **lifestyle** second to none

Have more time for friends and **family**

Enjoy great **housing**

Benefit from a booming **economy**

Contact us today and we will help you every step of the way.

Call: 01279 677000 Email: gp@dwsmedics.com

DWS Medics

Providing medical professionals to Australia

## COURSES &amp; CONFERENCES

College of Medicine and Veterinary Medicine  
Flexible online courses in  
Global Health



THE UNIVERSITY  
of EDINBURGH

Keep up to date with the global health agenda by studying for short, credit-bearing postgraduate modules in Epidemiology for Health Professionals or Evidence Based Medicine, or for a Certificate, Diploma or Masters in Global Health: Non-Communicable Diseases. Study in your own time through our interactive virtual learning environment.

Apply now for September 2012.

tinyurl.com/global-health-professional-dev



## Snapshots of a life in practice

In recent years, the way GPs are performance managed has changed the way we work - and



The 'Shoreditch Stories' project – a series of photos of patients at home – involved either me or another doctor from the practice accompanying Michael and

**Dr Kate Adams** is a GP in Hackney, east London. 'Shoreditch Stories' will be open to the public at Shoreditch Park Surgery until the end of August, when it moves to the new RCGP headquarters in September.



► [pulsetoday.co.uk/videos](http://pulsetoday.co.uk/videos)

## Itch relief that no scratch can match?



**PULSE BLOGS**  
Read Dr Ramscar's  
new blog at  
[pulsetoday.co.uk/ramscar](http://pulsetoday.co.uk/ramscar)

Response	Percentage
No	82%
Yes	18%

Turn inside for this  
Margaret McCart  
▶ pages 16, 17

Turn inside for this week's Phil Peverley and Margaret McCartney columns  
▶ **pages 16, 17**



**balneum** CREAM  
PLUS  
Urea 5% and lauramcrogols 3%

**Please Read Carefully:** Please refer to full Summary of Product Characteristics (SPC) before preparing. **Balmain Hair Care** contains sodium lauryl sulphate 3.0 w/w and some S.E. Water Use. For the treatment of dandruff, seborrheic dermatitis and scaling skin conditions, use an aqueous solution of sodium hydroxide 1 w/w. It may be used for the treatment of dandruff and scaling skin conditions. **Design and administration:** Adults, use daily and children daily, in a 100 ml solution to be used daily. The duration of treatment depends on the clinical response. **Contraindications:** Patients with scalp hypersensitivity to any of the ingredients. It should not be used to treat scalp psoriasis, seborrheic dermatitis, or other scalp conditions. **Special**

Warnings and precautions for use: May cause drowsiness if applied to broken or inflamed skin. Frequency and duration: There are no specific restrictions concerning its use (age, pregnancy, lactation, etc.) as to be used as the treated areas (dry to) to lower feeling during a operation. Undesirable effects: Bothersome skin reaction has been reported to cause skin burning, irritation, and/or, pruritus or the formation of a sticky aggregation of scales if applied to a flamed area. Contact allergy has also been reported. Package quantities: 110g tube and 500g pump spray. Price: 185 net, 220g 215 net, 500g 249.99. Legal category: 06. Product licence number: PL 32056/06/00. Product holder: Lohrle, AG, Alte Straße 64b, Schönbühl, 3, 42699 Solingen, Germany. Tel: 0212 4165. Gernot.

Date of preparation: January 2011. Further information is available from:  
Allison Taylor, The Solars, Strathely Park, Uddingston, U83 1E.

Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to Alimfall Ltd on 0800 05 87399.

Date of registration: July 06, 2011. UN5096003.

